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Antigen presentation is the process by which cells of the immune system display 
peptides from pathogens on their surface after binding the peptides to major 
histocompatibility complex (MHC) molecules. T helper cells recognize peptides from 
pathogens in this context then secrete cytokines that activate other cells, initiating an 
immune response. Antigen presentation is therefore a quisite for immunity to several 
pathogens including Mycobacterium tuberculosis (Mtb). To approach questions related to 
antigen presentation and disease, I represented antigen presentation at different scales 
using a series of mathematical and statistical models. At the molecular scale, I asked 
whether heterogeneity in peptide length affects binding to MHC class II, the class of 
MHC responsible for binding peptides from bacteria such as Mtb. By developing 
statistical models of peptide-MHC binding, I found that length has a nonlinear effect on 
binding affinity and that this information, or a more accurate representation of register 
shifting, could improve the accuracy of binding prediction. At the cellular scale, I asked 
why Mtb possesses multiple mechanisms to inhibit antigen presentation on the cell 
surface. My mathematical model shows that these mechanisms may be acting on different 
timescales and therefore complementary rather than merely redundant. Finally, at the 
multi-cellular level, I asked how polymorphisms in multiple genes related to antigen 
presentation might affect T cell response and susceptibility to infectious diseases such as 
tuberculosis. Using a multi-scale model representing both an antigen-presenting cell and 
T cell, I found that polymorphisms in two different genes may exert the same influence 
on the output, potentially canceling out their effects. Future work with these models may 
xiii 
include evaluation of candidate peptide-based vaccines to ensure high-affinity binding, T 




Antigen presentation is the process by which proteins from pathogens are partially 
degraded and then displayed (i.e., presented) on the surfaces of cells in complex with 
major histocompatibility complex (MHC) molecules. Once bound to MHC molecules, 
peptides can be recognized by cognate T cells which t en respond by either killing the 
original antigen-presenting cell (APC) or activating the APC and other cells. Proteins that 
elicit an immune response are known as antigens. While antigen presentation may appear 
to be dictated by events at the molecular and sub-cellular scales of the APC, events at 
other scales also affect the outcome (Fig. 1.1). For instance, once peptides have been 
bound by MHC molecules and trafficked to the surface of the APC, additional events are 
required by the T cell to result in a functional response, starting with the engagement of 
peptide-MHC (pMHC) complexes by T cell receptors (TCR) on the T cell surface. 
Activated TCRs then initiate a signaling cascade within the T cell, resulting in the 
elicitation of either cytotoxic molecules or activating cytokines including interleukin-2 
(IL-2) and interferon-γ (IFN-γ). Therefore, at a minimum, a representation of the ev nts 
of antigen presentation requires consideration of mlecular and sub-cellular events 
occurring in APCs and T cells. In addition, the larger tissue- or organ system-scale 
context may also be important in determining the outc me of antigen presentation, as this 
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environment may enhance or interfere with the ability of APCs to interact with T cells 
(Fig. 1.1). 
How best to represent events at these different scales using the tools of 
mathematical and statistical modeling and how then to apply these tools to the study of 
infectious diseases remain open questions. A vast amount of experimental research has 
been done, and continues to be done, to elucidate the s eps involved in antigen 
presentation. At the same time, computational models of one or more steps in antigen 
presentation have been developed. I review previous efforts in both experimental and 
computational areas in this chapter and then describe my efforts to improve on 
computational models and apply them to one infectious disease, tuberculosis, in 
subsequent chapters. 
1.1 Overview of Antigen Presentation 
Two main pathways for antigen presentation exist, depending on the source of the 
antigen. All nucleated human (and mammalian) cells perform antigen presentation to 
some extent by expressing one type of MHC molecule, MHC class I, which binds 
peptides derived primarily from proteins in the cytoplasm (Yewdell 2007). However, 
some cells are also capable of presenting peptides from proteins found in the extracellular 
medium by expressing another type of MHC molecule, MHC class II (Trombetta and 
Mellman 2005). These specialized cells include macrophages, dendritic cells, and B cells, 
constituting the professional APC. [A recently discovered pathway for presenting lipid 
antigens, the CD1 pathway, will not be considered hre. See Mahanty et al. (2003) for a 
review of this topic.] 
For the most part the two pathways for antigen presentation remain distinct within 
the cell. Proteins found in the cytoplasm, including those produced by most viruses, are 
considered endogenous and degraded (i.e., processed) into shorter peptides by the main 
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protein turnover machinery of the cell, the proteasome. A subset of these peptides is 
transported into the endoplasmic reticulum (ER) by the transporter associated with 
antigen processing (TAP). Within the ER peptides of a limited range of lengths (8-10 
amino acids) bind MHC class I molecules, and the resulting complexes are trafficked to 
the cell surface. 
In contrast antigens from pathogens that do not reside in the cytoplasm, including 
most bacteria and parasites, are considered exogenous and taken up and processed in the 
endosomal pathway of the APC. Within the endosomal pathway cathepsin proteases 
become activated by the increasingly acidified environment and cleave proteins into 
shorter peptides. Peptides of various lengths (often gr ater than 9 amino acids) then bind 
MHC class II molecules later in the pathway in a specialized vacuole known as the MHC 
class II compartment (MIIC). Peptide-MHC class II complexes are then trafficked to the 
cell surface as in the case of MHC class I. In both cases the final stage is recognition of 
the pMHC complexes by TCRs found on the surfaces of CD8+ cytotoxic T cells and 
CD4+ helper T cells which are specific for MHC class I and MHC class II, respectively. 
Although the two pathways are for the most part disinct, exceptions have been 
found. For instance, during cross-presentation, exog n us antigens gain access to MHC 
class I molecules within APCs and yield peptide-MHC class I complexes on the APC 
surface that stimulate CD8+ T cells. Some aspects of cross-presentation remain 
controversial such as the degree to which it occurs and the instances in which it may be 
important to the immune response (see Rock and Shen2005 for a recent review). 
1.2 Biology of the Molecular Scale: Peptide-MHC Binding 
One theme that arises from this cursory overview of the two antigen presentation 
pathways is the centrality of the peptide-MHC binding event. MHC class I and MHC 
class II molecules bind peptides in a similar manner, and this similarity can be traced to 
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similarities in the structures of the two molecules (Jones 1997). Both MHC class I and 
MHC class II molecules comprise heterodimers of poly eptides. In the case of MHC 
class I, a single transmembrane polypeptide (designated the α chain) is coupled to a 
smaller accessory protein (β2 microglobulin), and the peptide-binding groove is formed 
between two domains of the transmembrane polypeptid (α1 and α2). In the case of MHC 
class II, two transmembrane polypeptides of similar size are coupled (designed α and β 
chains), and the peptide-binding groove is formed by overlap of the membrane-distal 
domains of the two polypeptides (α1 and β1). 
In addition to overall structural similarities, the p ptide-binding grooves of the 
two classes of MHC molecule are also similar (Jones 1997). In both cases, eight β-
pleated sheets and two α-helices form the bottom and walls of the peptide-binding 
groove, respectively. Pockets within both grooves bind amino acids at select positions 
within the peptides which are similarly extended in a  α-helical conformation in both 
cases. However, in the case of MHC class I, the termini of the peptide attach at both ends 
of the peptide-binding groove, restricting peptide length to between 8 and 10 amino 
acids. In contrast, the ends of the MHC class II peptid -binding groove are open, 
allowing peptides to be of a greater range of lengths. 
1.2.1 Quantification of Peptide-MHC Affinity 
While peptide-MHC binding was formerly viewed as a dichotomous event, either 
occurring or not, a more quantitatively continuous view has accompanied advances in the 
ability to measure affinity.  In the most commonly used assay, the strength of binding is 
assessed by titrating reporter peptide-MHC complexes with increasing concentrations of 
the peptide of interest (Southwood et al. 1998). The concentration at which 50% of the 
reporter peptide is displaced then yields the 50% inhib tory concentration (IC50) which 
can be shown to approximate the equilibrium dissociation constant (KD) of the peptide of 
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interest with the MHC molecule. High-affinity binding, associated with smaller values of 
KD and IC50, is expected to yield more pMHC complexes on the APC surface and in turn 
facilitate T cell activation. 500 nM is commonly used as an upper limit for KD values that 
result in binding (Sette t al. 1994). According to one survey, the majority of functional 
pMHC complexes have KD values in the range of 10-100 nM (McFarland and Beeson 
2002). 
1.2.2 Genetic Polymorphism within the MHC 
Because affinity is specific to each combination of peptide and MHC, variations 
in either peptide or MHC sequence may affect binding. I  humans the genes encoding the 
MHC molecules, known as the human leukocyte antigens (HLA), are particularly 
variable. For example, among the three sets of genes coding MHC class II molecules in 
humans, HLA-DR, -DP, and -DQ, 875 alleles have currently been identified (Robinson et
al. 2003). In most cases, variation occurs in positions associated with peptide-binding or 
TCR-binding and can therefore be assumed to be functional. Recently attempts have been 
made to categorize alleles on the basis of their peptid -binding characteristics, thereby 
defining MHC supertypes and effectively reducing the number of alleles (Ou et al. 1998, 
Lund et al. 2004, Doytchinova and Flower 2005). 
1.2.3 Peptide-MHC Affinity and Disease Susceptibility 
The greater significance of peptide-MHC binding can also be discerned from the 
epidemiological literature. Various MHC alleles have been correlated with increased 
susceptibility to autoimmune and infectious diseases such as HLA-DRB1*1501 (a variant 
of the MHC class II β polypeptide) with tuberculosis (Vukmanovic et al. 2003). Other 
diseases for which MHC alleles have been found to affect susceptibility include type I 
diabetes, rheumatoid arthritis, and malaria. The mechanism behind these associations has 
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not yet been elucidated, though several hypotheses xist (Vukmanovic et al. 2003, 
Rajagopalan and Long 2005, Thorsby and Lie 2005). One possibility is that MHC 
variants associated with disease are deficient in their ability to bind key peptides that 
enable recognition of the pathogen and activation of the immune response. Consistent 
with this hypothesis, a correlation between peptide-MHC affinity and magnitude of 
response at the cellular level has been demonstrated, though the relevance to disease 
remains speculative (Geluk et al. 1998, Hill et al. 2003). 
1.3 Biology of the Sub-Cellular Scale: Events within APCs 
Peptide-MHC binding is by no means the only step that is regulated in the antigen 
presentation pathway. Other steps are controlled dynamically – by the amount of antigen 
available, for instance, or the constantly changing cytokine environment surrounding the 
APC – and allow antigen presentation to be fine-tuned. We describe these steps and 
others relevant to the MHC class II-mediated pathway in more detail below but refer the 
reader to a review for a full treatment (Bryant and Ploegh 2004). 
1.3.1 Antigen Processing 
Antigens for the MHC class II-mediated pathway are generally internalized by 
one of three routes before converging on the endosomal pathway: phagocytosis, fluid-
phase pinocytosis, and receptor-mediated endocytosis. Internalized antigens then progress 
through the endosomal pathway where they encounter cathepsin proteases that degrade 
the antigens into peptides (Honey and Rudensky 2003). Peptides then either bind MHC 
class II molecules or are directed to lysosomes for degradation. Questions remain 
regarding antigen processing, such as how the many c thepsin proteases differ in function 
and whether it might be possible that proteins are first bound by MHC and then processed 
into peptides (Villadangos and Ploegh 2000). 
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1.3.2 MHC Expression 
MHC class II expression normally occurs at low leves in resident APCs but can 
be up-regulated by cytokines such as IFN-γ and TNF (reviewed by van den Elsen t al. 
2004). After IFN-γ binds to its receptor on the APC surface, a signal is propagated 
through the JAK-STAT pathway increasing the level of class II transactivator (CIITA) in 
the cell. CIITA acts as the master regulator of MHC class II transcription, and increased 
levels of CIITA lead to parallel increases in MHC class II expression several hours after 
exposure to IFN-γ. Nascent MHC class II molecules enter the ER and are coupled to 
another protein, invariant chain (Ii). The luminal domain of Ii binds the peptide-binding 
groove of MHC class II, protecting it from proteases, while the cytoplasmic domain of Ii 
directs the paired molecules to the endosomal pathway. After reaching the endosomal 
pathway MHC class II molecules retain a remnant of Ii, the class II invariant peptides 
(CLIP), until released by the enzymatic activity H2-/HLA-DM (Denzin and Cresswell 
1995). Antigenic peptides then compete for binding to MHC class II with self peptides 
that are present at high levels and may bind greater than 80% of the available MHC class 
II in the absence of exogenous peptides (Adorini et al. 1988, Chicz et al. 1993). In 
complex with either self or exogenous peptides, MHC class II molecules then traffic to 
the cell surface where they may remain stably for days until they are recognized by CD4+ 
T cells or internalized and degraded. 
1.3.3 Differences among APC Types 
Macrophages, dendritic cells (DCs), and B cells constitute the professional APCs, 
expressing not only MHC class II molecules but also co-stimulatory and adhesion 
molecules necessary to engage T cells. Both macrophages and DCs derive from a 
common precursor, the monocyte, which differentiates into one of the two cell types 
based on environmental cues (Chomarat et al. 2000, Chomarat et al. 2003), while B cells 
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are derived from hematopoietic cells in the bone marrow (Bryant and Ploegh 2004). 
Macrophages and DCs are found in overlapping distributions within the body in areas 
such as the lymph nodes. 
Differences between macrophages and DCs occur in the rates at which they 
perform processes related to antigen presentation. DCs express 10-100 times the number 
of MHC class II molecules expressed by macrophages nd also perform antigen uptake at 
generally increased rates (Inaba and Steinman 1985, Inaba et al. 1997). Consistent with 
these findings, fewer DCs are required to activate T cells than macrophages (Inaba and 
Steinman 1985). Though both DCs and macrophages perform antigen presentation, their 
roles in the development of the immune response are thought to be distinct. DCs take up 
antigen at the site of infection and migrate to the nearest lymph node to present antigen to 
naïve T cells, while macrophages present antigen primarily at the infection site to re-
stimulate T cells (Reinhardt et al. 2001). 
1.4 Biology of the Cellular Scale: T Cells 
1.4.1 T Cell Receptor 
pMHC complexes on the APC surface provide signals to T cells when engaged by 
TCRs and the co-stimulatory molecules CD4 and CD8 found on the T cell surface. Each 
TCR comprises two trans-membrane subunits of approximately equal size (designated α 
and β) (reviewed by Rudolph et al. 2006). The membrane-distal domain of each subunit 
resembles the immunoglobulin variable (V) domain and e gages portions of both peptide 
and MHC molecule in the pMHC complex. A membrane-proximal domain resembles the 
immunoglobulin constant (C) domain and connects the membrane-distal domain to the 
transmembrane region and a short cytoplasmic tail. The CD3 molecule is associated with 
the cytoplasmic tail and plays an integral role in the signal transduction that follows TCR 
activation. 
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pMHC and TCR bind in a specialized structure that forms between the APC and T 
cell known as the immunological synapse. The structu e of the synapse has been the 
subject of intense investigation and revealed to comprise concentric zones: the central 
supramolecular activation cluster (cSMAC), the periheral supramolecular activation 
cluster (pSMAC), and the distal supramolecular activ tion cluster (dSMAC) (Cemerski 
and Shaw 2006). Within each zone is found a distinct complement of molecules 
contributed by the APC and T cell. For instance, pMHC and TCR are found within the 
cSMAC of the mature synapse, along with co-stimulatory molecules B7 and CD28 on 
APC and T cell surfaces, respectively. In the pSMAC surrounding the cSMAC is a 
palisade of structural molecules – complexes of intercellular adhesion molecule 1 
(ICAM1) and leukocyte function associated antigen 1 (LFA1) contributed by APC and T 
cell, respectively – along with other co-stimulatory molecules such as B7 and CD28. 
Finally, in the recently defined dSMAC surrounding the pSMAC additional signaling 
between pMHC and TCR has recently been observed, though the contribution of 
signaling in the dSMAC to the overall T cell response is still unknown (Yokosuka et al. 
2005, Varma et al. 2006). 
1.4.2 Signal Transduction 
Several intracellular signaling events follow engagement of pMHC by TCR. 
Briefly, these events include recruitment of kinases, activation of intermediate signaling 
molecules, and activation of transcription factors re ponsible for expression of molecules 
with effector function such as IL-2 and IFN-γ (reviewed in Samelson 2002, Liu 2005, and 
Weil and Israel 2006). Of the molecules involved, the most notable include the Src family 
kinases such as Lck, which phosphorylates the CD3 molecule after TCR activation, and 
ZAP-70, which is recruited to phosphorylated CD3 and phosphorylates the adapter 
protein LAT. In turn, phosphorylated LAT recruits other adapter proteins including 
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PLCγ1 and Grb2. Activation of several distinct signaling pathways follows which has 
several effects including a sustained increase in intracellular calcium and the activation of 
the transcription factors NF-AT, NF-κB, and AP-1. These transcription factors are 
ultimately responsible for the expression of molecus associated with T cell activation 
such as IL-2 and IFN-γ. 
1.5 Tuberculosis and Antigen Presentation 
1.5.1 Pathogenesis of Mycobacterium tuberculosis 
Mycobacterium tuberculosis, the causative agent of tuberculosis, infects nearly a 
third of the human population and results in nearly two million deaths per year (WHO 
2007). M. tuberculosis bacilli are inhaled on droplets, enter the lungs, and are 
phagocytosed by resident macrophages or dendritic cells (reviewed in Fenton 1998, 
Russell 2001). Residing in specialized phagosomes that do not fuse with lysosomes, the 
bacilli become dormant or slowly replicate. Meanwhile, monocytes are recruited to the 
site of infection and differentiate into macrophages which, together with infected 
macrophages and multinucleate macrophages (known as giant cells), form the center of a 
specialized structure known as a granuloma wherein the infection is contained. 
Surrounding the center are T cells which define the edge of the granuloma. When 
contained in a granuloma, the M. tuberculosis bacilli cannot be transmitted and the host 
has no signs of infection; this state called latency may persist for the lifetime of the host. 
In approximately one-tenth of these cases, however, th  granuloma fails to continue 
containing the M. tuberculosis bacilli, resulting in active disease. 
1.5.2 M. tuberculosis Inhibition of Antigen Presentation 
Many pathogens including M. tuberculosis interfere with antigen presentation to 
evade immune surveillance and effect their own survival. To avoid immune surveillance, 
11 
M. tuberculosis inhibits antigen presentation in chronically infected macrophages. This 
inhibition can be demonstrated in vitro. When cultured macrophages are infected with M. 
tuberculosis, their capacity to present model antigen to T cell hybridoma is greatly 
reduced compared to uninfected controls (Gercken et al. 1994). Though the mechanisms 
by which M. tuberculosis achieves this inhibition have not been completely elucidated, 
several hypotheses have been proposed (e.g., in Moreno et al. 1988, Hmama et al. 1998, 
Noss et al. 2000). I discuss these hypotheses in detail in Chapter 2. 
1.6 Models of Peptide-MHC Binding 
Peptide-MHC binding is a prerequisite for antigen presentation and the event 
most likely to be affected by polymorphisms that exist within the MHC of human 
populations. From a clinical perspective these polym rphisms may distinguish 
individuals who succumb to a particular infectious di ease from those who remain 
healthy, and significant effort has been expended to assess whether binding occurs 
between relevant peptide-MHC combinations. However, the sheer numbers of possible 
peptides (209 or ~1011 peptides of length nine) and MHC molecules (more than 2200 
known HLA alleles) make this task all but impossible for anything more than a small 
sampling of the peptide-MHC combination space. 
To circumvent this difficulty computational algorithms have been developed to 
predict whether binding occurs between particular combinations of peptide and MHC. In 
general these algorithms have the same aim as otheralgo ithms in bioinformatics: to 
identify patterns in sequences that are known to either possess or not possess a particular 
trait. In this case the trait is binding to a particular MHC molecule. Statistical methods of 
varying degrees of complexity have been applied to peptide-MHC binding prediction. 
The simplest algorithms were based on the identifica on of motifs within peptides 
binding particular MHC (Rammensee 1995). An example of such a motif is the 
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requirement for a hydrophobic amino acid at the N-terminus (position 1) of a 9mer to 
bind MHC of the DR1 serotype, a guideline still generally followed today (Southwood et 
al. 1998). The advent of competitive binding assays allowed a more nuanced view of 
binding. Motifs that required certain amino acids to be present in MHC-binding peptides 
were superseded by matrices scoring amino acids at each position within the peptide. 
Different statistical methods could be used to generate the elements of the matrix, 
including nonlinear and linear programming (Parker et al. 1994, Murugan and Dai 2005), 
stepwise discriminant analysis (Mallios 1999, Mallios 2001), and partial least squares 
(Doytchinova and Flower 2002, Doytchinova and Flower 2003). One simplifying 
assumption made in many of these algorithms is that binding of each amino acid within 
the peptide to the MHC molecule occurs independently of adjacent as well as more distal 
amino acids. Though this assumption was largely confirmed by available crystal 
structures, algorithms were also developed that did not rely on this assumption based on 
machine learning methods. Several machine learning methods have now been 
incorporated into prediction algorithms including artificial neural networks (Brusic et al. 
1998, Honeyman et al. 1998, Milik et al. 1998, Buus et al. 2003), hidden Markov models 
(Noguchi et al. 2002), and support vector machines (Zhao et al. 2003, Bhasin and 
Raghava 2004). A different approach has been to predict the structure of the peptide-
MHC complex and attempt to calculate the free energy change (Altuvia et al. 1997, 
Schueler-Furman et al. 2000, Altuvia and Margalit 2004, Bui et al. 2006, Fagerberg et al. 
2006). Structure-based prediction may someday supplant statistical- or machine learning-
based algorithms but is currently hampered by the limited availability of solved structures 
and high computational costs. For a more comprehensiv  review of algorithms, the reader 
is referred elsewhere (Yu et al. 2002, Brusic et al. 2004). 
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1.6.1 Scoring Peptide-MHC Binding Prediction 
An obvious question to ask about the preceding list of algorithms is how well 
each one performs compared to the others. To gauge prediction accuracy an algorithm is 
typically trained on one set of data comprising peptide sequences and their affinities for a 
particular MHC molecule and used to make predictions  a test set of peptides for which 
the affinities are also known. Algorithm output is then compared to the known affinities 
using one of several possible scoring measures. However, this task is complicated by 
differences in the nature of the available binding data and algorithm outputs. In some 
cases, affinity is measured directly as a continuous variable, other times only indirectly as 
a discrete variable (binding or non-binding). Some databases provide only lists of 
peptides that either bind or do not bind particular MHC variants (Rammensee 1999) 
while other databases provide a direct measure of affinity such as IC50 (Toseland et al. 
2005). The appropriate scoring measure therefore diff rs according to whether known 
and predicted affinities are both continuous (Pearson correlation coefficient), both 
discrete (Matthews correlation coefficient), or discrete and continuous, respectively (area 
under receiver operating characteristic curve, or AROC). Both correlation coefficients vary 
between -1 and 1 while AROC ranges from 0.5 to 1.0. In both cases higher scores indicate 
more accurate predictions. Continuous data can be converted into discrete data by 
assuming that a certain threshold affinity is required for binding such as an IC50 of 500 
nM (Sette et al. 1994) allowing some overlap between performance measures. Examples 
of scores obtained for several algorithms are provided in MHCBench (Singh and 
Raghava 2001). For example, using binding data for HLA-DRB1*0401 from which 
homologous sequences were removed, twelve algorithms were found to produce AROC 
scores between 0.57 and 0.76. 
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1.7 Models of the APC 
Peptide-MHC binding is only one step of many that constitute the antigen 
presentation pathway, and other steps confer additional specificity to or alter the 
dynamics of which peptides are ultimately presented. In both MHC class I- and MHC 
class II-mediated antigen presentation, antigens are acquired (from either intracellular or 
extracellular sources), degraded into peptides (i.e., processed), and trafficked to the cell 
surface after binding MHC. At the same time MHC molecules are synthesized, trafficked 
between cellular compartments, and degraded. Many of these steps are subject to 
regulation by the cytokine environment and feedback signals. The peptides found to bind 
a particular MHC variant may therefore only provide a rough, static approximation of 
peptides that are ultimately presented in a dynamic fashion. 
Models of antigen presentation must therefore account for more than peptide-
MHC binding. In the case of MHC class I-mediated antigen presentation, at least two 
additional events are known to confer selectivity: proteasomal cleavage and TAP 
transport. Algorithms have been developed to predict which peptides progress through 
these stages, and only recently have they been linked with algorithms of peptide-MHC 
binding to represent antigen presentation in toto (Petrovsky and Brusic 2004, Donnes and 
Kohlbacher 2005). The result is a more accurate but still static picture of the peptides 
encountered by CD8+ T cells. 
1.7.1 ODE Models 
In contrast, previous models of MHC class II-mediated antigen presentation have 
focused on its dynamic aspects (e.g., times required for certain steps to be completed and 
levels of pMHC presented on the APC surface) but not necessarily its specificity. These 
previous models were based on a mathematical representation known as ordinary 
differential equations (ODEs) in which each variable represents the level of a different 
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molecular species at a particular time, e.g., the number of pMHC complexes appearing on 
the APC surface a certain number of hours after the APC encounters antigen. Processes 
affecting the level of each species are then represnt d as terms in the equation for each 
variable. For instance, in the case of surface pMHC complexes, one term might represent 
the trafficking of pMHC complexes from the interior f the APC to its surface. The 
equation itself would then represent the rate of change in this variable as the sum total of 
these constituent processes. 
ODEs are commonly used to represent systems that are both continuous and 
deterministic. One assumption inherent in the use of ODEs is that the represented entities 
exist as well-mixed populations, allowing their interactions to be approximated by the 
law of mass action. For MHC class II-mediated antigen presentation the available data 
validate this assumption. Baseline estimates of the number of MHC class II molecules 
expressed by APCs are on the order of 105 and antigen is typically present at high 
concentrations, at least in vitro (>1012 peptides per cell in Hmama et al. 1998 and Noss et 
al. 2000). Furthermore, precedent for using ODEs has been provided by models of 
receptor-ligand systems of which peptide-MHC could be considered one instance 
(Lauffenburger and Linderman 1993). 
Previous models have used ODEs to represent MHC class II-mediated antigen 
presentation with increasing levels of detail. The first published model included only 
those intracellular processes thought to be essential to antigen presentation (antigen 
uptake and processing, peptide-MHC binding, and MHC trafficking and recycling) but 
was sufficient to generate realistic time courses of peptide-MHC levels on the APC 
surface (Singer and Linderman 1990). Parameters that would have been difficult to 
manipulate experimentally, e.g., the rate of antige uptake, were easily varied in the 
model, allowing the relationship between such parameters and the number of pMHC on 
the APC surface to be studied without concerns of inhibitor toxicity, etc. In later versions 
of this model, additional molecular species such as self peptides and TCR were included, 
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expanding the range of questions that could be appro ched (Singer and Linderman 1991, 
Agrawal and Linderman 1996). 
1.7.2 Sensitivity Analysis 
The creation of a mathematical model for antigen presentation or any other 
phenomenon entails the estimation of parameter values. In most cases these parameters 
represent rate constants of chemical processes, initial values for numbers of molecules, or 
probabilities of an event. Parameter values may be estimated in one of several ways, 
including direct experimental determination, fitting such that model output matches 
experimental observation, or constraints based on known relationships to other 
parameters. Each of these cases involves some degree of uncertainty which leads to 
uncertainty in the output of the model. 
The effect of uncertainty in model parameter values on model output can be 
determined for any given model using sensitivity analysis. Different methods for 
sensitivity analysis exist, but all involve the correlation of variance in parameter values to 
variance in model output. For example, in the Latin hypercube sampling (LHS) 
algorithm, each parameter is first assigned a distribution, typically uniform or normal and 
centered on a baseline or estimated value, allowing the effect of under- and over-
estimation to be examined. The entire range of each distribution is then sampled to 
generate a set of values for each parameter, and parameter values for each simulation are 
chosen to cover the entire parameter space efficiently. The extent to which each 
parameter affects the output can then be quantified using one of several metrics such as 
the partial rank correlation coefficient (PRCC). PRCC, like the more familiar Pearson 
correlation coefficient, varies between -1 and 1 indicating strongly negative and positive 
associations, respectively. A PRCC of 0 indicates no association. PRCC values can also 
be calculated at different time points of the simulation allowing the relative importance of 
17 
a particular parameter in determining model output o be examined over time. In addition 
a confidence interval can be determined for each PRCC, and differences between PRCCs 
can be tested for statistical significance (Meng t al. 1992). This allows parameters to be 
ranked in order of effect on output by PRCC magnitude. 
Sensitivity analysis identifies processes that are important to the behavior of the 
system. These processes may represent potential targets for therapeutic intervention; that 
is, one could target a pathway to which cell behavior is sensitive as identified by 
sensitivity analysis.  
1.8 Models of the T Cell 
Models of the APC provide a useful view of the first stages of the immune 
response but are limited if T cell response is not also considered. T cells provide 
functional responses to the appearance of pMHC on the APC surface, and several models 
have sought to capture different aspects of T cell activation. 
Some models have focused on the level of receptor-ligand engagement and how 
the kinetics of pMHC-TCR binding influence downstream events. For instance, in the 
model of Coombs et al. (2002), pMHC-TCR complexes are depicted in discrete, 
progressive states of activation, culminating in fully activated TCR that can either be 
internalized or return to a basal, inactivated state. Three zones of the surfaces of APCs 
and T cells are represented: a contact area, transition region, and remainder of the cell 
surfaces. pMHC-TCR binding occurs only within the contact area, though activated 
forms of the TCR are allowed to persist in the transition region. To represent pMHC and 
TCR, partial differential equations (PDEs) are used, allowing the level of each molecular 
species to be tracked with respect to a given distance way from the center of the contact 
area as well as a given time. TCR internalization serves as the output of this model, 
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occurring only after TCR are fully activated and free from pMHC in either the contact 
area or the transition region. 
Using this model, Coombs et al. (2002) found that an optimal half-life for the 
pMHC-TCR complex might exist resulting in maximal TCR internalization. This optimal 
half-life occurs as a result of competition between s rial engagement (the ability of a 
single pMHC to activate multiple TCRs, favoring a short half-life) and kinetic 
proofreading (the requirement for a pMHC-TCR complex to remain bound long enough 
to result in activation, favoring a long half-life). Subsequent iterations of this model 
recapitulated other experimental phenomena including the dissipation of an optimal half-
life at high initial pMHC densities (Gonzalez t al. 2005, Utzny et al. 2006). 
Other models have focused on signaling occurring within the T cell after TCR 
activation. For example, in the ODE model of Chan et al. (2004), two signaling 
molecules, a kinase (such as Lck) and a phosphatase, are depicted generically in 
inactivated and activated forms. pMHC-TCR binding leads to activation of the kinase 
which in turn promotes activation of the phosphatase  well as further activation of 
itself. The activated phosphatase then returns the kinase to its inactivated form. Two 
feedback loops are therefore represented, one positive (the kinase on itself) and the other 
negative (the phosphatase on the kinase). Like the model of Coombs et al. (2002), this 
model, which uses amount of activated kinase as its readout, shows how T cell response 
is sensitive to the kinetics of pMHC-TCR binding. Altan-Bonnet and Germain (2005) 
later created a model with similar feedback structure but focused on the role of one 
signaling pathway in particular, the MAP kinase cascade. 
1.9 Motivation and Goals 
Antigen presentation traverses several spatial and temporal scales in its 
mechanisms and its effects (Fig. 1.1). At the molecular scale, peptide-MHC binding must 
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occur but is by no means automatic. Variability exists in peptide sequence as well as in 
MHC sequence. At the cellular scale, a number of prcesses contribute to the appearance 
of pMHC complexes on the APC surface but many of these may be disrupted by 
pathogens. Finally, at the multi-cellular scale, the pMHC signal must be delivered to the 
T cell to attain a response, but the kinetics of pMHC-TCR binding or other, intracellular 
processes may determine whether this occurs. 
Therefore, a model of antigen presentation must account for events occurring at 
each of these scales. In the following chapters I describe how I developed computational 
models at each scale and applied them to questions, initially scale-specific and then more 
multi-scale in nature. I also describe how I applied the models to the study of tuberculosis 





Figure 1.1. Multiple scales involved in antigen presentation. 
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Why M. tuberculosis Has Multiple Mechanisms to Inhibit Antigen Presentation 
2.1 Introduction 
Macrophages play dual roles during tuberculosis (TB) infection (Fenton 1998). 
On the one hand, they serve as the preferred host for Mycobacterium tuberculosis (Mtb), 
the intracellular pathogen that causes TB. On the or hand, they also help to alert the 
immune system to the presence of Mtb and, if activated, can eliminate it directly. 
Activation depends on the presentation of antigenic peptide-MHC class II (pMHC) 
complexes on the macrophage surface that can bind T cell receptors (TCRs) on cognate 
CD4+ T helper cells. pMHC-TCR binding induces CD4+ T helper cells to secrete IFN-γ 
which stimulates macrophages to produce molecules capable of killing Mtb such as nitric 
oxide (Chan et al. 2001). This process constitutes an important arm of cell-mediated 
immunity and may determine infection outcome (Kaufmann 1999). 
The fact that Mtb inhibits antigen presentation in macrophages is now well 
established (Pancholi et al. 1993). Initial studies showed that fewer macrophages infected 
with mycobacteria express detectable levels of antige  on their surface compared to 
uninfected macrophages (Kaye et al. 1986, Mshana et al. 1988).  Functional assays later 
confirmed that infected macrophages are deficient in their ability to signal CD4+ T helper 
cells by measuring T cell response. The magnitude of T cell response is in turn 
proportional to pMHC levels, assuming a lower thresold number of pMHC complexes 
has been exceeded (Bekkhoucha et al. 1984, Demotz et al. 1990). Using such an assay 
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Gercken et al. (1994) found that monocytes co-cultured with Mtb for six days exhibit a 
three- to ten-fold reduction in their ability to stimulate T cell proliferation compared to 
uninfected controls. Furthermore, higher numbers of Mtb bacilli, e.g., MOI (multiplicity 
of infection) of 50 versus MOI of 10, correlated with lower T cell response levels. 
Subsequent studies provided further evidence that an inverse relationship exists between 
Mtb infectious dose and T cell response (Noss et al. 2000, Mazzaccaro et al. 1996). 
After it was established that Mtb inhibits antigen presentation in macrophages, 
several intracellular mechanisms were proposed (reviewed in Harding et al. 2003). 
Moreno et al. (1988) observed that macrophages co-cultured with the Mtb cell wall 
component lipoarabinomannan (LAM) fail to present aigen from whole inactivated 
virus though presentation of synthesized epitope is un mpaired. This observation led to 
the hypothesis that Mtb inhibits antigen presentation at the stage of antige  processing, a 
hypothesis also made by Noss et al. (2000). Later, based on the observation that Mtb-
infected monocytes do not produce stable pMHC complexes and do not localize labeled 
MHC class II molecules and antigens to the same intracellular compartment, Hmama et
al. (1998) proposed that Mtb affects MHC class II at a post-translational stage such as 
maturation (delivery to the MIIC endosome or Ii processing) or peptide loading. Finally, 
based on the observation that infected macrophages express lower levels of MHC class II 
mRNA than uninfected macrophages, Noss et al. (2000) proposed that Mtb inhibits MHC 
class II mRNA synthesis. 
The goal of the present study is to investigate why multiple mechanisms have 
been proposed to explain how Mtb inhibits antigen presentation. In particular, we address 
three issues using a mathematical model: (1) what purpose multiple mechanisms may 
serve, (2) if experimental protocols may have favored the detection of some mechanisms 
over others, and (3) if alternative mechanisms exist that may be used to guide future 
experiments. Our immediate motivation stems from conflicting data in the literature 
regarding these mechanisms. Specifically, we refer to the observation by Hmama et al. 
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(1998) that MHC class II mRNA levels were unchanged in infected cells and the 
observation by Noss et al. (2000) that MHC class II mRNA levels decreased in infected 
cells. Because the two studies differed with respect to experimental conditions (e.g., 
macrophage cell type, Mtb strain, and degree of IFN-γ-induced activation), it is unclear if 
the conclusions hold in general. We seek to help clarify these observations with our 
model. 
2.2 Methods 
2.2.1 Model Overview 
Our mathematical model comprises a set of ordinary differential equations 
representing the major intracellular processes thatcontribute to antigen presentation 
within the context of a single macrophage (Fig. 2.1). These processes relate to MHC class 
II expression (at both mRNA and protein levels), antigen processing, and peptide-MHC 
binding and trafficking and include the processes hypothesized to be targeted by Mtb. 
Our model also accounts for the effects of IFN-γ which is typically added to cultured 
macrophages during studies on antigen presentation (Hmama et al. 1998, Noss et al. 
2000). 
To represent these processes we use ordinary differential equations which allow 
large numbers of molecules to be tracked. For each molecular species we derive an 
equation for the rate of change using the law of mass ction and estimate parameter 
values using published experimental data. In total ur model uses 16 equations and 30 
parameters to simulate antigen presentation within t e context of a single macrophage. 
Equations and parameter values, as well as details of how equations were derived and 
parameter values estimated, can be found in Supporting Information. 
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2.2.2 Simulations Using the Mathematical Model 
The baseline model comprises Equations 1-16, the parameters in Table 2.3, and 
the initial conditions in Table 2.4 (Supporting Information). Protocol-specific parameter 
values and initial conditions can also be found in Supporting Information. To generate 
simulations using the mathematical model, we use the NDSolve function of Mathematica 
v4.2 (Wolfram Research, Inc.) as well as our own differential equation solver coded in C 
and run on Sun UNIX machines for confirmation of numerical results. We analyze model 
output in terms of major features such as relative changes in numbers of molecules and 
times at which highest levels are reached. As a marker for antigen presentation, we 
generally use the number of surface-localized exogen us peptide-bound MHC class II 
molecules (Equation 16, Supporting Information). 
2.2.3 Representation of the Inhibitory Effects of Mtb on Intracellular Processes 
To represent the inhibitory effect that Mtb is hypothesized to have on an 
intracellular process, we decrease the corresponding parameter in the model by a factor 
proportional to experimental infectious dose. We assume that the number of Mtb bacilli 
does not change significantly on the timescales of the protocols being simulated based on 
the observation that the doubling time of Mtb is on the order of days (Dunn and North 
1995). We also assume that the inhibitory effect exert d by Mtb on any given 
intracellular process saturates at high levels of bacilli. Therefore, we represent the 
inhibitory effect as a multiplicative factor having a value between 0 and 1 (corresponding 
to complete inhibition and no inhibition, respectively) that approaches 0 as the number of 
bacilli increases. Further details are provided in Supporting Information. 
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2.2.4 Sensitivity Analysis 
The goal of sensitivity analysis is to correlate variances in parameter values to 
variances in model output and is useful when parameter values are not known with 
certainty. Sampling-based sensitivity analysis entails specifying a distribution for each 
parameter from which values are selected at random and used in model simulations 
(Helton and Davis 2001). In particular we use Latin hypercube sampling which allows 
several parameters to be analyzed simultaneously in a computationally efficient manner. 
To quantify the correlation of model output with each parameter, we calculate a partial 
rank correlation coefficient (PRCC) value. PRCC values vary between -1 and 1, 
corresponding to perfect negative and positive correlations, respectively, and can be 
further differentiated based on p values derived from Student’s t-tests. We use the 
algorithm of Blower and Dowlatabadi (1994) implemented in both Mathematica and our 
own differential equation solver. In general, we specify a uniform distribution for each 
parameter with a range of 10% and 190% of the baseline value, allowing us to examine 
the effects of both decreases and increases in each parameter. 
2.3 Results 
2.3.1 Baseline Characteristics 
In the absence of IFN-γ and antigen, conditions that we used as a negative control, 
seven molecular species in the model were present in on-zero quantities: free IFN-γ 
receptors, MHC class II mRNA, free intracellular and surface MHC class II molecules, 
self peptides, and intracellular and surface self pptide-MHC class II complexes. These 
results are consistent with the finding that cultured macrophages constitutively express 
several molecules relevant to antigen presentation at basal levels including IFN-γ 
receptors and MHC class II molecules (Hume 1985, Celada et al. 1985). 
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2.3.2 Dynamics of IFN-γ Response 
As one positive control we simulated the addition of IFN-γ to macrophages and 
compared dynamics of the response to experimental observations. In response to IFN-γ 
treatment, CIITA mRNA levels in the model increased immediately and reached a 
maximum approximately 14 hours later, while MHC class II mRNA levels increased 
more gradually and continued to increase for the first 24 hours (Fig. 2.2A). Pai et al. 
measured levels of CIITA and MHC class II mRNAs 6, 12 and 24 hours after adding 
IFN-γ and observed highest levels at the 12- and 24-hour time points, respectively, in 
agreement with our model (Fig. 2.2B, Pai et al. 2002). We also compared the coupled 
dynamics of MHC class II mRNA and protein expression from our model to 
experimental data. In our simulations highest MHC class II mRNA and protein levels 
were attained approximately 45 and 60 hours after IFN-γ treatment, respectively (Fig. 
2.2C). In comparison, highest MHC class II mRNA and protein levels were observed 
experimentally 48 and 72 hours after IFN-γ treatment, respectively (Fig. 2.2D, Cullell-
Young et al. 2001). Although MHC class II protein expression reaches its highest levels 
in the model in less time than observed experimentally, this apparent difference may be 
attributable to the sparseness of experimental time points. 
2.3.3 Dynamics of Antigen Presentation 
In the presence of exogenous antigen the number of surface pMHC complexes in 
our model rapidly increases, reaches a maximum approximately 3 hours later, and then 
decreases over the course of several hours (Fig. 2.2E). Antigen presentation by 
macrophages not pretreated with IFN-γ has been found to exhibit similar dynamics 
experimentally (Fig. 2.2F, Buus and Werdelin 1986, Ziegler and Unanue 1981). In such 
cases antigen presentation can be detected by T cell hybridoma assay minutes after the 
addition of antigen (Buus and Werdelin 1986, Ziegler and Unanue 1981). These 
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macrophages elicit maximal responses after one to four hours and remain capable of 
eliciting responses at the same or slightly decreased levels for several more hours (Buus 
and Werdelin 1986, Ziegler and Unanue 1981). Another feature of our model is dose-
dependence between exogenous antigen concentration and maximum number of resultant 
surface pMHC complexes (data not shown) which has also been observed experimentally 
with T cell responses (Demotz et al. 1990, Reske-Kunz et al. 1984). 
2.3.4 Increases in Antigen Presentation Due to IFN-γ Pretreatment 
Experimental studies on antigen presentation by macrophages typically use both 
IFN-γ and exogenous antigen. Timing of IFN-γ treatment may be important, as studies in 
which IFN-γ is added prior to antigen show that pretreated macrophages are capable of 
eliciting T cell responses at levels several fold higher than untreated macrophages 
(Delvig et al. 2002). We simulated the addition of IFN-γ 16 h prior to exogenous antigen 
and observed a two-fold increase in surface pMHC levels compared to untreated levels 
(Fig. 2.2G). This result is consistent with T cell proliferation data from Delvig et al. 
(2002) (Fig. 2.2H). In subsequent simulations we avoided the issue of pretreatment 
timing by using the simultaneous addition of IFN-γ and antigen unless stated otherwise. 
2.3.5 Simulations of Mtb and Its Hypothesized Mechanisms 
After testing the model under the preceding conditions, we used the model to 
simulate the inhibition of various intracellular processes targeted by Mtb. These processes 
included: antigen processing (Moreno et al. 1998), MHC class II protein maturation 
(Hmama et al. 1998), MHC class II peptide loading (Hmama et al. 1998), and MHC class 
II mRNA synthesis which we consider MHC class II transcription (Noss et al. 2002); we 
designate these hypotheses as H1, 2, H3, and H4, respectively. We then simulated the 
simultaneous addition of IFN-γ and antigen and recorded surface pMHC levels at time
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points spanning four orders of magnitude (0.1, 1.0,0, and 100 hours). These results 
were compared to results from the baseline model in which no processes were inhibited. 
In general, inhibiting any particular intracellular p ocess had either immediate or 
delayed effects on antigen presentation (Table 2.1). When antigen processing (H1) or 
MHC class II peptide loading (H3) was inhibited, surface pMHC levels were immediately 
affected as indicated at the earliest time point, 0.1 h. The deviation from baseline levels 
was reduced at intermediate 1 h and 10 h time points a d then increased by the final 100 
h time point. In contrast, inhibition of MHC class II maturation (H2) or MHC class II 
transcription (H4) resulted in negligible reductions in surface pMHC levels at the 0.1 h 
time point. However, these levels increasingly deviated from baseline levels at 1 h, 10 h, 
and 100 h time points. Both H2 and H4 targeted MHC class II expression and required a 
delay of at least 10 h to have substantial effects (greater than 25% change in surface 
pMHC levels). We also simulated the inhibition of pairs of intracellular processes to 
determine the effect multiple mechanisms may have on antigen presentation when acting 
together (cf. H1+H4 and H2+H3 in Table 2.1). Inhibitory mechanisms were synergistic and 
decreased antigen presentation levels to a greater x nt in pairs than singly. In these 
simulations each intracellular process was inhibited to the same degree. In a separate set 
of simulations we used varying degrees of inhibition, further differentiating mechanisms 
targeting MHC class II expression from other mechanisms (Fig. 2.5, Supporting 
Information). 
2.3.6 Simulations of Previous Experimental Protocols 
To determine if previous experimental protocols may h ve favored the detection 
of some mechanisms over others and if any of the four previously hypothesized 
mechanisms could account for all of the observed changes in macrophages infected with 
Mtb, we simulated two different experimental protocols under each hypothesized 
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mechanism (Hmama et al. 1998, Noss et al. 2000). These protocols differed in several 
ways that could be accounted for in our model, including duration for which cells were 
exposed to IFN-γ and Mtb as well as concentration of IFN-γ and number of Mtb bacilli 
used (Fig. 2.3A, B). These protocols also differed with respect to the macrophage cell 
line and Mtb strain used, but these factors fell outside the scope of our model and were 
not considered. 
In our simulations of the experimental protocol of Hmama et al. (1998), we found 
that only an inhibition of MHC class II protein maturation (H2) was consistent with all of 
their observations. In the absence of Mtb the levels of several molecules rose over 
baseline levels during the course of this protocol including CIITA mRNA, MHC class II 
mRNA, and MHC class II protein (Fig. 2.3C, D, E). Only H2 and another hypothesized 
mechanism, inhibition of MHC class II transcription (H4), led to reductions in surface 
MHC class II expression of the same magnitude as tho e observed by Hmama et al. 
(1998): 42% and 86% using heat-killed and live Mtb bacilli, respectively (Fig. 2.3E). 
However, H4 also led to a significant reduction in MHC class II mRNA levels which was 
not observed by Hmama et al. (1998) and could therefore be ruled out as a possible 
mechanism (Fig. 2.3D). 
When we simulated the experimental protocol of Noss et al. (2000), we found that 
only an inhibition of MHC class II transcription (H4) was capable of producing 
substantial changes in the levels of all three molecules they monitored. In our simulations 
this mechanism reduced levels of MHC class II mRNA, total MHC class II protein, and 
surface pMHC by 54%, 31%, and 31%, respectively (Fig. 2.3F, G, H). Another 
mechanism, inhibition of MHC class II protein maturation (H2), reduced levels of these 
molecules by 0%, 55%, and 55%, respectively (Fig. 2.3F, G, H). In comparison, Noss et 
al. (2000) measured reductions of 80%, 30%, and between 40% and 80%, respectively, 
consistent with H2 but not H4. Interestingly, in our simulations of this protocol neither 
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inhibition of antigen processing (H1) nor inhibition of MHC class II peptide loading (H3) 
had any significant effect on surface pMHC levels (Fig. 2.3H). 
2.3.7 Sensitivity to Changes in Other Intracellular Processes 
While many intermediates of the antigen presentation pathway have been 
monitored in macrophages following Mtb infection in vitro (Hmama et al. 1998), assays 
for other processes represented in our model have eith r not been developed or not been 
applied to this context. To determine what effect changes in these processes might have 
on antigen presentation, we varied all of the corresponding rates, rate constants, and 
scaling factors as well as experimental conditions in the model over a defined range and 
tracked surface pMHC levels over time. We then calcul ted the correlation between these 
levels and specific parameter values at 1 h, 10 h, and 100 h time points. 
We found that surface pMHC levels correlated signifcantly with a number of 
different intracellular processes, including several not previously considered (Table 2.2). 
In particular, at times less than 10 hours following exposure to IFN-γ and antigen, surface 
pMHC levels correlated positively with rate constants for antigen uptake by pinocytosis 
and MHC class II trafficking to the cell surface as well as with the concentration of 
exogenous antigen. When the concentration of exogenous antigen was sufficiently low, 
other processes correlated strongly with surface pMHC levels on this timescale including 
delivery of antigen to lysosomes and self peptide production (data not shown). At times 
greater than 10 hours following exposure to IFN-γ and antigen, surface pMHC levels 
correlated with factors affecting MHC class II expression including CIITA transcription 
and translation and the concentration of IFN-γ in the medium as well as MHC class II 
transcription and protein maturation. 
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2.4 Discussion 
Multiple hypotheses have been offered to explain how Mtb inhibits antigen 
presentation in macrophages to escape immune surveillanc . These hypotheses stem from 
different experimental protocols that appear in at least one instance to have led to 
conflicting results. In this study we address why several mechanisms have been 
hypothesized by formulating a mathematical model of antigen presentation that accounts 
for different experimental conditions and can be usd to simulate each mechanism. 
2.4.1 Mtb Mechanisms Differ in Timing of Effect 
We found that hypothesized Mtb mechanisms generally fall into one of two 
categories: those having an immediate effect on the ability of the cell to present antigen 
and those requiring a delay of approximately 10 hours to have an effect. The first subset 
of mechanisms targets intracellular processes involved in the initial formation of pMHC 
complexes including antigen processing and MHC class II peptide loading. In our 
simulations the effectiveness of these mechanisms in inhibiting antigen presentation 
decreased after an intermediate length of time (at 1 h and 10 h) and later increased (at 100 
h). The intermediate decrease resulted from new rounds of pMHC binding resulting from 
prolonged exposure to IFN-γ and increasing numbers of free MHC class II. The second 
subset of mechanisms targets intracellular processes necessary for the continued supply 
of nascent MHC class II molecules including MHC class II transcription and protein 
maturation. In our simulations the effect of these m chanisms on antigen presentation 
steadily increased over time as a greater proportion of surface pMHC complexes involved 
nascent MHC class II. 
These results are consistent with the intuitive notion hat disruptions at different 
points along the antigen presentation pathway, or any multi-enzymatic pathway, require 
different lengths of time to manifest in the end product. These results are also consistent 
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with the interpretation of the experimental data of N ss et al. (2000) given by Heldwein 
and Fenton (2002), that substantial inhibition of MHC class II expression requires 
prolonged (> 18 h) incubation with Mtb. The requirement of a delay of greater than 10 
hours for inhibition of MHC class II expression to affect antigen presentation was also 
evident in our sensitivity analysis. 
The fact that these four hypothesized mechanisms appear to impair the same 
cellular function, antigen presentation, raises the qu stion: do these mechanisms serve the 
same purpose and act redundantly or do they serve subtly different purposes? Our results 
suggest that these mechanisms act on different timescal s and therefore serve different 
purposes. As demonstrated in our simulations of pairs of mechanisms, having 
mechanisms that operate on both shorter and longer tim scales may allow Mtb to exert 
continuous inhibition on antigen presentation despit  external sources of IFN-γ. In 
contrast, having only a single mechanism or multiple mechanisms that act on the same 
timescale may result in an inhibitory effect that eith r abates with time (if MHC class II 
expression increases) or is delayed. 
Nascent and recycling MHC class II molecules may have distinct roles in antigen-
presenting cells (Pinet and Long 1998), and Mtb may have evolved mechanisms to 
undermine both sources of MHC class II. T cells require at least 2 to 4 hours of 
stimulation to become fully activated (Weiss et al. 1987), and mechanisms acting on 
timescales of both minutes and hours may be physiologically relevant. A recent study by 
Huppa et al. shows that signaling between an antigen-presenting cell and a T cell has a 
cumulative effect over 10 hours and is sensitive to disruptions that occur even several 
hours after initial contact (Huppa et al. 2003). 
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2.4.2 Previous Protocols Favor Detection of Mechanisms Targeting MHC Expression 
Our simulations of previous experimental protocols suggest that Mtb mechanisms 
targeting MHC class II expression may have been responsible for most of the changes 
observed in levels of various molecules. Specifically, in simulations of the protocols of 
Hmama et al. (1998) and Noss et al. (2000), only mechanisms targeting processes 
associated with MHC class II expression were found to produce changes of the same 
magnitude as those observed. While no single mechanism was found to account for all of 
the observations, these results do support the individual conclusions of Hmama et al. 
(1998) and Noss et al. (2000) who implicated inhibition of MHC class II protein 
maturation and MHC class II mRNA synthesis, respectiv ly. 
Why did Noss et al. (2000) observe a decrease in MHC class II mRNA levels but 
not Hmama et al. (1998)? Noss et al. (2000) attribute this discrepancy to differences in 
macrophage cell lines, macrophage activation, and infection lengths and methods. Our 
model accounts for some of these factors, including o e aspect of macrophage activation 
(IFN-γ-stimulated MHC class II expression) and one consequence of infection length 
(inhibition of particular intracellular processes), as well as experimental differences in 
duration of IFN-γ stimulation and amount of IFN-γ used. In our model, none of these 
factors accounted for the observed discrepancy in MHC class II mRNA levels. 
Hmama et al. (1998) and Noss et al. (2000) also hypothesized that Mtb inhibits 
either MHC class II peptide loading or antigen processing. Our simulations show that 
neither of these mechanisms could have accounted for the observed changes in levels of 
molecules given the experimental protocols that were used. On the timescales of both 
protocols MHC class II expression is expected to be the limiting factor on antigen 
presentation as suggested by the half life of MHC class II and our sensitivity analysis. 
Indeed, in the protocol used by Noss et al. (2000), we predict that the high level of MHC 
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class II expression masks whatever reductions in antigen presentation may result from an 
inhibition of antigen processing or MHC class II peptide loading. 
Because these experimental protocols may have favored the detection of 
mechanisms targeting MHC class II expression, the actual contribution of mechanisms 
targeting other processes to the overall ability of Mtb to inhibit antigen presentation may 
not have been accurately assessed. Without experimental vidence to the contrary, the 
possibility even exists that mechanisms targeting atigen processing and MHC class II 
peptide loading are incidental to Mtb infection and do not significantly affect the ability 
of macrophages to present antigen in the presence of IFN-γ. While an experiment using 
an Mtb mutant specifically unable to inhibit either intracellular process would quickly 
answer this question, such a mutant is not yet available to our knowledge. 
Therefore, we propose an alternative experimental protocol to determine whether 
mechanisms targeting intracellular processes besides MHC class II expression actually 
contribute to the ability of Mtb to inhibit antigen presentation (Fig. 2.4A). In this protocol 
macrophages are infected with Mtb in vitro and treated with IFN-γ for varying durations 
prior to assaying for antigen presentation using model antigen and T cell hybridoma. If 
mechanisms targeting MHC class II expression are the only means by which Mtb inhibits 
antigen presentation, the difference in the levels of T cell response (e.g., IL-2 production) 
elicited by uninfected and infected macrophages should increase as the duration of IFN-γ 
stimulation increases (Fig. 2.4B). On the other hand, if mechanisms targeting other 
intracellular processes play a significant role in the inhibition of antigen presentation, the 
difference in T cell response should be apparent even with short durations of IFN-γ 
stimulation and remain relatively constant as the duration of IFN-γ stimulation increases. 
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2.4.3 Additional Mechanisms May Target Other Processes Affecting Presentation 
As part of our analysis we also identified all of the parameters in our model that 
strongly correlate with the number of pMHC complexes on the macrophage surface. 
These parameters represent intracellular processes likely to affect antigen presentation if 
perturbed and may serve as attractive targets to pathogens that evade immune 
surveillance such as Mtb. Other processes related to MHC class II expression, besides 
those already considered by previous hypotheses, strongly correlated with surface pMHC 
levels at long timescales. Recent evidence indicates that one of these processes, CIITA 
transcription, may be targeted by Mtb (Kincaid and Ernst 2003, Pai et al. 2003). It would 
be interesting to test experimentally whether Mtb also affects any other candidate process 
such as IFN-γ receptor-ligand binding. 
We found that several intracellular processes also negatively correlated with 
antigen presentation. In contrast to positively correlated processes such as those in Table 
2.1, these processes are expected to inhibit antigen pr sentation if up-regulated rather 
than down-regulated. In the presence of low levels of exogenous antigen, one such 
process is the delivery of antigens (both self and exogenous) and derived peptides to 
MHC class II-inaccessible lysosomes. Conceivably, an intracellular pathogen such as Mtb 
could decrease the availability of its own antigens by increasing the rate at which this 
process occurs, though benefit to the pathogen may be somewhat offset by a concurrent 
decrease in competing self antigens (Chicz et al. 1993, Rosloniec et al. 1990). 
Nevertheless, the possibility that some pathogens up-regulate delivery to lysosomes 
cannot be ruled out since the rate of this process and the concentration of self peptide 
have not been carefully measured. 
Most of the experimental data on which we base our model originates from 
studies using murine cell lines. Therefore, the dynamics of human macrophages infected 
with Mtb may differ somewhat from those observed in our simulations. However, based 
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on our sensitivity analysis, we believe that our results are robust and can be generalized 
to the human host. 
2.5 Supporting Information 
2.5.1 IFN-γ Receptor-Ligand Binding 
IFN-γ binds to receptors on the macrophage surface, initiat g a cascade of events 
leading to an increase in MHC class II expression (Steimle et al. 1994). We assume that 
this increase is the primary mechanism by which IFN-γ facilitates antigen presentation. 
To represent IFN-γ receptor-ligand binding, we use the general reaction scheme ligand + 
receptor ↔ complex. Other processes are likely to affect the number of IFN-γ receptor-
ligand complexes on the time scales of IFN-γ treatment used experimentally, 20-36 hours 
(Hmama et al. 1998, Noss et al. 2000). Celada et al. (1984) observed that IFN-γ levels in 
solution decrease 13% and 83% after 4 h in the absence and presence of macrophages, 
respectively, indicating that appreciable levels of IFN-γ both degrade in solution and are 
taken up by macrophages. Therefore, in addition to representing IFN-γ receptor-ligand 
binding, we also represent degradation of IFN-γ in solution and within the macrophage 
following uptake (Eqns. 2.1-3). 
dG/dt = (−kon-IFN-γ G R + koff-IFN-γ C) [ncells / (NA vrxn)] − kdeg-IFN-γ G [2.1] 
dR/dt = −kon-IFN-γ G R + koff-IFN-γ C + krecyc C [2.2] 
dC/dt = kon-IFN-γ G R − koff-IFN-γ C − krecyc C [2.3] 
where G is the molar concentration of IFN-γ in the medium and R and C are the numbers 
of free IFN-γ receptors and IFN-γ receptor-ligand complexes on the surface of each 
macrophage, respectively. Values for the parameters ncells, the number of macrophages to 
which IFN-γ is added, and vrxn, the volume of the medium containing both IFN-γ and 
macrophages, depend on the protocol being simulated, n  NA is Avogadro’s number. 
Values for kon-IFN-γ and koff-IFN-γ, the association and dissociation rate constants of the IFN-
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γ receptor-ligand complex, can be found in the literatu e (Sadir et al. 1998), while a value 
for kdeg-IFN-γ, the rate constant for the degradation of IFN-γ in solution, can be derived 
from the observed decrease in IFN-γ levels when macrophages are not present if first-
order decay is assumed (Celada et al. 1984). We estimate a value for krecyc, the rate 
constant for receptor internalization and recycling, to match the observed decrease in 
IFN-γ levels when macrophages are present (Celada et al. 1984), given the experimental 
conditions of that study. Celada et al. (1985) also found that the total number of IFN-γ 
receptors on the surface of the macrophage, Rtot, does not change over time in the 
presence of IFN-γ. Therefore, we assume that Rtot is constant, allowing either Eqn. 2.2 or 
Eqn. 2.3 to be eliminated when the formula Rtot = R + C is used to derive an expression 
for either R or C. In all of our simulations, we set the initial conditions for R and C to Rtot 
and 0, respectively. 
2.5.2 MHC Class II Transcription 
The formation of IFN-γ receptor-ligand complexes on the macrophage surface 
activates the Jak-Stat signaling pathway, increasing CIITA expression over its basal level 
(Darnell et al. 1994, Steimle et al. 1994). Because CIITA expression may be delayed by 
as much as two hours in response to IFN-γ (Morris et al. 2002) and this delay may 
contribute to the longer delay observed prior to an increase in MHC class II expression 
(Cullell-Young et al. 2001), we represent both CIITA and MHC class II at the mRNA 
and protein levels explicitly in the model (Eqns. 2.4-6 and 11). To represent transcription 
and translation, we use the same basic formulation as Maynard Smith (1968). Nascent 
MHC class II molecules undergo several posttranslation l events, including coupling of 
constituent subunits to invariant chain (Ii), transport through the transGolgi network, and 
degradation of Ii into class II-associated invariant chain peptide (CLIP) (Hudson and 
Ploegh 2002). The presence of low levels of mature MHC class II molecules in 
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unstimulated macrophages suggests that these processes occur constitutively (Hume 
1985). We do not distinguish these processes in our model but refer to them collectively 
as MHC class II protein maturation. In practice, weconsider MHC class II protein 
maturation to be part of MHC class II translation which we represent in our model 
explicitly. There is evidence that IFN-γ up-regulates MHC class II translation 
independent of its effect on MHC class II transcription (Cullell-Young et al. 2001). 
Therefore, we represent IFN-γ receptor-ligand complexes as having an effect on bth 
processes (Eqns. 2.4 and 11). 
dT1/dt = ktxn1 (1 + α C / Rtot) − kdeg-mRNA1 T1 [2.4] 
dP/dt = ktsl1 T1 − kdeg-P P [2.5] 
dT2/dt = ktxn2 P − kdeg-mRNA2 T2  [2.6] 
where T1, P, and T2 are levels of CIITA mRNA, CIITA protein, and MHC class II mRNA 
per macrophage, respectively. ktxn1, ktsl1, and ktxn2 are rate constants for CIITA 
transcription, CIITA translation, and MHC class II transcription, whereas kdeg-mRNA1, kdeg-
P, and kdeg-mRNA2 are rate constants for degradation of CIITA mRNA, CIITA protein, and 
MHC class II mRNA, respectively. We assume that unstimulated macrophages possess 
steady-state levels of CIITA mRNA, CIITA protein, and MHC class II mRNA (i.e., T1’ = 
0 h-1, T1 = T1,0, P’ = 0 h
-1, P = P0, T2’ = 0, and T2 = T2,0 when C = 0 mol L
-1), allowing 
values for ktxn1, ktsl1, and ktxn2 to be estimated from known values of kdeg-mRNA1, kdeg-P, and 
kdeg-mRNA2. The quantity C/Rtot represents the fraction of surface IFN-γ receptors occupied 
at any given time, while α is a scaling factor for CIITA transcription. We assume that the 
rate of CIITA transcription increases linearly with e fraction of occupied IFN-γ 
receptors based on receptor occupation theory (Kenakin 1987) and observed correlation 
between IFN-γ receptor occupancy and tumoricidal activity in macrophages (Celada and 
Schreiber 1987). The scaling factor α allows MHC class II mRNA levels in the model to 
match increases observed experimentally in response t  IFN-γ. To find a value for α, we 
simulate the experimental conditions used in two studies (Cullell-Young et al. 2001, Pai 
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et al. 2002) and approximate values for α that most closely yield the observed maximal 
increases in MHC class II mRNA. 
2.5.3 Exogenous Antigens 
Exogenous antigens generally enter macrophage endosomes by pinocytosis, 
phagocytosis, or receptor-mediated endocytosis. Because soluble model antigens such as 
hen egg lysozyme are typically used to assess the ability of macrophages to present 
antigen in vitro (compare Gercken et al. 1994, Hmama et al. 1998, Noss et al. 2000), we 
represent only pinocytosis in the model (Eqns. 2.7 and 8). We assume that endocytosed 
antigens either undergo partial degradation resulting in the production of MHC class II-
binding peptides, i.e., antigen processing, or are transported to lysosomes and degraded. 
Although a small number of exogenous antigens may also be shunted to the MHC class I 
pathway (Yewdell et al. 1999), we do not consider the loss of antigen due to this pathway 
in the current model. We assume that peptides resulting from antigen processing then 
either bind MHC class II molecules or are transported to lysosomes and degraded (Eqn. 
2.9). The portions of our model representing antige processing as well as peptide-MHC 
class II binding are similar to those used in a simpler model by Singer and Linderman 
(Singer and Linderman 1990). 
dA*/dt = −(kpino ncells / vrxn) A* − kdeg-A* A*  [2.7] 
dA/dt = (kpino / vMIIC) A* − kdeg-A A − klys A  [2.8] 
dE/dt = kdeg-A A − kon-MHC M E + koff-MHC Me − klys E  [2.9] 
where A*, A, and E are molar concentrations of native antigen in the medium, native 
antigen in the endosomal compartments of each macrophage, and antigen-derived peptide 
in the endosomal compartments of each macrophage, respectively. Values for the average 
rate of pinocytic uptake, kpino, and the total volume of the MHC class II-accessible 
endosomal compartments, vMIIC, can be found in the literature (Dean 1979, Marsh et al. 
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1986). The parameters ncells and vrxn are the same as those found in Eqn. 2.1. We assume 
that the rate constant for the degradation of native antigen in the medium, kdeg-A*, has the 
same value as the rate constant for the degradation of IFN-γ in solution, kdeg-IFN-γ. The rate 
constant for antigen processing, kdeg-A, represents what is likely a group of reactions, 
including the unfolding of native antigen and proteolytic degradation by one or more 
cathepsin proteases. We derive a value for kdeg-A based on the length of time required for 
macrophages to degrade 50% of internalized mannosylated BSA (Diment and Stahl 
1985), assuming that processing of most antigens yields only one peptide capable of 
binding MHC class II. We also assume that all soluble materials in the endosomal lumen 
are delivered to MHC class II-inaccessible lysosomes with the same kinetics and that 
therefore a single rate constant for this process, klys, is sufficient. We derive a value for 
klys based on the length of time required for receptor degradation (Lauffenburger et al. 
1987). The rate constants kon-MHC and koff-MHC represent association and dissociation of 
pMHC complexes, respectively, and are described in more detail below. 
2.5.4 Self Peptides 
Macrophages constitutively produce a population of self-peptides capable of 
binding MHC class II molecules within endosomes (Chicz et al. 1993). In the absence of 
exogenous antigens, these peptides may bind 80% or more of available MHC class II 
molecules (Chicz et al. 1993). MHC class II-binding self-peptides are deriv d 
predominantly from transmembrane proteins including several MHC-related proteins 
(Chicz et al. 1992). In our model we consider both MHC-derived an non-MHC-derived 
self-peptides as a single population (Eqn. 2.10). We treat self-peptides similarly to 
peptides derived from exogenous antigen and assume that they either bind MHC class II 
molecules or are transported to lysosomes and degrad. Our treatment of self-peptides is 
similar to that used in a previous model by Singer and Linderman (1991). 
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dS/dt = ksource + [kdeg-MHC (Ms + Ms* ) – kon-MHC M S + koff-MHC Ms] [1 / 
(NA vMIIC)] – klys S  
[2.10] 
where S is the molar concentration of self-peptides within macrophage endosomes and M, 
Ms, and Ms*  are the numbers of free intracellular MHC class II molecules, intracellular 
self-peptide-MHC class II complexes, and surface self-peptide-MHC class II complexes 
per macrophage, respectively. We assume that the rae of self-peptide synthesis, ksource, 
for which we did not find a value in the literature, is equal to the rate of self-peptide 
degradation in resting macrophages, klys S0. An additional source term, kdeg-MHC Ms [1 / 
(NA vMIIC)], is used to represent the replenishment of MHC-derived self-peptides that are 
ultimately lost when pMHC complexes are degraded. For the initial value of the 
endosomal self-peptide concentration, S0, we use the steady-state value which we did not 
find in the literature but approximate to be 6 × 10-4 mol L-1 by solving Eqn. 2.10 when S’
= 0 mol L-1 h-1, Ms = Ms,0, and M = M0. During simulations of hypothesis H3 (i.e. when 
the value of kon-MHC was changed) the values of S0 and ksource were recalculated 
accordingly. However, during simulations to determine PRCC values, all rate constants 
were changed independently and the values of S0 and ksource were not recalculated. 
2.5.5 MHC Class II Translation and Peptide-MHC Class II Binding 
We assume that the reaction scheme peptide + MHC ↔ peptide-MHC complex is 
accurate on the timescales of most in vitro experimental protocols allowing us to forego 
more complicated representations (e.g., those in Beeson and McConnell 1995). We also 
assume that the enzyme HLA-DM is expressed at sufficiently high levels within 
endosomes so that dissociation of CLIP from MHC class II is not rate limiting and does 
not require explicit representation. In addition, because the signal sequence that localizes 
MHC class II to endosomes is found in the cytoplasmic domain of Ii and removed from 
mature forms of MHC class II, we assume that all forms of MHC class II in our model 
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are free to be transported to and from the plasma membrane. Consistent with this 
assumption, peptide-free MHC class II molecules have been detected on the surface of 
antigen-presenting cells (Germain and Hendrix 1991, Santambrogio et al. 1999). In our 
model, we represent MHC class II using six variables to distinguish between intracellular 
and surface localizations as well as free, self-peptid -bound, and exogenous peptide-
bound forms (Eqns. 2.11-16). 
dM/dt = ktsl2 (1 + β C / Rtot) T − kon-MHC M S + koff-MHC Ms − kon-MHC M 
E + koff-MHC Me − kout M + kin M*  − kdeg-MHC M  
[2.11] 
dM*/dt = kout M − kin M*  − kdeg-MHC M [2.12] 
dMs/dt = kon-MHC M S − koff-MHC Ms − kout Ms + kin Ms*  − kdeg-MHC Ms [2.13] 
dMs* /dt = kout Ms − kin Ms*  − kdeg-MHC Ms*  [2.14] 
dMe/dt = kon-MHC M P − koff-MHC Me − kout Me + kin Me* − kdeg-MHC Me [2.15] 
dMe* /dt = kout Me − kin Me*  − kdeg-MHC Me*   [2.16] 
where M, Ms, and Me are the numbers of free MHC class II proteins, self-p ptide-MHC 
class II complexes, and exogenous peptide-MHC class II complexes within the 
endosomal compartments of each macrophage, respectively, and M* , Ms* , and Me*  are 
the numbers of the same MHC class II species on the surface of each macrophage. We 
did not find a measurement in the literature for the rate constant representing MHC class 
II translation, ktsl2, but derive a value by assuming that unstimulated macrophages 
maintain a constant total number of MHC class II proteins in the absence of exogenous 
antigen [i.e., (M + M*  + Ms + Ms* )’ = 0 mol L
-1 h-1 when G0 = 0 mol L
-1 and E0 = 0 mol 
L-1]. Therefore, given Eqns. 2.11-14, ktsl2 is equal to the combined rates of MHC class II 
protein degradation, kdeg-MHC (M0 + M* 0 + Ms,0 + Ms* 0). We also assume that all MHC 
class II proteins are degraded with the same rate constant, kdeg-MHC, whose value we 
derive from the half-life of MHC class II proteins on the surface of cultured macrophages 
(Poutsiaka et al. 1985). We estimate a value for the translation scaling factor, β, in a 
manner similar to that used for the transcription scaling factor, α. That is, we simulate the 
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experimental conditions used by Cullell-Young et al. (2001) who observed a maximum 
increase of 37-fold in the MHC class II protein levels of macrophages incubated with 
IFN-γ (ncells = 5 × 105, vrxn = 1 × 10-3 L, G0 = 3 × 102 units/mL ≈ 2 × 10-9 mol L-1) and 
approximate a value for β that matches this output. We derive a value for the rate 
constant of MHC class II protein transport from endosomes to the plasma membrane, kout
based on the length of time this process takes in cultured macrophages (between 5 and 15 
min, Harding and Geuze 1993), assuming that 50% of the proteins are transported during 
this time. Cultured macrophages retain approximately one-third of their MHC class II 
proteins intracellularly (Harding and Unanue 1989), a ratio we define as pin. Based on 
this ratio we derive a value for the rate constant of MHC class II protein internalization 
from the plasma membrane, kin, by assuming that (M* 0 + Ms* 0) / Mtot = pin where Mtot = 
(M0 + M* 0 + Ms,0 + Ms* 0) and that therefore (M*0 + Ms* 0) = [(1 − pin) / pin] (M0 + Ms,0). 
We solve Eqns. 2.12 and 14 for the steady-state values of M*  and Ms*  which we use as 
initial conditions, set their sum, kout (M0 + Ms,0) / (kin + kdeg-MHC), equal to the expression 
for (M* 0 + Ms* 0) above, and solve for kin. 
Values for the rate constants of peptide-MHC class II association and 
dissociation, kon-MHC and koff-MHC, vary widely in the literature depending on the particular 
peptide being used.  For example, complexes with peptid s derived from OVA and 
myelin basic protein (MBP) dissociate in solution at rates of 3 × 10-6 s-1 and 4 × 10-4 s-1, 
respectively (Buus et al. 1986, Mason and McConnell 1994). By using the formula t95% = 
−ln(0.05) / [kd (1 + L0 / KD)] where t95% is the time required to reach 95% of equilibrium 
binding, kd the dissociation rate constant, L0 the initial ligand concentration, and KD the 
equilibrium dissociation constant (Lauffenburger and Linderman 1993), we estimate t95% 
values to be on the order of 100 h and 1 h for OVA and MBP peptides, respectively, 
when L0 = KD. Considering that the length of time between the administration of 
exogenous antigen and the assay for surface pMHC complexes is on the order of 1 h in 
the experimental protocols of interest (Hmama et l. 1998, Noss et al. 2000), these values 
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for t95% suggest that, at least in some cases, the number of complexes does not reach 
equilibrium. If this is true, the choice of kon-MHC and koff-MHC values would be important to 
the outcome of the simulations. However, the presence of the enzyme HLA-DM 
increases the dissociation rate constant of pMHC complexes by 104-fold (Weber et al. 
1996), resulting in t95% values of 1 × 10
-2 and 1 × 10-4 h for OVA and MBP peptides, 
respectively, when L0 = KD. In both cases, the number of pMHC complexes is expected to 
reach equilibrium well before the conclusion of theassay. Therefore, we assume that the 
choice of peptide-specific kon-MHC and koff-MHC values from the literature does not 
significantly affect the outcome of the simulations due to the enzymatic activity of HLA-
DM. 
In all simulations, we set the initial conditions for the variables representing the 
different MHC class II species (i.e., M0, M* 0, Ms,0, Ms*0, Me,0, and Me* 0) based on two 
ratios, pin and pbound, the fractions of all MHC class II that are intracellular and bound to 
self-peptide, respectively, in unstimulated macrophages when exogenous antigen is not 
present. We assume that pin and pbound apply to both free and peptide-bound MHC class 
II, so that M0 / (M0 +M* 0) = Ms,0 / (Ms,0 + Ms* 0) = pin and Ms,0 / (M0 + Ms,0) = pbound. We 
express M* 0, Ms*0, and Ms,0 in terms of M0, the number of free endosomal MHC class II 
proteins, sum M0, M* 0, Ms* 0, and Ms,0 to the known total number of MHC class II 
molecules in unstimulated macrophages (Mtot, Harding and Unanue 1989), and solve for 
each value. 
2.5.6 Inclusion of Mtb and Its Inhibitory Effect on Intracellular Process 
We simulate the inhibitory effect of Mtb on various intracellular processes by 
multiplying the corresponding rate constant in the baseline model by the quantity [1 − B / 
(KM + Β)] where B is the multiplicity of infection (moi, or bacteria-to-macrophage ratio) 
used in vitro and KM is the moi needed to inhibit a process by 50%. For simplicity we use 
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a single value for KM in all of our simulations and derive this value from the data of Noss 
et al. (2000) who found that MHC class II transcription decreases by 20% and 80% when 
the infectious dose of Mtb is 5 and 40, respectively. We fit these data to the function kinf = 
kuninf [1 − B / (KM + Β)] where kinf and kuninf are rate constants for a given process in 
infected and uninfected macrophages, respectively, r sulting in KM ≈ 18. To measure the 
effect on antigen presentation, we calculate (Me* uninf – Me* inf) / Me* uninf where Me* uninf and 
Me* inf are surface exogenous peptide-MHC class II levels (Me* ) using kuninf and kinf, 
respectively. 
2.5.7 Parameters and Initial Conditions 
Model simulations generating the figures and tables in the main text used the 
following parameters and initial conditions in place of the baseline parameters and initial 
conditions in Tables 3 and 4. 
For Figure 2.2. A and B, ncells = 4 × 10
6, vrxn = 8 × 10
-3 L, G0 = 2 × 10
-6 mol L-1, 
A*0 = 0 mol L
-1, Pai et al. 2002; α and kpino were set to 200 and 1 × 10-12 L h-1, 
respectively. C and D, ncells = 5 × 10
5, vrxn = 1 × 10
-3 L, G0 ≈ 2 × 10
-9 mol L-1, A*0 = 0 mol 
L-1, Cullell-Young et al. (2001); α and kpino were set to 30 and 1 × 10-12 L h-1, 
respectively. E and F, ncells = 5 × 10
6, vrxn = 1 × 10
-3 L, G0 = 0 mol L
-1, A*0 ≈ 1 × 10
-8 mol 
L-1, Buus and Werdelin (1986); α = 30, kpino = 1 × 10-12 L h-1. G and H, ncells = 9 × 104, 
vrxn = 4 × 10
-4 L, G0 = 0 mol L
-1 or G0 ≈ 6 × 10
-11 mol L-1, A*0 = 0 mol L
-1, A*16 = 2 × 10
-
6 mol L-1, Delvig et al. (2002); α = 30, kpino = 1 × 10-12 L h-1. 
For Table 2.1. ncells = 1 × 10
5, vrxn = 1 × 10
-3 L, G0 = 1 × 10
-9 mol L-1, A*0 = 1 × 
10-4 mol L-1; α = 30, kpino = 1 × 10-12 L h-1. B = 40. H1, H2, H3, and H4 correspond to 
model parameters kdeg-A, ktsl2, kon-MHC, and ktxn2, respectively. 
For Figure 2.3. C, D, and E, ncells = 1 × 10
5, vrxn = 1 × 10
-3 L, B = 50, G0 = 0 mol 
L-1, A*0 = 0 mol L
-1, and G24 ≈ 1.3 × 10
-9 mol L-1 where subscript n refers to a condition 
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at the nth hour of the experiment; α and kpino were set to 30 and 1 × 10-12 L h-1, 
respectively. F, G, and H, ncells = 5 × 10
4, vrxn = 3.7 × 10
-4 L, B = 40, G0 = 1.3 × 10
-10 mol 
L-1, A*0 = 0 mol L
-1, G22 = 0 mol L
-1, G24 = 1.3 × 10
-10 mol L-1, G46 = 0
 mol L-1, and A*46 
= 2.0 × 10-1 mol L-1; α and kpino were set to 30 and 1 × 10-12 L h-1, respectively. 
For Table 2.2. ncells = 1 × 10
5, vrxn = 1 × 10
-3 L, G0 = 1 × 10
-9 mol L-1, A*0 = 1 × 
10-4 mol L-1; α = 30, kpino = 1 × 10-12 L h-1 were used as baseline values. MHC class II 
export, antigen concentration in medium, antigen uptake, MHC class II protein 
maturation, and IFN-γ stimulation of MHC class II translation correspond to model 
parameters kout, A*0, kpino, ktsl2, and β, respectively. IFN-γ receptor-ligand binding, IFN-γ 
concentration in medium, MHC class II transcription, CIITA translation, and CIITA 
transcription correspond to model parameters kon-IFN-γ, G0, ktxn2, ktsl1, and ktxn1, 
respectively. IFN-γ stimulation of CIITA transcription, IFN-γ degradation in solution, 
MHC class II degradation, CIITA protein degradation, CIITA mRNA degradation, and 
IFN-γ receptor-ligand dissociation correspond to model parameters α, kdeg-IFN-γ, kdeg-MHC, 
kdeg-P, kdeg-mRNA1, and koff-IFN-γ, respectively. 
For Figure 2.4. ncells = 1 × 10
5, vrxn = 1 × 10
-3 L, B = 40, G0 = 0 mol L
-1, A*0 = 0 
mol L-1, G24 ≈ 1.3 × 10
-10 mol L-1, and A*t+24 = 1 × 10
-9 mol L-1 where subscript n refers 
to conditions at the nth hour of the experiment and t is variable; α and kpino are set to 30 





Figure 2.1. Model schematic. Molecular species represented in the model include: 
extracellular IFN-γ (G), IFN-γ receptors (free: R, bound: C), CIITA (mRNA: T1, protein: 
P), MHC class II mRNA (T2), exogenous antigen (extracellular: A*, intracellular: A, 
peptide: E), self peptide (S), free MHC class II molecules (intracellular: M, surface: M* ), 
self peptide-bound MHC class II molecules (intracellular: Ms, surface: Ms* ), and 
exogenous peptide-bound MHC class II molecules (intracellular: Me, surface: Me* ). Solid 
arrows indicate one-step reactions and dashed arrows indicate regulatory interactions. 
Degradation is represented in the model for the following molecules but not shown: G, 
T1, P, T2, A*, M, M* , Ms, Ms* , Me, Me* . Up-regulation of M by C directly and 
contribution of Ms and Ms*  to S are also included in the model but not shown. 
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Figure 2.2. Model testing using various controls. A and B, Simulation results and 
experimental data for levels of CIITA mRNA (solid lines) and MHC class II mRNA 
(dashed lines) in IFN-γ treated macrophages from Pai et al. (2002). C and D, Simulation 
results and experimental data for levels of MHC class II mRNA (solid lines) and MHC 
class II protein (dashed lines) in IFN-γ-treated macrophages from Cullell-Young et al. 
(2001). E and F, Simulation results for surface pMHC levels (in arbitrary units) and 
experimental data for T cell response in non-IFN-γ-treated macrophages exposed to 
antigen from Buus and Werdelin (1986). G and H, Simulation results for surface pMHC 
levels (in arbitrary units) and experimental data for T cell response in non-IFN-γ-treated 
macrophages (solid lines) and IFN-γ-treated macrophages (dashed lines) exposed to 
antigen from Delvig et al. (2002). 16 h pretreatment with medium or IFN-γ is not shown; 
hence, the x-axis is enumerated from 16 h onward (i.e. when antigen is present). 
58 
 
Figure 2.3. Simulation results of two in vitro experimental protocols using four published 
hypotheses. In A and B, large circles represent macrophages, highlighted circles IFN-γ-
treated macrophages, and small circles T cell hybridomas. A, Protocol of Hmama et al. 
(1998). 105 monocytes were infected with Mtb at MOI 50 for 24 h, treated with 200 U/ml 
IFN-γ for 36 h, pulsed with 1 mg/ml BSA for 0.5 h, and chased for 0.5 h, 1 h, or 4 h. B,
Protocol of Noss et al. (2000). 5 · 104 macrophages were treated with 2 ng/ml IFN-γ for 
20-24 h, infected with Mtb at MOI 40 for 2 h, treated with 2 ng/ml IFN-γ for an 
additional 18-26 h, and pulsed with 0-100 µg/ml hen egg lysozyme or 0-1000 µg/ml 
RNase for 1-3 h. C, D, and E, Simulation results using the protocol of Hmama et l. 
(1998) for levels of CIITA mRNA, MHC class II mRNA, and surface MHC class II 
protein, respectively. F, G, and H, Simulation results using the protocol of Noss et al. 




Figure 2.4. Proposed experimental protocol to determine the contribution of different 
mechanisms to Mtb of antigen presentation. A. Protocol schematic using representations 
of Fig. 2.3A and B. B, Surface pMHC levels expected in uninfected macrophages, Mtb-
infected macrophages if mechanisms target primarily MHC class II expression (in this 
case, MHC class II transcription), Mtb-infected macrophages if mechanisms target 
primarily other processes (in this case, antigen processing). Percentage reductions in 




Table 2.1. Changes in surface pMHC levels following inhibition f various intracellular 
processes hypothesized to be affected by M. tuberculosis.a 
Hypothesis: Affected 
process 
0.1 h 1.0 h 10 h 100 h 
H1: Antigen processing
 
▼47% ▼8.4% ▼7.2% ▼43% 
H2: MHC class II 
maturation 
▼1.4% ▼8.2% ▼49% ▼69% 
H3: MHC class II peptide 
loading 
▼44% ▼11% ▼12% ▼57% 
H4: MHC class II 
transcription 
▼0.0026% ▼0.16% ▼26% ▼66% 
H1 + H4 ▼47% ▼8.6% ▼31% ▼81% 
H2 + H3 ▼45% ▼18% ▼55% ▼86% 
a Identical experimental conditions were used in each simulation, and comparisons were 




Table 2.2. Additional intracellular processes significantly correlated with surface pMHC levels.a 
Time:                   1.0 h 10 h 100 h 
Description (Correlation coefficient) Description (Correlation coefficient) Description (Correlation coefficient) 
MHC class II export (0.79) 
Antigen concentration in medium (0.41) 
Antigen uptake (0.40) 
MHC class II protein maturation (0.38) 
IFN-γ stimulation of translationb (0.33) 
 
MHC class II protein maturation (0.72) 
IFN-γ stimulation of translationb (0.62) 
MHC class II export (0.55) 
IFN-γ receptor-ligand binding (0.52) 
IFN-γ concentration in medium (0.52) 
MHC class II transcription (0.49) 
CIITA translation (0.44) 
IFN-γ stimulation of transcriptionc (0.36) 
CIITA transcription (0.36) 
MHC class II transcription (0.57) 
MHC class II protein maturation (0.56) 
CIITA translation (0.56) 
CIITA transcription (0.53) 
IFN-γ concentration in medium (0.51) 
IFN-γ receptor-ligand binding (0.49) 
IFN-γ stimulation of transcriptionc (0.47) 
Antigen concentration in medium (0.36) 
Antigen uptake (0.33) 
MHC class II export (0.32) 
  IFN-γ degradation in solution (-0.87) 
MHC class II degradation (-0.56) 
CIITA protein degradation (-0.53) 
CIITA mRNA degradation (-0.49) 
IFN-γ receptor-ligand dissociation (-0.48) 
a 1000 simulation runs were performed using different sampled parameter values. PRCC values determined to be significant (p ≤ 10-30) 
are shown in parentheses. Intracellular processes considered in previous hypotheses (H1- 4) are italicized. 
b MHC class II translation 





Table 2.3. Parameters used in the APC model. 
Parameter Value (ref.) Parameter Value (ref.) 
kon-IFN-γ 
2.6 × 1010 mol-1 liter  h-1 
(Sadir et al. 1998) 
kdeg-MHC 
3 × 10-1 h-1 (Poutsiaka et 
al. 1985) 
ncells Varies by experiment vMIIC 
4 × 10-16 L (Marsh et al. 
1986) 
vrxn Varies by experiment kon-MHC 
4 × 105 mol-1 L h-1 (Buus 
et al. 1986) 
koff-IFN-γ 
1.8 × 101 h-1 (Sadir et al. 
1998) 
koff-MHC 
6 × 103 h-1 (Buus et al. 
1986) 
kdeg-IFN-γ 
3.5 × 10-2 h-1 (Celada et al. 
1984) 
klys 
6 h-1 (Lauffenburger et al. 
1987) 
krecyc 1 h
-1 (Gercken et al. 1994) kpino 
5 × 10-14 - 1 × 10-12 L h-1 
(Dean 1979, Selby et al. 
1995) 
ktxn1 kdeg-mRNA1 T1,0 = 0.12 h
-1 kdeg-A* 
3.5 × 10-2 h-1 (Celada et 
al. 1984) 
α 30 - 200 (Cullell-Young et al. 2001, Pai et al. 2002) kdeg-A 
4 h-1 (Diment and Stahl 
1985) 
kdeg-mRNA1 0.12 h
-1 (Pai et al. 2002) ktsl2 
kdeg-MHC (M0 + M* 0 + Ms,0 
+ Ms* 0) ≈ 2 × 10
-2 h-1 
ktsl1 kdeg-mRNA1 P0 / T1,0 = 1.4 h
-1 β 10 (Cullell-Young et al. 2001) 
kdeg-P 
1.4 h-1 (Schnappauf et al. 
2003) 
kout 
4 h-1 (Harding and Geuze 
1998) 
ktxn2 kdeg-mRNA2 T2,0 ≈ 4 × 10
3 h-1 pin 
1/3 (Harding and Unanue 
1989) 
Rtot 1 × 10
4 (Celada et al. 1984) kin 
[pin/(1-pin)] kout – kdeg-MHC 
≈ 1.97 h-1 
kdeg-mRNA2 4 × 10
-2 h-1 (Cullell-Young pbound 4/5 (Chicz et al. 1993) 
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et al. 2001) 
ksource 
klys S0 ≈ 3.6 × 10
-3 mol L-1 h-
1 
Mtot 
2 × 105 (Harding and 
Unanue 1989) 
 
Table 2.4. Initial conditions used in the APC model. 
Parameter Value (ref.) Parameter Value (ref.) 
G Varies by experiment A 0 mol L-1 
R 1 × 104 (Celada et al. 1985) E 0 mol L-1 
C 0 M 
pin (1 − pbound) Mtot ≈ 1.3 × 
104 
T1 1 M* 
[(1 − pin) / pin] M0 ≈ 2.7 × 
104 
P 1 Ms 
[pbound / (1 − pbound)] M0 ≈ 
5.3 × 104 
T2 1 Ms* 
[(1 − pin) / pin] Ms,0 ≈ 1.1 × 
105 
S 6 × 10-4 mol L-1 Me 0 
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How Peptide Length Affects Binding to MHC Class II 
3.1 Introduction 
Major histocompatibility complex (MHC) molecules, also known as human 
leukocyte antigens (HLA), are a vital component to the development of the immune 
response to pathogens (Kaufmann 2005). These molecules act as receptors for peptides 
derived from foreign antigens as well as self peptides and enable the long-term display of 
antigens on the cell surface. T cells recognize antige ic peptides in the context of MHC, 
and depending on the class of MHC involved, recognition can lead to the death of the 
presenting cell or its activation. In either case peptide-MHC binding is an important 
prerequisite event and has far-reaching consequences to the ensuing response. 
Prediction of peptide-MHC binding therefore represent  an important goal in 
bioinformatics, particularly as applied to immunology, and a number of computational 
approaches have been developed (reviewed in Buus 1999; see also Robinson et al. 2003 
for other MHC-specific bioinformatics tools). The simplest are based on motifs, i.e. 
requirements for particular amino acids at positions within the peptide as determined 
from pool sequencing of eluted peptides (Falk et al. 1991, Rammensee 1995 and 
references therein). Such approaches have largely be n superseded by algorithms using 
matrices to score the relative contribution of amino acids at each position within the 
peptide (Parker et al. 1994, Davenport et al. 1995, Marshall et al. 1995). Machine 
learning methods including hidden Markov models andrtificial neural networks have 
 
72 
also been applied, with peptide sequence serving as input and binding/non-binding as 
output (Brusic and Harrison 1994, Honeyman et al. 1998, Mamitsuka 1998). More 
recently, attempts have been made to predict the structure of the peptide-MHC complex 
and free energy changes associated with binding (Altuvia et al. 1997, Rognan et al. 1999, 
Schueler-Furman et al. 2000, Davies et al. 2003, Schafroth and Floudas 2004; for a 
review of current structural information and nomenclature see Kaas and Lefranc 2005). It 
is also possible to combine some of these approaches, as Sturniolo et al. (1999) did using 
matrices to represent each pocket lining the peptid-b nding groove. 
Continued progress in the development of these algorithms faces a number of 
challenges including how to handle differences betwe n the two classes of MHC. Most 
prediction algorithms were first developed in the context of peptide-MHC class I binding 
which involves peptides of a narrow range of lengths, usually 8-10 amino acids. These 
algorithms were then applied to peptide-MHC class II binding, typically with little or no 
modification. 
Despite the fact that both classes of MHC share suprficial similarities and bind a 
core of nine amino acids within peptides (Jones 1997), important differences exist. In 
particular the open-ended nature of MHC class II peptid -binding groove allows for a 
wide range of peptide lengths (Brown et al. 1993). Peptides binding MHC class II usually 
vary between 13 and 17 amino acids in length, thoug shorter or longer lengths are not 
uncommon (Chicz et al. 1992, Sercarz and Maverakis 2003). As a result pepides are 
hypothesized to shift within the MHC class II peptide-binding groove, changing which 
9mer window (register) sits directly within the groove at any given time. In contrast the 
capped nature of the MHC class I peptide-binding groove does not allow variation in 
length or such register shifting. 
Variation in peptide length may have important consequences for the binding and 
function of antigenic peptides (Malcherek t al. 1994, Vogt et al. 1994). For instance, 
Srinivasan et al. (1993) found that a 23mer peptide derived from cyto hrome c was 32 
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times more immunogenic than a 10mer peptide containi g the same putative binding 
core. A direct relationship between peptide length and binding affinity has been observed 
for some MHC class II alleles, but whether this holds true for most alleles remains 
unknown, as does an explanation for why this relationship exists (Bartnes et al. 1999, 
Fleckenstein et al. 1999, Arnold et al. 2002, Sercarz and Maverakis 2003). In addition to 
having more binding registers, longer peptides also possess peptide-flanking residues 
(PFR) which lie outside of the peptide-binding groove and may interact with the MHC 
class II molecule at more distal locations (Sercarz nd Maverakis 2003). Whether 
information regarding peptide length, or any other p ptide property lost by considering 
only 9mers, may aid prediction also remains unknown. 
In this study we address several issues related to peptide length and binding to 
MHC class II. Using aggregate data that are now available from online databases, we first 
examine whether a relationship exists between length and affinity for several MHC class 
II alleles. We then attempt to incorporate length into two existing binding algorithms in a 
number of ways, including using regression to pre-process the data, treating length as an 
additional variable within the algorithms, and deriving a formula to more accurately 
represent register shifting (Fig. 3.1). We show that improvements to more than one 
current algorithm for predicting peptide-MHC class II binding are possible with relatively 
simple amendments. We also comment on which mechanisms are likely to be affecting 
binding as peptide length increases. 
3.2 Methods 
3.2.1 Data Sources 
Peptide data sets used in this study are available from the AntiJen database 
(http://www.jenner.ac.uk, Blythe et al. 2002) and can be downloaded using the perl 
LWP::Simple module. Other peptide-MHC databases listing affinities are also 
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available, including the Immune Epitope Database (currently in beta version at 
http://www.immuneepitope.org, Peters et al. 2005), but were not used in this study. Our 
data sets comprised the sequences and IC50 values of peptides binding the MHC class II 
alleles HLA-DRB1*0101, -DRB1*0401, and -DRB1*1501 from AntiJen. IC50 refers to 
the concentration of peptide required to inhibit 50% of reporter peptide-MHC binding. 
When more than one IC50 measurement was available for a given peptide-MHC complex, 
the first measurement listed was used, unless otherwis  indicated. IC50 values were 
converted into pIC50 using the formula pIC50 = -log IC50 where IC50 has units of molar. 
Homologous sequences and their IC50 measurements were removed using UniqueProt 
(Mika and Rost 2003). Other algorithms for removing homologous sequences are also 
available, including Hobohm 1 and Hobohm 2 (Hobohm et al. 1992), but were not used 
in this study. The data sets were of the following sizes (before/after filtering by 
UniqueProt): DRB1*0101 (464/303), DRB1*0401 (606/414), DRB1*1501 (343/213). 
Two additional data sets were used to assess the effect of data set size, those for 
DRB1*0404 (81/54) and DRB1*0405 (116/102). To asses the role of data quality in 
determining algorithm performance, data sets for DRB1*0101, DRB1*0301, 
DRB1*0401, DRB1*1101, DRB1*1501, and A*0201 were obtained from AntiJen, and 
data points for which the concentration of reporter peptide was unavailable were 
excluded. Data sets are available as part of the online Supplementary Data at 
http://malthus.micro.med.umich.edu/Bioinformatics/. 
3.2.2 Regression of Binding Affinity Versus Peptide Length 
Both parametric and nonparametric fits were made to plots of affinity vs. length in 
the data. Parametric fits were made with one, two, and three fitted parameters (linear, 
quadratic, and cubic, respectively) using the open-source statistical program R 
(http://www.R-project.org, R Development Core Team 2005) and the function lm. 
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Nonparametric local regression fits were made using the R function loess with default 
settings (Cleveland and Devlin 1988). To evaluate fit quality, analysis of variance was 
performed using the R function anova. An F statistic was generated which we used to 
compare linear with nonlinear parametric fits (Motulsky and Christopoulos 2004). 
Nonparametric local regression fits were evaluated using a permutation test. In 
this test each pIC50 value was reassigned to a different peptide sequence at random, and a 
loess fit was re-derived for the shuffled values. This was repeated 1000 times, and the 
smallest 25 (2.5%) and largest 25 (2.5%) fitted values at each length were excluded. The 
local regression fit to the original, non-shuffled data set was then compared to the 
remaining 95% of permuted values at each length and was determined to be significant if 
it fell outside of this interval. 
3.2.3 Simulations of Register Shifting 
To simulate the effects of register shifting on peptide-MHC class II binding 
affinity over a range of peptide lengths, we derived a formula for the expected value of 
the affinity of a single hypothetical peptide with multiple registers: 
E[K(X)] = ∑ K(xi) p(xi) [3.1] 
where K(X) is the equilibrium association constant, or affinity, of a peptide X, K(xi) is the 
affinity of a complex with a single register xi, and p(xi) is the probability of register xi 
occurring. We assume that p(xi) can be approximated by the proportion of complexes 
having register xi: 
p(xi) = N(xi) / ∑ N(xi) [3.2] 
where N(xi) denotes the number of complexes having register xi and the sum is taken over 
all possible registers. Belmares and McConnell (2001) found that the kinetics of shifting 
between two registers could be accurately representd as x1 ↔ P + M ↔ x2 where P and 
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M are peptide and MHC, respectively. Based on this re ult, at equilibrium [x1] = 
K(x1)[P][M] and [x2] = K(x2)[P][M]. Because both x1 and x2 exist in the same solution, it 
follows that: 
N(x1) / [ N(x1) + N(x2) ] = K(x1) / [ K(x1) + K(x2) ]. [3.3] 
 
More generally, 
N(xi) / ∑ N(xi) = K(xi) / ∑ K(xi). [3.4] 
Combining Equations 3.1, 3.2, and 3.4, we obtain the following result for the expected 
affinity of a given complex when multiple registers are available: 
E[K(X)] = ∑ K(xi)
2 / ∑ K(xi) [3.5] 
This result can also be applied to log-transformed asures of affinity such as log 
K(X). Henceforth we refer to Equation 3.5 or its log-transformed counterpart as the 
equilibrium-based formula for reconciling multiple r gisters. 
We assume that every overlapping 9mer window within a peptide can result in 
binding to MHC and therefore set the lower and upper limits of summation at 1 and l − 8, 
respectively, where l represents peptide length and is varied between 9 and 25, the 
shortest and longest lengths typically observed in our data sets. K(xi) was generated from 
a lognormal distribution with mean 107.5 and standard deviation 100.5, based on the 
observation that most values for the equilibrium dissociation constant KD of peptide-
MHC binding fall in the range of 10-7-10-8 M (McFarland and Beeson 2002). Moreover, a 
lognormal distribution was chosen based on the equation for standard free energy change, 
∆G° = -RT ln (1/KD) where R and T are the gas constant and temperature, respectively 
(Eisenberg and Crothers 1979), and the assumption that free energy change for peptide-
MHC binding is normally distributed. For each value of l between 9 and 25, a set number 
of values were generated (in our case, either 10 or 100), resulting in a scatter plot of 
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simulated pIC50 values versus length. A curve was then fit to this plot using local 
regression (the loess function in R) with default settings. 
3.2.4 Peptide-MHC Binding Affinity Prediction 
Two algorithms were selected to generate baseline predictions against which the 
effects of modifications based on length could be compared. One of these algorithms was 
the iterative self-consistent (ISC) partial-least-squares (PLS) algorithm of Doytchinova 
and Flower (2003). We implemented this matrix-based algorithm for predicting peptide-
MHC binding affinity in perl and R. Briefly, this algorithm uses partial least squares 
regression to identify underlying factors (also know  as latent variables) relating multiple 
predictor variables to an outcome variable. In the case of peptide-MHC binding, 180 
predictor variables were used to denote the presenc or absence of the 20 possible amino 
acids within each 9mer window, and the outcome variable was binding affinity as pIC50. 
The initial steps of the algorithm were performed using perl scripts: splitting each 
data set into training and test sets; generating all possible 9mers for each training set 
peptide; selecting only those 9mers having position 1 anchor residues (F, I, L, M, V, W, 
and Y); and converting 9mers thus selected into bit str ngs. PLS regression was then 
performed in R using the bit-encoded 9mers and their corresponding pIC50 values. PLS is 
available for R as the pls.pcr library (available at http://cran.r-project.org) and was 
called from within a perl script using the IPC::Open2 module. Default settings were 
used for PLS; however, some options in the commercial software used by Doytchinova 
and Flower (2003) were not available in R, namely scaling method and column filtering. 
Subsequent steps in the algorithm were performed using additional perl scripts: selecting 
those 9mers in the training set yielding predicted pIC50 values closest to experimental 
pIC50 values during cross-validation and repeating the algorithm until the selected set of 
9mers matched the previously selected set, i.e. when self-consistency was achieved. For 
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computational expediency we limited the number of PLS iterations for any given peptide 
to 10. At that point the final PLS model was extracted and used to generate predictions on 
the test set. 
For test set peptides having more than one 9mer with an anchor residue in 
position 1, multiple predictions were generated and rule was needed to make a final 
prediction. One option is to assume only one registr predominates and to take the 
highest score from among the predictions. More complicated rules are also possible such 
as the combination rule of Doytchinova and Flower (2003) whereby the mean of the 
pIC50 predictions is chosen if they fall within a one log range; otherwise, the highest is 
chosen. 
To measure the performance of the algorithm we used fiv -fold cross-validation 
(5x-CV), setting aside one-fifth of each data set to use as a test set and using the other 
four-fifths as the training set. This process was repeated on the same data set four 
additional times until a prediction was made for each peptide in the data set and complete 
coverage was achieved. (This instance of cross-validation was independent of the leave-
one-out-cross validation used in the ISC-PLS algorithm.) The accuracy of each set of 
predictions was scored by calculating the area under receiver operating characteristic 
curve (AROC). This calculation can be done in R using the prediction and 
performance functions of the ROCR library. By repeating each 5x-CV multiple times, 
we were able to calculate the standard error of the AROC scores which could then be used 
to determine whether two mean AROC scores significantly differed by Student’s  test. 
Pearson correlation coefficients between predicted an  experimentally determined pIC50 
values were also used to score performance and are provided in the online Supplementary 
Data (Lund et al. 2005). 
A second algorithm that was selected was the TEPITOE algorithm of Sturniolo 
et al. (1999). In this algorithm amino acid-binding profiles are generated for each pocket 
within the peptide-binding groove, and these profiles are combined according to MHC 
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sequence. We did not regenerate these matrices but rather used the matrices available on 
the ProPred website (http://www.imtech.res.in/raghava/propred, Singh and Raghava 
2001). Using the appropriate matrix a sum was calcul ted for each peptide in a selected 
AntiJen data set. To this value we added an approximation of the binding affinity of an 
all-alanine 9mer (pIC50 = 6.169, Doytchinova and Flower 2003) generating a fin l 
prediction. Performance was scored by calculating the AROC. 
3.2.5 Incorporating Length into Existing Prediction Algorithm 
Peptide length was incorporated into the ISC-PLS algorithm using one of three 
modifications. In Modification 1 (Mod. 1) a local regression fit was first made to the 
peptide lengths and pIC50 measurements in each training set. (In the event that the pIC50 
value for either the shortest or the longest length peptide was excluded from the training 
set but included in the test set, a local regression fit at that length could not be generated; 
instead, we assigned the average fitted values at the remaining lengths.) The value of the 
fit was then subtracted from the original pIC50 value for each peptide, and the resulting 
difference, i.e. the residual, was then used in place of the original pIC50 value. The ISC-
PLS algorithm was performed as described earlier providing initial predictions on the test 
set. To these predictions the value of the regression fit was added yielding final 
predictions. Alternatively, in Alternative Modification 1 (Alt. 1), peptide length was 
appended as the 181st predictor variable to the bit-encoded training set and test set 9mers. 
The remainder of the algorithm was then performed as described earlier. Finally, in 
Modification 2 (Mod. 2) the formula derived to reprsent register shifting (Equation 5) 
was used to reconcile predictions made on multiple candidate 9mers, i.e. registers, within 
a test set peptide. This modification occurred at the last stage of the ISC-PLS algorithm 
and was used in place of the combination rule described above. 
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Only Mod. 2 was used to incorporate length into theTEPITOPE/ProPred 
algorithm. When TEPITOPE/ProPred is applied to peptid s with multiple registers, the 
highest score among the different registers is typically taken to be the score of the entire 
peptide (Brusic et al. 1998, Nielsen et al. 2004, Murugan and Dai 2005). We reconciled 
individual register scores using the equilibrium-based formula (Equation 5) but did not 
regenerate the pocket profiles and therefore did not apply Mod. 1 or Alt. 1 in this case. 
3.2.6 Data Filtering by Experimental Parameters 
To gauge the sensitivity of binding affinity measurements to variations in 
experimental parameters, we used the Cheng-Prusoff equation (1973) which relates the 
equilibrium dissociation constant of a peptide-MHC complex (KD) to its observed IC50 
value: 
KD = IC50 (1 + Lr/Kr) 
-1 [3.6] 
Here Lr and Kr represent the concentration of the reporter peptid and the 
equilibrium dissociation constant of the reporter pptide-MHC complex, respectively. 
These parameters frequently vary by protocol, Lr explicitly so and Kr by virtue of being 
specific to each combination of peptide and MHC (Sette 1989, Roche 1990, Southwood 
1998). Other experimental parameters are also likely to affect IC50 measurements, 
including temperature and pH, but were not considere  xplicitly. 
As a measure of peptide-MHC binding affinity, KD has the benefit of not being 
dependent on the identity or concentration of the repo ter peptide used (Kenakin 1997). 
Additionally, KD is directly proportional to the change in standard free energy of a 
reaction ∆G° when log transformed as indicated by the equation ∆G° = -RT ln (1/KD) 
where R and T are the gas constant and temperature, respectively (Eisenberg 1979). 
Because the Cheng-Prusoff equation (Equation 3.6) show  that the ratio Lr/Kr 
distinguishes IC50 from KD, we used this ratio to estimate the degree to which IC50 
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measurements are affected by reporter peptide variation in experimental protocols. The 
value of Lr depended on what was reported in the database. A single value was used if 
provide; otherwise, the reported range became the low r and upper limits of a uniform 
distribution. To approximate values for Kr which is usually unreported, we used a 
lognormal distribution based on the equation for standard free energy change and the 
assumption that changes in free energy for peptide-MHC binding reactions are normally 
distributed. From the observation that most KD values for peptide-MHC binding fall in 
the range of 10-7-10-8 M (McFarland 2002), we assigned the lognormal distribu ion a 
mean of 10-7.5 and a standard deviation of 100.5. For each peptide we generated 1000 
values of Lr/Kr and calculated the mean and standard error of the mean. Filtered data 
subsets were created by excluding IC50 values associated with mean Lr/Kr exceeding 
either 1 or 9, representing deviations from KD of 2- or 10-fold, respectively. 
3.3 Results 
3.3.1 Peptide Length Affects Binding Affinity to MHC Class II 
To determine the nature of the relationship between p ptide length and peptide-
MHC class II binding affinity, we derived a number of regression fits to binding data for 
several MHC class II alleles from the AntiJen databse. In all cases homologous 
sequences were first removed from the data sets using a pre-filtering algorithm, 
UniqueProt (Mika and Rost 2003). Parametric fits were then made based on polynomials 
with one, two, or three fitted parameters (linear, quadratic, and cubic, respectively). 
Analysis of variance from these fits showed that for these MHC class II alleles the nature 
of the relationship was most likely nonlinear (Table 3.1). A quadratic or cubic fit resulted 
in a significant reduction in sum of squares in all three cases at the 0.05 level. 
To better characterize the apparent nonlinearities n the length-affinity data we 
then made nonparametric fits to the data and analyzed the fits. Local regression was used 
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to make nonparametric fits, and analysis was done using a permutation test. In this test 
binding affinities were reshuffled among peptide lengths to create 1000 new data sets, 
and a local regression fit was re-derived for each data set. If the fit to the original data fell 
outside of the middle 95% of permutation fits at any particular length, the nonlinearity at 
that length was determined to be significant. In each data set we found that the 
nonlinearity between length and affinity was significant at one or more lengths (Fig. 3.2). 
Lengths associated with strongest affinity could be identified, as could lengths associated 
with weakest affinity. For example, for DRB1*0401 affinity appeared strongest for 
peptides of 12 amino acids and weakest for peptides of 20 amino acids. When the data 
sets were combined and the local regression fits were regenerated, the same trends were 
seen (Fig. 3.2D): shorter peptide lengths, of approximately 12 amino acids, were 
associated with higher affinity, while longer peptide lengths, of approximately 20 amino 
acids, were associated with lower affinity. 
Nonlinearities may have been present in the length-affinity data for several 
reasons, including the ability of peptides to shift registers within the MHC class II 
peptide-binding groove. To simulate the effect of register shifting on the mean affinity 
observed for peptides of different lengths, we used a simple statistical model based on 
two assumptions: first, that longer peptides are lik ly to contain more registers than 
shorter peptides, and secondly, that the measured affinity of a given peptide-MHC 
complex approximates the weighted average of the affinities of all the registers in a 
peptide (Equation 5). For a simulated peptide of a given length l, the affinities of l − 8 
registers were generated and averaged. This process wa  repeated until the average 
affinities of either 10 or 100 peptides at each length (i.e. each value of l) were obtained, 
resulting in data sets of two sizes (one of the same magnitude as those typically obtained 
from databases, the other an order of magnitude larger). At this point a regression curve 
was derived (Fig. 3.3). For the larger sized data set the fitted curve was nonlinear and 
monotonically increasing (Fig. 3.3A). The same trend was seen in the smaller data set; in 
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this case, however, deviations were also possible, resulting in maxima at mid-length 
peptides (Fig. 3.3B). Together these results suggest that register shifting may be one 
mechanism behind the nonlinearities in the length-affinity relationship from experimental 
data sets. 
We also estimated the lengths of the amino- and carboxyl-terminal portions of 
each peptide extending outside of the MHC class II peptide-binding groove to determine 
if particular lengths at either end of the peptide w re favorable or unfavorable for 
binding. 9mer cores were identified by position 1 anchor residues (F, I, L, M, V, W, Y), 
and the lengths remaining at each end were calculated. Local regression fitting and 
permutation testing were done as with overall peptide length. In most cases fits to amino- 
and carboxyl-terminal peptide extensions were determined to be significant at one or 
more lengths (Fig. 3.4 and additional data not shown). In comparing fits we found that 
extensions of 2-4 amino acids at the amino terminus and extensions of 1-2 at the carboxyl 
terminus generally appeared favorable for binding (Fig. 3.4 and additional data not 
shown). Likewise, longer extensions (8 and 10 amino acids at the amino and carboxyl 
termini, respectively) generally appeared unfavorable for binding (Fig. 3.4 and additional 
data not shown). We also found that in at least some cases fits to overall peptide length 
could be decomposed into amino- and carboxyl-terminal contributions. For example 
binding to DRB1*0401 was strongest when amino and carboxyl termini were 2 and 1 
amino acids, respectively (Fig. 3.4). Together with the 9mer core, these lengths sum to 
match the overall length associated with strongest binding, 12 amino acids (Fig. 3.2B). 
3.3.2 Incorporating Peptide Length Improves Algorithm Performance 
We incorporated peptide length into two peptide-MHC class II binding prediction 
algorithms in one of three ways. First, as a pre-processing event (Mod. 1 in Fig. 3.1) a 
local regression fit was made for affinity vs. length in the training/fitting data and the 
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value of the fit was subtracted from each affinity measurement. The resulting residuals 
were used in place of the original pIC50 values in the training set. After the algorithm was 
used to make initial predictions for the target set p ptides, the value of the regression fit 
for each target set peptide length was added to yield final predictions. Alternatively (Alt. 
1 in Fig. 3.1) length was also incorporated directly into the existing algorithm as an 
additional variable (in the case of ISC-PLS, as the 181st variable). Training/fitting was 
then performed as published, and predictions were made on test set peptide sequences 
and peptide lengths. Lastly we used a formula derived from the equilibrium-based 
statistical model to reconcile predictions made by existing algorithms on multiple 
registers within the peptide (Mod. 2 in Fig. 3.1). We point out that Mod. 1 and Alt. 1 are 
similar modifications that both consider peptide length directly (by fitting length as a 
discrete variable); in contrast Mod. 2 considers binding registers (i.e. 9mers with a valid 
position 1 anchor) and the relationship among them. Therefore, Mod. 1 and Alt. 1 are not 
used together, although either can be used with Mod. 2. 
Incorporating peptide length by one or more modifications into the ISC-PLS 
algorithm improved the performance of the algorithm for all alleles examined (Table 3.2). 
Performance was measured by area under receiver operating characteristic curves (AROC) 
when a threshold of 500 nM was used to differentiate binding from non-binding affinities 
(Sette et al. 1994). The performance of ISC-PLS in conjunction with a combination rule 
(mean if less than one order range; highest otherwis ) to reconcile register predictions 
was used as a baseline (Doytchinova and Flower 2003). Taking the highest scoring 
register to be representative of the entire peptide was also done as a reference. In general 
using any of three modifications resulted in increases in algorithm performance. However 
the modification resulting in the greater increase differed by MHC class II allele. In the 
case of DRB1*0101, deriving a regression fit (Mod. 1) resulted in significantly greater 
improvements than either using length as an additional variable or using the equilibrium-
based formula to reconcile register predictions. In the case of DRB1*0401, all three 
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modifications resulted in the same magnitude of increase in performance. Finally in the 
case of DRB1*1501 only an application of both the regression fit (Mod. 1) and the 
equilibrium-based formula (Mod. 2) resulted in the greatest increase in performance. 
Differences in which modifications resulted in the greatest increase in performance may 
be suggestive of allele- or data set-specific mechanisms behind the length-affinity 
relationships. 
We also incorporated peptide length into the TEPITOPE/ProPred algorithm 
(Sturniolo et al. 1999) and without re-deriving the pocket-specific matrices that define 
that algorithm found that increases in performance could be obtained by use of the 
equilibrium-based formula alone (Table 3.3). Typically in applications of 
TEPITOPE/ProPred to MHC class II, predictions on multiple registers are reconciled by 
taking the highest scoring register to be representative of the whole peptide (Brusic et al. 
1998, Nielsen et al. 2004, Murugan and Dai 2005). We therefore used this rule to 
generate baseline predictions against which we could compare the performance of the 
equilibrium-based formula. Applying the formula for register shifting increased algorithm 
performance for all three data sets examined. 
We also investigated whether our modifications might be applied to alleles for 
which fewer data exist. In analyzing the data for two other alleles, DRB1*0404 and 
DRB1*0405, we found no significant nonlinearities in regression fits of length versus 
affinity (Supplementary Data). Consistent with the results of these fittings, we observed 
no increase in performance after applying either Mod. 1 or Alt. 1 to the ISC-PLS 
algorithm when training sets were derived from these data sets (Supplementary Data). An 
increase in performance was observed, however, for the larger of the two data sets using 
Mod. 2 (Supplementary Data). These results suggest that our proposed modifications, like 




3.3.3 Experimental Variation in Data Sets Does Not Affect Algorithm Performance 
In addition to the nonrandom effect of peptide length, another source of variation 
in the peptide-MHC class II binding data may be theuse of multiple experimental 
protocols. Two parameters that frequently vary among protocols designed to measure 
peptide-MHC IC50 are the concentration of reporter peptide Lr and the equilibrium 
dissociation constant of the reporter peptide-MHC complex Kr. We made estimates of the 
ratio Lr/Kr for IC50 measurements in several data sets and used this ratio as the basis of 
classifying the data (Fig. 3.5). 
Specifically, estimates of Lr/Kr were used to create two pIC50 data subsets that 
varied in their degree of deviation from pKD and subsequently ∆G°. Lr/Kr values of 1 and 
9 were used as cutoffs, filtering out pIC50 values that differed from pKD by more than 
approximately 2- and 10-fold, respectively. 29% of the total non-overlapping data had 
mean Lr/Kr values of greater than 1, while 5% had mean Lr/Kr values of greater than 9. 
To determine whether variability in these experimental parameters affects data 
quality, we compared the accuracy of binding predictions using filtered and unfiltered 
data sets (Table 3.4). Successive rounds of leave-one-out cross-validation were 
performed such that predictions were made for each peptide in a given data set. 
Prediction accuracy was scored by calculating the Pearson correlation coefficient 
between experimental and predicted pIC50 values, and differences between scores were 
evaluated for statistical significance. Because data set size is known to affect prediction 
accuracy, random data subsets of the same sizes as the filtered subsets were used as 
controls. 
In general, filtering data based on reporter peptid-specific parameters did not 
significantly improve the accuracy of prediction at either level of filtering (Table 3.4). 
While taking random subsets of the same data sets oft n resulted in only small changes to 
prediction accuracy, filtering sometimes resulted in significant degradation, particularly 
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for the smallest data sets (DRB1*0301, e.g.). An alternative approach, using the mean 
estimated Lr/Kr to convert pIC50 to pKD, also failed to improve prediction accuracy (data 
not shown). 
The effect of other experimental parameters on IC50 measurements could be 
observed indirectly. When the reporter peptide was identical to the peptide of interest, Kr 
was equal to KD, allowing KD to be calculated directly from the Cheng-Prusoff equation 
(Equation 3.6) as KD = IC50 - Lr. In the DRB1*0401 data set, this condition was fulfilled 
for multiple IC50 measurements of the peptide PKYVKQNTLKLAT (HA 307-319), two 
of which were also made at the same temperature and usi g the same method of reporter 
peptide labeling (Hansen 1998, Consogno 2003). For these measurements, KD was 
calculated to be 41 and 700, indicating that variation in parameters unrelated to 
temperature and reporter peptide concentration and affinity to MHC could also lead to 
variation in IC50 measurements. 
3.4 Discussion 
Information is typically lost during the prediction of peptide-MHC class II binding because most 
algorithms focus exclusively on 9mers within the peptide. An underlying assumption is that properties of the parent 
peptides that cannot be captured in their 9mers are irrel vant. This assumption may be true for MHC class I binding 
which involves peptides of nine amino acids almost exclusively but may not be true for MHC class II binding. Peptides 
that bind MHC class II are variable in length and may contain segments that extend past the ends of the peptide-binding 
groove, also known as peptide-flanking residues or PFR (Brown et al. 1993). PFR-MHC interactions may in turn affect 
peptide-MHC binding in a manner that is consistent and useful to prediction. Longer peptides also allow f r register 
shifting, i.e. the ability of peptides to bind MHC using different core 9mers. PFR-MHC interactions and register 
shifting represent two possible mechanisms by which variability in peptide length affects affinity to MHC class II. 
In this study we found that nonlinear relationships exist between peptide length 
and peptide-MHC class II binding affinity in a number of aggregate data sets available 
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online. When these nonlinearities were examined in more detail, they were found to be 
significant at several lengths, suggesting some lengths were more favorable for binding 
than others. This is consistent with the data from a number of experimental studies 
(Malcherek et al. 1994, Vogt et al. 1994, Bartnes et al. 1999, Fleckenstein et al. 1999). In 
these studies affinity was generally found to increase with length up to the longest lengths 
examined, typically between 15 and 17 amino acids. In our simulations register shifting 
was found to be one mechanism that could account for the direct relationship between 
length and binding affinity. However, our analysis of aggregate data sets suggests that 
additional mechanisms also contribute to the effect of length on affinity. For example, 
register shifting alone cannot explain why certain le gths at the amino and carboxyl 
termini are advantageous or disadvantageous for binding DRB1*0401. In this case other 
mechanisms such as hypothesized PFR-MHC interactions that are either attractive or 
repulsive may also be playing a role (Sercarz and Maverakis 2003). 
Incorporating peptide length into existing binding prediction algorithms by one or 
more of our modifications consistently improved performance for multiple MHC class II 
alleles. Three modifications were used—one at the lev l of the training set data (Mod. 1), 
another within the algorithm itself (Alt. 1), and the last after 9mer predictions were 
generated (Mod. 2)—and all resulted in performance gains over reference algorithms 
ISC-PLS and TEPITOPE/ProPred. Baseline AROC scores for two different algorithms 
varied between 0.57 and 0.73. By comparison AROC scores for modified algorithms 
varied between 0.68 and 0.77, consistent with the range of scores listed in MHCBench 
(http://www.imtech.res.in/raghava/mhcbench/). The modification resulting in the largest 
performance increase differed by allele, and this may in part reflect differences in the 
mechanisms by which length affects affinity. For DRB1*0401, for example, using the 
formula for register shifting resulted in performance gains that were statistically 
indistinguishable from those obtained using other modifications. For DRB1*0101, 
however, modifications based on regression modeling resulted in significantly greater 
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performance increases. These data therefore support roles for both register shifting and 
other mechanisms. 
Previous studies have provided indirect evidence that accounting for variability in 
peptide length could improve prediction. Godkin et al. (1998), for example, found that 
matrices based on 15mers generally outperformed matrices based on shorter lengths, 
showing the usefulness of considering information outside of the core 9mer. Likewise, 
Bui et al. (2005) have proposed deriving a separate matrix fo each length of peptide (Bui 
et al. 2005). Despite the suggestion that explicit consideration of peptide length could 
improve binding prediction (McFarland and Beeson 2002), to our knowledge no previous 
study has implemented this idea. Our results affirm the use of peptide length in binding 
prediction. In addition our modifications are sufficiently general that they could be 
incorporated into other current algorithms based on scoring 9mers. 
Thus far experimental evidence of either register shifting or PFR-MHC 
interactions has involved only a small sampling of MHC class II alleles and been of 
indeterminate generality. For example, register shifting has been demonstrated to occur 
with alleles I-Ad and I-Au in mice and DR2 in humans (McFarland et al. 1999, Li et al. 
2000, Seamons et al. 2003, Bankovich et al. 2004). Solved structures exist for a 
somewhat wider array of alleles, including I-Ad and I-Ak in mice and DR1, DR3, and 
DR4 in humans (see McFarland and Beeson 2002 for a review). Although these 
structures show the presence of PFRs in peptide-MHC class II complexes, they fail to 
capture the dynamics of either register shifting or PFR-MHC interactions. 
Our analysis of regression fits to different aggregat  binding data sets suggests 
that longer PFRs (i.e. in peptides longer than approximately 16 amino acids) may 
generally be deleterious to binding. At the same time, however, PFRs of a certain 
minimum length increase the probability of a peptide having multiple binding registers 
which, our simulations show, increases overall binding affinity. An optimal peptide 
length for binding each MHC class II variant may therefore exist. Further computational 
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analysis of aggregate data sets may provide a complement to more direct, observation-
based studies in continuing to elucidate the role of peptide length in MHC class II 
binding. In addition these findings may be of use to the design of peptide vaccines which 
often comprise only short segments of disease-relevant protein antigens (Larche and 







Figure 3.1. Schematic of modifications made to existing algorithms to incorporate 
peptide length. Modification 1, Alternative Modification 1, and Modification 2 are 
abbreviated Mod. 1, Alt. 1, and Mod. 2. Also shown are examples of sources of data, 
algorithms used to remove homologous sequences from data, and algorithms to predict 




Figure 3.2. Local regression fits of peptide-MHC class II binding affinity versus peptide 
length for three HLA data sets: A, DRB1*0101; B, DRB1*0401; C, DRB1*1501; and D, 
the three data sets combined. 95% boundaries of permutation distributions are shown 
(dotted) with fits to the original, non-shuffled data (solid). 
 
 
Figure 3.3. Statistical simulations of the effects of register shifting on MHC class II 
binding affinity over a range of peptide lengths: A, for a 1700-peptide data set; B, for a 




Figure 3.4. Local regression fits of peptide-MHC class II binding affinity versus lengths 
of portions of the peptide extending outside of the peptide-binding groove for the HLA-
DRB1*0401 data set: A, at the N terminus and B, at the C terminus. 95% boundaries of 




Figure 3.5. Variance among experimental parameters used in measuring peptide-MHC 
binding affinity. Mean estimates of the ratio Lr/Kr for the IC50 measurements in six data 
sets are shown with error bars. Dotted lines indicate Lr/Kr cutoffs of 1 and 9. Data for the 






Table 3.1. Evidence of non-linear relationships in length-affinity data for several MHC 
class II alleles. 
 DRB1*0101 DRB1*0401 DRB1*1501 
Quadratic, F 11.745 (<0.001) 8.575 (0.004) 3.670 (0. 57) 
Cubic, F 5.849 (0.016) 0.708 (0.401) 4.871 (0.028) 
F statistics are shown for analysis of variance results with p values in parentheses. 
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Table 3.2. Evidence of non-linear relationships in length-affinity data for several MHC 
class II alleles. 
DRB1*0101 ISC-PLS 
Mod. 1: Regression 
fit 
Alt. 1: Length as 
variable 
Combination rule 0.615 ± 0.0091 0.754 ± 0.009 0.690 ± 0.013 
Highest scoring 
register 
0.652 ± 0.008 0.758 ± 0.006 0.705 ± 0.013 
Mod. 2: Equilibrium 
formula 
0.709 ± 0.005 0.770 ± 0.009 0.752 ± 0.003 
DRB1*0401 ISC-PLS 
Mod. 1: Regression 
fit 
Alt. 1: Length as 
variable 
Combination rule 0.730 ± 0.0071 0.741 ± 0.010 0.749 ± 0.009 
Highest scoring 
register 
0.732 ± 0.015 0.750 ± 0.006 0.751 ± 0.005 
Mod. 2: Equilibrium 
formula 
0.757 ± 0.008 0.757 ± 0.004 0.754 ± 0.008 
DRB1*1501 ISC-PLS 
Mod. 1: Regression 
fit 
Alt. 1: Length as 
variable 
Combination rule 0.574 ± 0.0091 0.596 ± 0.015 0.584 ± 0.020 
Highest scoring 
register 
0.575 ± 0.021 0.626 ± 0.014 0.603 ± 0.011 
Mod. 2: Equilibrium 
formula 
0.609 ± 0.019 0.677 ± 0.014 0.609 ± 0.018 
Five-fold cross-validation (5x-CV) was used and repeated five times. Mean AROC scores 
between predicted and experimentally determined pIC50 values are shown with standard 
errors of the mean. Highest scores are shown in bold with multiple scores in bold if pair-
wise differences were not statistically significant. A threshold of 500 nM (Sette t al. 
1994) was used to distinguish binding from non-binding peptides. 1The ISC-PLS 




Table 3.3. Binding prediction accuracy of ProPred algorithm for different MHC class II 








Combination rule 0.685 0.741 0.669 
Highest scoring 
register 
0.6671 0.7541 0.6351 
Mod. 2: Equilibrium 
formula 
0.702 0.764 0.680 
Matrices were obtained from the ProPred website and used to calculate a score for each 
register within a peptide. To each score the approximate affinity of an all-alanine 9mer to 
MHC was added (pIC50 = 6.169, Doytchinova and Flower 2003). AROC scores between 
predicted and experimentally determined pIC50 are shown, using a threshold of 500 nM 
(Sette et al. 1994) to distinguish binding from non-binding peptides. 1Highest ProPred-
predicted scores from all eligible registers were us d as baseline predictions following 
recent precedents (Brusic et al. 1998, Nielsen et al. 2004, Murugan and Dai 2005). 
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Table 3.4. Accuracy of peptide-MHC binding affinity predictions when made using data 






























































































Pearson correlation coefficients between predicted an experimental pIC50 values are 
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How Multiple Host Polymorphisms Affect Immune Response to Tuberculosis 
4.1 Introduction 
Tuberculosis (TB) continues to pose a global health problem. An estimated one-
third of the human population is infected with the pathogen Mycobacterium tuberculosis 
(Mtb), and approximately two million individuals succumb to the disease annually 
(WHO, www.who.int/mediacentre/factsheets/fs104). However, only a fraction of infected 
individuals ever progress to disease (Small and Fujiwara 2001). What distinguishes those 
who are able to control the infection from those who are not? In addition to 
environmental factors such as nutrition and HIV co-infection, host genetics are likely to 
play a role, and identifying polymorphisms in genes that predispose individuals to TB 
continues to be an area of active research (reviewed in Bellamy 2005, Fernando and 
Britton 2006, Hill 2006). 
Identification of genetic polymorphisms that affect susceptibility to TB proceeds 
primarily on the basis of epidemiological data from association studies (Casanova and 
Abel 2002). In association studies the frequency of a polymorphism-based allele is 
compared in patients and healthy controls. If the allele is found to be over-represented in 
patients, it can then be hypothesized to encode a protein variant that renders its bearer 
more susceptible to TB. 
Association studies do not always yield consistent r sults, however, and an allele 
that is correlated with TB in one study might not be correlated with TB in another study 
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(Fernando and Britton 2006). Several reasons might explain this inconsistency (Alcais et
al. 2001). Small samples sizes (i.e., insufficient numbers of subjects) may lead to 
unreliable detection of low-frequency alleles. Alternatively, alleles may have been 
detected using indirect, serological tests that are unable to distinguish between closely 
related alleles, unlike more direct, sequence-based tests. 
Even more difficult to account for is the problem of genetic heterogeneity. 
Because the number of polymorphisms affecting immune f ction is vast, and many have 
yet to be discovered, epidemiological studies necessarily fail to assay all polymorphisms. 
In most studies only a single polymorphism is assayed. Other polymorphisms may 
compound or counteract the effect of a single polymrphism, and such interactions can be 
difficult to detect without additional testing. For instance, a polymorphism X1 in gene X 
may render the human host more susceptible to TB in the presence of polymorphism Y1
in gene Y but not in the presence of an alternative polymorphism Y2. Such interactions 
underlie the difficulty in comparing studies done on different populations (Alcais et al. 
2001), even when the same allele is being studied and study design is identical. 
Antigen presentation requires the contribution of several genes, and many of these 
genes bear polymorphisms that have been associated wi h TB (c.f. Bellamy 2005, 
Fernando and Britton 2006, Hill 2006; Table 4.2 in Supplementary Information). During 
antigen presentation, cells bind peptides from pathogens to receptors known as MHC 
(major histocompatibility complex) molecules and display the resulting peptide-MHC 
(pMHC) complexes on their surface (Fig. 4.1A). Two classes of MHC molecule exist: 
class I, primarily for peptides found in the cytoplasm, and class II, primarily for peptides 
found in endosomal compartments. Cells known as antige -presenting cells (APCs) 
express both classes of MHC, allowing them to display peptides from a variety of 
pathogens. 
A T cell response to antigen presentation begins when a T cell scans the surface 
of the APC (Fig. 4.1A, reviewed in Santana and Esquivel-Guadarrama 2006). If T cell 
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receptors (TCRs) expressed by a T cell bind pMHC complexes displayed on the APC 
surface with sufficient affinity, and co-stimulatory molecules such as B7 and CD28 are 
present, a signaling cascade is initiated that ultimately results in T cell activation. Within 
minutes of APC-T cell contact, intracellular calcium levels rise and TCRs from the 
surface are internalized. After several hours cytokines including IL-2 and IFN-γ are 
produced by T cells leading to T cell proliferation a d activation of other cell types. 
Antigen presentation therefore involves events occurring on timescales of seconds to 
hours and at molecular, cellular, and multi-cellular length scales. 
Among the antigen presentation-specific polymorphisms associated with TB, 
perhaps the best studied are those in genes for HLA(human leukocyte antigen), the 
human form of MHC. Of the two classes of HLA, HLA class II is particularly relevant to 
TB because HLA class II molecules bind peptides from antigens in endosomal 
compartments where Mtb resides. Over 800 HLA class II alleles have been identified, 
among which are several that have been associated with increased or decreased 
susceptibility to TB (Robinson et al. 2003, Bellamy 2005). In particular, the DRB1*1501 
allele has been associated with susceptibility to TB in numerous studies (Mehra et al. 
1995, Ravikumar et al. 1999, Teran-Escandon et al. 1999, Sriram et al. 2001; Table 4.2 
in Supplementary Information). Generally polymorphisms in HLA map to the peptide-
binding regions of the molecule and can therefore be assumed to affect function 
(Rammensee 1995). A general mechanism explaining how HLA polymorphisms affect 
the immune response to TB, however, has not been established. Other polymorphisms 
affect HLA expression rather than the peptide-binding properties of HLA; to our 
knowledge, none of these polymorphisms has yet beentested for TB association (Louis et 
al. 1994, Cowell et al. 1998). 
MHC expression occurs constitutively in APCs but is subject to the up-regulatory 
effects of signals from the extracellular environmet including the cytokine IFN-γ. 
Polymorphisms in the IFN-γ gene have also been associated with TB susceptibility. In 
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particular, the +874A allele was found to be significantly over-represented in TB patients, 
suggesting +874A increases susceptibility to TB (Lio et al. 2002, Lopez-Maderuelo et al. 
2003, Rossouw et al. 2003; Table 4.2 in Supplementary Information). PBMCs (peripheral 
blood mononuclear cells which include APCs and T cells) from +874A individuals 
produce significantly less IFN-γ in vitro than PBMCs from +874T individuals after 
antigenic stimulation (Pravica et al. 1999, Lopez-Maderuelo et al. 2003). In addition to 
its up-regulatory effects on MHC expression, IFN-γ has a number of other functions 
including activation of macrophages and NK cells and inhibition of the TH2 phenotype in 
T cells (Maher et al. 2007), but exactly which of these functions is undermined in +874A 
individuals has not been determined. 
Finally polymorphisms affecting antigen processing (the partial degradation of 
proteins into peptides) have been associated with susceptibility to TB, though thus far 
only for MHC class I-mediated antigen presentation. The transporter associated with 
antigen processing (TAP) is responsible for translocating peptides from the cytoplasm 
into the endoplasmic reticulum where they can be bound by MHC class I molecules. A 
polymorphism in TAP2, one of the subunits that constitute TAP, was found over-
represented in TB patients (Rajalingam et al. 1997, Gomez et al. 2006; Table 4.2 in 
Supplementary Information). Other enzymes perform analogous functions for the MHC 
class II-mediated pathway, namely the cathepsin proteases responsible for antigen 
processing. Polymorphisms are known to exist in genes for cathepsins (Taggart 1992), 
but to our knowledge, none has been tested for TB association. 
How polymorphisms in HLA, IFN-γ, and other genes interact to ultimately 
determine genetic susceptibility to TB remains an open question. Mathematical modeling 
can help to provide a unifying framework with which to consider these polymorphisms. 
Such a framework would ideally have immunologically relevant readouts such as 
cytokine production and allow the effect of each polymorphism to be simulated and 
observed, both individually and with other polymorphisms. Several questions could then 
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be approached theoretically. For example, could a polymorphism that up-regulates IFN-γ 
expression compensate for a polymorphism that results in HLA deficient in binding Mtb 
peptides? How might T cell response differ among individuals with different 
combinations of polymorphisms? 
To approach these questions we developed a multi-sca e mathematical model of 
antigen presentation that represents both APCs and T cells and tracks events from the 
molecular scale to cellular and multi-cellular scales. Particular detail was given to 
pathways involving MHC and IFN-γ, allowing polymorphisms affecting both pathways 
to be simulated. The extent to which a polymorphism in one gene compounded or 
counteracted the effect of a polymorphism in another gene could be observed, allowing 
us to determine whether the presence of multiple poym rphisms could be a confounding 
factor in association studies. 
4.2 Methods 
The multi-scale model comprises three models that were developed separately 
(Fig. 4.1): an APC model representing the events leading up to the appearance of pMHC 
on the APC surface, a T cell model representing the ev nts leading up to TCR 
internalization, and an intracellular T cell signali g model representing the events leading 
up to cytokine (IFN-γ) production. We provide an overview of the three models here. 
4.2.1 APC Model 
We describe the APC model elsewhere in detail (Singer and Linderman 1990, 
Singer and Linderman 1991, Agrawal and Linderman 1996, Chang et al. 2005). Briefly, 
we represented the major events leading up to antigen presentation within APCs, e.g., 
macrophages, using ordinary differential equations (ODEs). These events include novo 
synthesis of MHC, the up-regulatory effect of IFN-γ, uptake and processing of 
 
110 
extracellular antigens, formation of peptide-MHC (pMHC) complexes, and trafficking of 
pMHC to and from the APC surface (Fig. 4.1B). Equations are provided in 
Supplementary Information, and parameters in Tables 4.3 and 4.4. 
4.2.2 T Cell Model 
To represent T cell response to antigen presentatio, we developed a T cell model 
and linked it to the APC model. The T cell model was based on a model originally 
published in Coombs et al. (2002), further developed in Gonzalez t al. (2005), which 
represents two important features of T cell signaling, namely kinetic proofreading (i.e., 
the requirement for pMHC-TCR engagement to persist for a certain duration to result in 
TCR activation) and serial triggering (i.e., the ability of one pMHC to engage multiple 
TCR). In the Coombs model as well as in our model, the events following APC-T cell 
contact are represented, specifically engagement of pMHCs by TCRs, progression of 
pMHC-TCR complexes through various states of activation, and finally internalization of 
fully activated TCRs as a marker of T cell activation (Fig. 4.1C). Co-stimulatory 
molecules such as B7, CD28, ICAM-1, and LFA-1 were assumed to be present in non-
limiting quantities. In order to be internalized, TCRs in the model were required to be 
fully activated in either free or pMHC-bound forms; the contribution of constitutively 
recycling TCRs to the pool of internalized TCRs was excluded. Only the contact zone 
between the APC and T cell was considered. The degree of TCR internalization occurring 
in the contact zone was therefore assumed to be repr s ntative of the degree of TCR 
internalization occurring elsewhere on the T cell surface. The T cell model comprises a 
set of ODEs separate from the ODEs of the APC model (equations provided in 
Supplementary Information, parameters in Supplementary Tables 4.5 and 4.6). 
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4.2.3 Cytokine Secretion Model 
To provide an additional, longer-term readout of T cell activation, we extended 
the T cell model to include signaling events that follow TCR activation culminating in the 
production of cytokines, particularly IFN-γ. These events include the recruitment of 
kinases such as Lck and ZAP-70, the activation of intermediate signaling molecules such 
as phospholipase C and calcineurin, and ultimately the activation of transcription factors 
NF-AT, NF-κB, and AP-1 (reviewed in Liu 2005). We developed a simplified model of 
these events representing transcription factor activ tion, cytokine gene expression, and 
cytokine production (Fig. 4.1D). More detailed features of T cell signaling such as the 
synthesis and breakdown of transcription factor intermediates were assumed to have a 
negligible effect on long-term (> 12 h) responses and therefore not considered in our 
model; such features are considered in other models (Hoffmann et al. 2002, Fisher et al. 
2006). The cytokine production model comprises a third set of ODEs in addition to the 
sets of ODEs constituting the APC and T cell models (equations provided in 
Supplementary Information, parameters in Supplementary Tables 4.5 and 4.6). 
4.2.4 Solving the Multi-Scale Model 
Together these three models constitute the multi-scale model of antigen 
presentation. The models were run in three sequential phases: (1) exposure of APC to 
IFN-γ in the absence of exogenous antigen for 24 h (APC model only); (2) exposure of 
APC to exogenous antigen in the absence of IFN-γ for 4 h (APC model only); and (3) 
exposure of APC to T cell for 24 h (T cell model and cytokine production models only). 
Information was passed between APC and T cell models in the form of number of pMHC 
on the APC surface appearing 4 h after APC exposure to antigen, i.e., in a feed-forward 
manner. Feedback from T cell to APC, in the form of IFN-γ that could increase MHC 
expression, was assumed to be negligible on the timscales being simulated (≤ 24 h) and 
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therefore not represented; such feedback may be easily accommodated by the model if 
longer timescales are investigated. The three variables serving as outputs were the 
number of pMHC complexes on the APC surface 4 h after exposure to exogenous antigen 
(APC model), fraction of TCR internalized 5 h after APC-T cell contact (T cell model), 
and concentration of cytokine IFN-γ produced 24 h after APC-T cell contact (cytokine 
production model), which we consider indicative of short-, medium-, and long-term 
responses, respectively. These outputs have been considered intermediate indicators of 
cellular response in the experimental literature (Valitutti et al. 1995, Hemmer et al. 1998, 
Itoh et al. 1999). A minimum threshold of approximately 200-350 pMHC on the APC 
surface is needed to elicit a T cell response, thoug  numbers may vary between tens and 
thousands (Demotz et al. 1990, Harding and Unanue 1990). Internalization of 
approximately 10-90% of TCRs from the T cell surface occurs within hours of APC 
contact depending on the amount of antigen initially present (Valitutti et al. 1995, Itoh et 
al. 1999). No threshold level of TCR internalization required for T cell activation has 
been determined, though a correlation with other responses such as T cell proliferation 
has been observed (Itoh et al. 1999). Cytokine IFN-γ production by T cells in response to 
antigenic stimulation varies over several logs, though pM amounts in vitro are typical 
(Hemmer et al. 1998, Laaksonen et al. 2003, Listvanova et al. 2003). The ODEs 
constituting the multi-scale model were solved using the NDSolve function of 
Mathematica 4.2 (Wolfram Research, Inc.) using default options, and the model was 
tested against experimental dose-response data available for each of the three outputs 
(Valitutti et al. 1995, Hemmer et al. 1998, Itoh et al. 1999). 
4.2.5 Sensitivity Analysis of the Multi-Scale Model 
We determined how variability in the processes represented in the model affects 
the three model outputs using sensitivity analysis. Briefly, we varied parameter values in 
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the model, generated an output for each different st of parameter values, and then 
determined the degree of correlation between each prameter and the output. A particular 
parameter was varied if a genetic polymorphism was known to exist for the process 
represented or to ensure that each of three constituen  models had approximately the 
same number of parameters represented during the analysis. A total of 16 parameters 
were varied (Table 4.7 in Supplementary Information). Parameters were assigned log-
uniform distributions. That is, minimum and maximum values were assigned to each 
parameter, and sampling was done uniformly on a range defined by the log-transform of 
these values. When several biological values were available in the literature the 
approximate range of these values was used: for pMHC dissociation, 10-6-10-2 s-1 
(Rothbard and Gefter 1991, McFarland and Beeson 2002); for pMHC-TCR dissociation, 
10-3-100 s-1 (Davis et al. 1998); for IFN-γ dose, 10-12-10-6 M (c.f. Lin et al. 1996); and for 
antigen dose, 10-9-10-4 M. For all other cases, a range of one order of magnitude above 
and below the baseline value was specified (Supplementary Information). 500 values for 
each parameter were generated by a Latin hypercube sampling scheme (LHS, Helton and 
Davis 2000), resulting in 500 different sets of parameter values. An equivalent number of 
output values were then derived, and correlations between output values and parameter 
values were then quantified by using partial rank correlation coefficients (PRCC, Blower 
and Dowlatabadi 1994). Significance was assigned based on a Bonferroni-corrected α 
value of 0.05 (Bland and Altman 1995). 
4.2.6 Experimental Scenarios Simulated 
Using the multi-scale model of antigen presentation, we were able to simulate in
vitro protocols intended to test responsiveness of host cells to particular antigens (as used 
in Katial et al. 1998, e.g.). In such a protocol peripheral blood mononuclear cells 
(PBMCs) are isolated from patient blood, exposed to antigens such as purified protein 
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derivative (PPD) from Mtb, and then assayed for response either indirectly (by measuring 
tritiated thymidine uptake as a marker of proliferation) or directly (by enzyme-linked 
immunsorbent assay, or ELISA, for cytokine). Because monocytes, a precursor of 
macrophages, serve as APCs in PBMC and there is likely little to no IFN-γ present in the 
blood, the model can simulate PBMC protocols when the amount of IFN-γ initially 
present is set to zero. The model can also simulate the in vivo scenario of antigen 
presentation at a site of infection where macrophages and activated T cells are present. In 
this case, the amount of IFN-γ initially present is set at a non-zero value in the model. 
Both of these scenarios were examined during sensitivity analysis. 
4.2.7 Trade-Off Plots 
In addition to performing sensitivity analysis by varying several parameters 
concurrently, we also examined the relationship betwe n processes represented in the 
model in a pair-wise manner, by varying two parameters at a time. Pairs of parameter 
values that yielded approximately the same target output value were compiled and 
plotted. Because such plots show how a change in one parameter is able to compensate 
for a change in another parameter, we refer to suchplots as trade-off plots. When values 
for both parameters are plotted as log-transforms, egions in which the plots are diagonal 
(slope approximately 1 or -1) identify conditions under which a compensatory 
relationship exists. That is, a one-log change in one parameter is able to compensate for a 
one-log change in another parameter to maintain a given output value. In contrast, 
regions in which the plots are horizontal or vertical identify conditions under which one 
parameter has dominant effect on the output over the o er parameter. In such regions the 
output is relatively insensitive to changes in one f the two parameters. Parameters that 
were chosen to generate trade-off plots were either from the same-scale sub-model (the 
intra-model case) or from different-scale sub-models (the inter-model case). A 
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sufficiently wide range of values was assigned to each parameter in generating each 
trade-off plot to capture the full range of behaviors in each curve. Biologically realistic 
values were then overlaid on each plot, shown as boxes whose edges represent the range 
of values from in vitro measurements when available. When in vitro measurements were 
not available, a range of one order of magnitude above and below the baseline value was 
specified (Tables 4.3-4.6 in Supplementary Information). When pMHC dissociation rate 
constant or pMHC-TCR dissociation rate constant wasv ried, parameter values were 
plotted as their respective equilibrium dissociation constants KD, assuming invariant 
association rate constants (Kasson et al. 2000). We chose different values for the three 
outputs to serve as target output values, generally accepting pairs of parameter values that 
resulted in output values between 80% and 120% of the target output values. Target 
output values were 100, 500, or 1000 pMHC on the APC surface; 10%, 40%, or 80% 
internalization of total TCR; and 0.1 pM, 1 pM, or 5 pM IFN-γ production corresponding 
to ~2, ~20, and ~200 pg/ml IFN-γ. To assist visualization of plots, curve-fitting was done 
using the SplineFit function (Bezier option) of the NumericalMath library in 
Mathematica 4.2 (Wolfram Research, Inc.), except in cases where more than one y-value 
mapped to the same x-value (pMHC-TCR affinity vs. pMHC affinity plots and TCR 
internalization vs. pMHC affinity plots) when curves were fit by hand. 
4.3 Results 
To relate genetic polymorphisms to changes in APC and T cell responses, we 
developed a multi-scale model of antigen presentation that traverses several biological 
and temporal scales (from molecular to multi-cellular and seconds to hours). This model 
represents several different immunological processes that could potentially vary due to 





Initially we tested the model by comparing three model outputs to expected 
behaviors from experimental data. As a negative control we checked baseline results of 
the model: In the absence of exogenous antigen, no exogenous peptide-MHC complexes 
were formed, no TCRs were internalized, and no IFN-γ was produced (data not shown). 
As a positive control, we examined outputs of the model when exogenous antigen was 
present. The dynamics of pMHC display, TCR internalization, and IFN-γ production 
approximated experimentally observed time courses (Fig. 4.2A-C). Specifically, the 
number of pMHC on the APC surface peaked within four hours of antigen exposure (Fig. 
4.2A, Harding and Unanue 1990); the majority of TCR internalization occurred within 
the first two hours of T cell exposure to APC (Fig. 4.2B, Valitutti et al. 1995); and IFN-γ 
production continued to rise through the first 24 h of T cell exposure to APC (Fig. 4.2C, 
Listvanova et al. 2003). The model also recapitulated dose-response data available for the 
various outputs (Fig. 4.2D-F). 
4.3.1 Sensitivity of T Cell Response to Genetically Variable Processes 
To determine how biological variability due to genetic polymorphism or other 
causes might affect APC and T cell responses, we simulated variability in the multi-scale 
model and correlated changes in output variables to changes in input parameters (Table 
4.1). These outputs were found in either the same sub-model as the parameter being 
varied (the intra-model case) or in a different sub-model (the inter-model case). Two 
scenarios were simulated, the absence and presence of IFN-γ initially, scenarios 
representing antigen presentation during PBMC protocols and at the site of infection, 
respectively. 
Multiple parameters were found to correlate significantly with model outputs, 
identifying biological processes that may positively or negatively govern antigen 
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presentation and T cell response. Variability in a umber of these processes is known to 
exist and in some cases has been associated with susceptibility to TB. For example, both 
peptide-MHC binding affinity and IFN-γ expression (as IFN-γ dose) correlated 
significantly with all three outputs (Table 4.1). Other processes bear polymorphisms that 
may affect their level of expression or function but have not previously been associated 
with TB susceptibility. Antigen processing correlatd significantly with all three outputs 
but more strongly at early time points than later time points (Table 4.1). Likewise, MHC 
expression correlated significantly with all three outputs, more strongly at early time 
points than at later time points, but only in the absence of IFN-γ, a scenario resembling 
PBMC protocols rather than infection i vivo, illustrating the overlapping effects of 
changes in IFN-γ expression and MHC expression (Table 4.1). 
Most parameters displayed a similar degree of influence on both T cell responses 
of TCR internalization and IFN-γ production (Table 4.1). One exception was the rate
constant for the internalization of free, activated TCR which correlated positively with 
TCR internalization and negatively with IFN-γ production. In the model internalized 
TCRs are incapable of initiating signal transduction and therefore cease to contribute to 
cytokine production. 
4.3.2 Possible Confounding Effects Among Multiple Polymorphisms 
Sensitivity analysis demonstrated that multiple processes, including several that 
may vary due to genetic polymorphisms, govern the dynamics of antigen presentation 
and subsequent T cell responses. To examine interactions between polymorphisms in 
more detail, we varied parameters in a pair-wise manner and determined the extent to 
which one parameter could compensate for another in governing the dynamics of antigen 
presentation and T cell response. 
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IFN-γ expression and HLA binding polymorphisms can be compensatory. The 
polymorphisms in the antigen presentation pathway most commonly associated with TB 
susceptibility affect the level of IFN-γ expressed by T cells and peptide-binding by MHC 
(Bellamy 2005). The consequences of polymorphisms in two genes acting simultaneously 
on antigen presentation have not been examined either experimentally or theoretically to 
our knowledge. To simulate these polymorphisms, we varied parameters for IFN-γ levels 
and peptide-MHC binding affinity in the APC model and plotted those pairs of parameter 
values resulting in approximately the same output levels (Fig. 4.3A-C). 
In the trade-off plots, three distinct regions can be discerned (described here for 
Fig. 4.3B, the case of TCR internalization). First, at low IFN-γ concentrations (< 10-10 
M), TCR internalization is determined almost entirely by pMHC affinity and is invariant 
to small changes in IFN-γ concentration, apparent as nearly vertical lines on the plots. 
Under these conditions few of the IFN-γ receptors are bound, and small changes in IFN-γ 
concentrations do not alter MHC expression. Secondly, at intermediate IFN-γ 
concentrations (between 10-10 M and 10-6 M), IFN-γ has an effect on TCR internalization 
nearly equal to the effect of pMHC affinity, apparent as diagonal lines on the plots. In 
this region, for example, 80% TCR internalization can be achieved by pairing either 10-9 
M IFN-γ and 10-9 M pMHC binding affinity (as KD) or 10-8 M IFN-γ and 10-8 M pMHC 
binding affinity. Finally, at high IFN-γ concentrations (> 10-6 M), TCR internalization is 
again determined almost entirely by pMHC affinity, apparent as nearly vertical lines on 
the plots. Under these conditions most of the IFN-γ receptors are bound, and small 
changes in IFN-γ concentrations do not affect near-maximal increases in MHC 
expression. 
Superimposing experimental data on these plots allows realistic regions to be 
defined. IFN-γ expression in PBMC from individuals with +874A and +874T alleles have 
been measured and found to differ by as much as 3-fold, in the range of 10-10-10-11 M 
(Pravica et al. 1999, Lopez-Maderuelo et al. 2003, I. Aguilar-Delfin, personal 
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communication). A wider range of IFN-γ concentrations (between 10-9 and 10-12 M) is 
typically applied in vitro; this wider range is shown as boxes in Fig. 4.3A-C.  Likewise, 
the affinities of different peptide-MHC class II complexes have been measured and found 
to vary largely between 10-9 and 10-6 M (Rothbard and Gefter 1991, Peters t al. 2005). 
These measurements make it possible to define a region on the trade-off plots in which 
realistic combinations of parameters could be expected. The plots show that at realistic 
levels of IFN-γ expression, pMHC affinity has a stronger effect on all outputs, from 
number of pMHC displayed through amount of cytokine produced. 
HLA expression and HLA binding polymorphisms can be compensatory. Though 
polymorphisms in HLA promoters have been identified, none have yet been associated 
with susceptibility to TB (Louis et al. 1994, Cowell et al. 1998). One reason may be the 
difficulty involved in measuring the total level ofexpression of a particular HLA class II 
variant within and on the surface of an APC simultaneously. Another reason may be the 
difficulty involved in attributing an association with TB to the HLA promoter and not the 
HLA coding sequence with which it is likely in linkage disequilibrium. In the model 
HLA expression and binding affinity are separate parameters and were found to exert a 
nearly equivalent influence on output values (Fig. 4.3D-F). For instance, a pMHC affinity 
of 10-9 M when 105 MHC molecules were present resulted in nearly the same degree of 
TCR internalization (~80%) as a weaker pMHC affinity of 10-8 M when more (106) MHC 
molecules were present (Fig. 4.3E). At lower levels of MHC expression (< 105 MHC 
molecules per APC), however, pMHC affinity becomes much more determinative of T 
cell response. The possibility that higher levels of expression might compensate for lower 
affinity binding has been raised previously in non-human studies (Kaufman and 
Salomonsen 1997, Wegner t al. 2006). 
Antigen processing and HLA binding polymorphisms can be compensatory. Like 
polymorphisms affecting MHC expression, polymorphisms affecting antigen processing 
have also been identified, though none have yet been associated with susceptibility to TB 
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(Taggart 1992). Polymorphisms affecting antigen processing can be expected to either 
increase or decrease the availability of antigenic peptides available to bind MHC and 
therefore affect antigen presentation and subsequent T cell responses. In the model 
variability in antigen processing was found to compensate for variability in pMHC 
affinity (Fig. 4.3G-I). For example, to elicit 5 pM IFN-γ production, an increase in the 
rate constant for antigen processing (from 100 to 101 h-1) could be coupled with a 
decrease in pMHC binding affinity (from 10-9 to 10-8 M, Fig. 4.3I). The extent to which 
polymorphisms in antigen processing cathepsins affect enzymatic activity is not known 
(Taggart 1992), but within a one-log range of the leve  of activity observed in vitro, the 
trade-off plots show that variability in cathepsin activity may affect antigen processing 
and T cell response to the same extent as variability in pMHC affinity. 
Optimal pMHC-TCR affinity affects TCR internalization, not IFN-γ secretion. 
The binding affinity of the pMHC-TCR tri-molecular complex has been shown to be an 
important quantity in determining T cell response (Matsui et al. 1994). We examined 
trade-offs between peptide-MHC and pMHC-TCR affinities in eliciting different 
responses (Fig. 4.4A-C). Because the parameter for pMHC-TCR affinity does not occur 
in the APC model, variability in pMHC-TCR affinity does not affect pMHC numbers. 
This lack of effect is apparent as vertical lines on the trade-off plot for this output (Fig. 
4.4A). Coombs et al. (2002) and Gonzalez et al. (2005) showed that under certain 
conditions an optimal half-life for pMHC-TCR interaction exists resulting in maximal 
TCR internalization. Because our model of the T cell was based on the model of Coombs 
et al. (2002), it was not surprising to see an optimal binding affinity for pMHC-TCR 
appear on the trade-off plot for TCR internalization (Fig. 4.4B). However, the peak 
showing this optimal affinity was greatly lessened at lower pMHC affinities, particularly 
when IFN-γ production was considered the output (Fig. 4.4C). Indeed, at biological 
values (10-9-10-6 pMHC KD), pMHC affinity was more determinative of T cell response 
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than pMHC-TCR affinity, apparent as vertical lines on the plots (Fig. 4.4B and 4.4C, 
boxed regions). 
Internalization of activated TCR is oppositely correlated with different T cell 
responses. We also examined trade-offs between peptide-MHC affinity and the rate 
constant for TCR internalization (Fig. 4.4D-F). While most parameters in the model were 
correlated consistently (i.e., either positively or negatively) with the three different 
responses, the parameter for internalization of free, activated TCR differed in that it was 
positively correlated with one response, TCR internalization, and negatively correlated 
with another, IFN-γ production (Fig. 4.4E-F, c.f. Table 4.1). This effect persisted up to a 
certain threshold value for the internalization rate constant (~1 h-1), above which other 
processes such as pMHC binding became limiting. These r sults were obtained under the 
assumption that internalized TCR do not continue to signal. This assumption has 
previously been challenged for TCRs as well as for other receptors (Luton et al. 1997, 
Burke et al. 2001). If internalized TCRs are assumed to continue signaling in the model, 
then vertical trade-off plots with pMHC affinity are observed and TCR internalization has 
little effect on IFN-γ production (data not shown). 
4.4 Discussion 
A large body of epidemiological literature links polymorphisms in various host 
genes to increased susceptibility to TB (c.f. Bellamy 2005, Fernando and Britton 2006, 
Hill 2006). Mechanistic explanations are still lacking, however, for how the 
polymorphisms identified in the epidemiological literature increase susceptibility to TB. 
We posed a fundamental question: how do polymorphisms in multiple genes acting 
simultaneously affect immune functions such as antige  presentation? For example, 
considering that IFN-γ up-regulates MHC expression, could an allele of IFN-γ increase 
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the number of MHC molecules per APC enough to offset d ficiencies in binding 
exhibited by a particular HLA allele to elicit the same T cell response? 
To approach these questions, we developed a multi-scale model of antigen 
presentation that links molecular and intracellular events to cellular and multi-cellular 
outcomes. By varying parameters for IFN-γ expression, peptide-MHC binding, and other 
processes, we were able to simulate changes in different processes that might occur due 
to genetic variation or other causes and then analyze the sensitivity of antigen 
presentation and T cell responses to these changes. Sen itivity analysis showed that many 
of the processes in the model exerted strong and comparable influences on the outputs. 
For instance, both IFN-γ expression (as represented by the amount of IFN-γ to which 
APC were initially exposed) and peptide-MHC binding were found to significantly affect 
all outputs in the model, both at the same scale (within the APC, intra-scale) and at 
different scales (within the T cell, inter-scale). These outputs included the number of 
pMHC appearing on the APC surface, the degree of TCR internalization, and the amount 
of cytokine produced by T cells (Table 4.1). 
We then analyzed interactions between genetically variable processes in more 
detail using trade-off plots and found that changes in these processes may compensate for 
one another. Furthermore, we determined conditions under which such compensatory 
relationships may exist. For instance, within a certain range of concentrations (10-10-10-6 
M), alterations in the amount of IFN-γ to which APCs were exposed affected T cell 
response as strongly as alterations in pMHC affinity (Fig. 4.3B and 4.3C). Outside of this 
range, however, pMHC affinity had a more dominant effect on T cell response, 
minimizing the contribution of IFN-γ. In primary cultures of PBMC re-stimulated with 
antigen, IFN-γ has been detected at concentrations of 10-11 to 10-10 M. At these 
concentrations polymorphisms in HLA may mask the eff cts of polymorphisms in IFN-γ. 
This interaction may account for inconsistencies in the epidemiological association data. 
The +874A IFN-γ polymorphism results in decreased IFN-γ expression and has been 
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associated with susceptibility to TB in some but not all studies (e.g., Moran et al. 2007). 
Could variability in peptide-binding exhibited by different HLA alleles be masking the 
effect of IFN-γ polymorphisms in such studies? Jepson et al. (1997) found that variability 
in the immune response to TB antigens was the result of variability in both non-HLA 
genes (such as IFN-γ) and HLA genes. Given the significant presence of HLA 
polymorphisms in human populations, our study suggests that the accuracy and 
consistency of association studies could be increased by comparing the frequencies of 
concurrent pairs of polymorphisms (such as IFN-γ +874A / HLA-DRB1*1501) in TB 
patients rather single polymorphisms alone. 
We also found that polymorphisms need not affect the same cell or the same 
timescale (intra-scale) to be compensatory. Parameters affecting different scales (inter-
scale) may be compensatory as well. For instance, peptide-MHC affinity and pMHC-
TCR affinity have a compensatory relationship, though the first affects APCs while the 
second affects the interface between APC and T cell. B cause TCRs are generated by 
somatic recombination, TCRs do not exist in the human population as alleles, though an 
individual can be expected to express a diverse set of TCRs, each differing in its affinity 
for a given pMHC ligand (Davis et al. 1998). The importance of pMHC-TCR affinity in 
determining T cell response has been demonstrated experimentally (Matsui et al. 1994, 
McMahan et al. 2006). Previous models have suggested that trade-offs can exist between 
pMHC affinity and pMHC-TCR affinity, but the conditions under which changes in one 
of these processes can compensate for changes in the other process has not been 
previously defined (Eberl et al. 1995, Agrawal and Linderman 1996). Verification of our 
results awaits measurements made on pMHC-TCR tri-molecular complexes. 
In the future we hope to consider additional question  regarding the dynamic 
interplay between host and pathogen. A threshold minimum number of pMHC exists to 
elicit a T cell response (Demotz et al. 1990, Harding and Unanue 1990), and presumably 
many combinations of parameter values (e.g., for antige  dose, IFN-γ expression, and 
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pMHC affinity) yield this threshold. Plotting these combinations of values would produce 
a surface (shown in gray in Fig. 4.5), above which all parameter values would yield a 
successful T cell response (Fig. 4.5, point 1). Within the span of an infection, either host 
or pathogen may alter one or more processes underlying these parameters. The pathogen, 
for example, might produce less antigen thereby providing a temporary advantage (Fig. 
4.5, point 2). The host might then respond, increasing the rate of another process, leading 
to a point placed on the other side of the surface (Fig. 4.5, point 3). This dynamic 
interplay would resemble the “cycle of antigen frust ation” hypothesized to occur during 
TB (Murray 1999). A path traced by these points on b th sides of the surface would 
represent this cycle, and the final point of this path, the resolution of the cycle, resulting 






Figure 4.1. Schematic of multi-scale model of antigen presentation and T cell response. 
(A) Overview of antigen presentation by APC and T cell response. (B) APC model 
(input: IFN-γ, exogenous antigen; output: surface pMHC). (C) T cell model (input: 
surface pMHC from APC model; outputs: activated TCR, internalized TCR). (D) 
Cytokine production model (input: activated TCR; output: cytokine, specifically IFN-γ). 
Abbreviations are as follows: Ag for antigen, pep for exogenous peptide, self for self 
peptide, B with subscripts 0 through N for pMHC-TCR complexes in different stages of 
activation, and TF for transcription factor. Direct (mechanistic) reactions in the model are 
indicated by solid arrows, while indirect (regulatory) interactions in the model are 





Figure 4.2. The multi-scale model conforms to expected behaviors during testing. (A) 
Time course of pMHC on APC surface in the model. (B) Time course of TCR 
internalization in T cells in the model. (C) Time course of IFN-γ production in the model. 
(D) Dose-response curve for pMHC as antigen concentration is varied in the model and 
experimental data. (E) Dose-response curve for TCR internalization as the number of 
peptide-MHC on the APC surface is varied in the model and experimental data. (F) Dose-
response curve for IFN-γ production as antigen concentration is varied in the model and 
experimental data. Parameter values for each simulation are given in Supplementary 
Information. When more than one curve was available from the experimental data, the 




Figure 4.3. Trade-off plots show multiple polymorphisms can compensate for 
polymorphisms in pMHC binding to achieve the same response. Pairs of parameter 
values resulting in the same target output value are plotted. (A-C) IFN-γ expression (as 
amount initially present) vs. peptide-MHC binding. (D-F) MHC expression vs. peptide-
MHC binding. (G-I) Antigen processing vs. peptide-MHC binding. Target output values 
were 100, 500, or 1000 pMHC on the APC surface; 10%, 40%, or 80% internalization of 
total TCR; and 0.1 pM, 1 pM, or 5 pM IFN-γ production corresponding to ~2, ~20, and 
~200 pg/ml IFN-γ. Boxes delineate realistic biological ranges. Values of other parameters 




Figure 4.4. Trade-off plots show compensatory relationships betwe n APC and T cell 
(inter-model) parameters. (A-C) pMHC-TCR affinity vs. peptide-MHC binding. (D-F) 
Internalization of free, activated TCR vs. peptide-MHC binding. Target output values 
were 100, 500, or 1000 pMHC on the APC surface; 10%, 40%, or 80% internalization of 
total TCR; and 0.1 pM, 1 pM, or 5 pM IFN-γ production corresponding to ~2, ~20, and 
~200 pg/ml IFN-γ. Boxes delineate reasonable biological ranges. Values of other 




Figure 4.5. Conceptualized multi-dimensional trade-off plot showing how host and 
pathogen respond to efforts by the other to circumvent and bolster antigen presentation, 
respectively, during the course of an infection. The surface shown in gray represents all 
parameters that lead to a threshold number of pMHC on the APC surface or its 
corresponding T cell response. Points represent combinations of parameter values 
measured at time points throughout an infection, with points above and below the surface 




Table 4.1. Sensitivity analysis of the multi-scale model. 
 No IFN-γ initially present IFN-γ initially present 
 pMHC1 TCR2 IFN-γ3 pMHC1 TCR2 IFN-γ3 
IFN-γ dose4 N/A N/A N/A 0.64 0.14 0.15 
MHC 
expression5 
0.41 0.19 0.15 0.29 (0.07) (0.05) 
pMHC 
affinity6 
-0.80 -0.44 -0.40 -0.65 -0.29 -0.28 
Ag dose 0.97 0.70 0.68 0.97 0.71 0.72 
Ag 
processing7 
0.66 0.17 0.16 0.62 0.21 0.24 
TCR 
expression 
N/A 0.55 0.42 N/A 0.55 0.34 
pMHC-TCR 
affinity8 
N/A -0.58 -0.60 N/A -0.56 -0.60 
pMHC-TCR 
activation9 




N/A (0.08) -0.24 N/A (0.07) -0.23 
IFN-γ 
signaling11 
N/A N/A 0.56 N/A N/A 0.66 
PRCC values measuring sensitivity of model outputs to parameter variability when IFN-γ 
is either not present initially or present initially, akin to PBMC (monocyte-T cell) and 





-5 molecule-1s-1). Shown are PRCC values when 16 
parameters in the model were varied (see Methods for detail). Parameters corresponding 
to processes in which genetic polymorphisms have been observed are indicated in bold. 
Non-significant PRCC values (α = 0.05, Bonferroni-adjusted) are in parentheses. 
1Number of pMHC on the APC surface 4 h after Ag exposure. 2Number of TCR 
internalized by the T cell 5 h after APC-T cell contact. 3Amount of IFN-γ produced by 
the T cell 24 h after APC-T cell contact. 4Amount of IFN- γ to which APCs are exposed 
24 h prior to Ag exposure. 5Number of MHC molecules initially expressed on the cell. 
6As pMHC KA when pMHC dissociation rate constant was varied. 
7Rate constant for 
antigen processing. 8As pMHC-TCR KA when pMHC-TCR dissociation rate constant 
was varied. 9Rate constant for progressive activation of pMHC-TCR complexes. 10Rate 
constant for TCR-induced IFN-γ transcription. 
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4.5 Supplementary Information 
4.5.1 APC Model Equations 
Equations 4.1-4.16 constitute the APC model and are identical to the equations 
presented in Chang et al. (2005). 
  
dG/dt = [−kon-IFN-γ G RG + koff-IFN-γ CG] [ncells / (NA vmedium)] − kdeg-IFN-γ G [4.1] 
dRG/dt = −kon-IFN-γ G RG + koff-IFN-γ CG + krecyc CG [4.2] 
dCG/dt = kon-IFN-γ G RG − koff-IFN-γ CG − krecyc CG [4.3] 
dC2m/dt = ktxn-C2 (1 + αC2 CG) − kdeg-C2m C2m [4.4] 
dC2/dt = ktsl-C2 C2m − kdeg-C2 C2  [4.5] 
dMm/dt = ktxn-M C2 − kdeg-Mm Mm  [4.6] 
dA*/dt = −(kpino ncells / vmedium) A* − kdeg-A* A* [4.7] 
dA/dt = (kpino / vMIIC) A* − kdeg-A A − klys A [4.8] 
dE/dt = kdeg-A A + (−kon-MHC M E + koff-MHC ME) [1 / (NA vMIIC)] − klys E [4.9] 
dS/dt = ksource + [kdeg-MHC (MS + MS* ) – kon-MHC M S + koff-MHC MS] [1 / 
(NA vMIIC)] – klys S 
[4.10] 
dM/dt = ktsl-M (1 + αM CG) Mm − kon-MHC M S + koff-MHC MS − kon-MHC M 
E + koff-MHC ME − kout M + kin M* − kdeg-MHC M  
[4.11] 
dM*/dt = kout M − kin M*  − kdeg-MHC M*  [4.12] 
dMS/dt = kon-MHC M S − koff-MHC MS − kout MS + kin MS*  − kdeg-MHC MS [4.13] 
dMS* /dt = kout MS − kin MS*  − kdeg-MHC MS* [4.14] 
dME/dt = kon-MHC M E − koff-MHC ME − kout ME + kin ME*  − kdeg-MHC ME [4.15] 
dME* /dt = kout ME − kin ME*  − kdeg-MHC ME*  [4.16] 
Descriptions of the terms in each equation are provided in Chang et al. (2005). 
Variables and parameters are defined, and values provided, in Table  4.3 and 4.4. 
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4.5.2 TCR Internalization Model Equations 
Equations 4.17-4.27 constitute the T cell model andre approximated from the 
PDEs of Coombs et al. (2002) that pertain to the contact zone. 
 
dME
C/dt = −kon-B (TC + TactivC) MEC + koff-B (B0 + B1 + B2 + B3 + B4+ B5 + 
BN) − λB BN − kdeg-MHC,C MEC 
[4.17] 
dTC/dt = − kon-B T
C ME
C + koff-B (B0 + B1 + B2 + B3+ B4+ B5 + BN) [4.18] 
dB0/dt = kon-B T
C ME
C − (koff-B + kp) B0 [4.19] 
dB1/dt = kp B0 − (koff-B + kp) B1  [4.20] 
dB2/dt = kp B1 − (koff-B + kp) B2 [4.21] 
dB3/dt = kp B2 − (koff-B + kp) B3 [4.22] 
dB4/dt = kp B3 − (koff-B + kp) B4 [4.23] 
dB5/dt = kp B4 − (koff-B + kp) B5  [4.24] 
dBN/dt = kon-B Tactiv
C ME
C + kp B5 − koff-B BN  [4.25] 
dTactiv
C/dt = −kon-B Tactiv
C ME
C + koff-B BN − λT TactivC  [4.26] 
dTint/dt = λT (Tactiv + TactivT) + λB BN [4.27] 
Briefly, Equations 4.17-4.19 describe the processes by which free pMHC 
complexes on the APC surface and free TCRs on the T cell surface bind and form 
pMHC-TCR tri-molecular complexes. (Superscript C represents molecular species 
occurring in the contact zone between the APC and T cell.) Equations 4.20-4.25 describe 
the progressive activation of pMHC-TCR tri-molecular complexes that occurs during 
kinetic proofreading. Finally, Equations 4.26 and 4.27 describe the association and 
dissociation of fully activated TCRs to and from pMHC-TCR tri-molecular complexes 
and the internalization of activated TCR in free or b und forms. In this model, only the 
contact zone of Coombs et al. (2002) was represented, and therefore terms representing 
diffusion between the contact zone and other zones in the Coombs model were excluded. 
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Variables and parameters are defined, and parameter values provided, in Tables 4.5 and 
4.6. The model recapitulated major features of the model of Coombs et al. (2002) and 
Gonzalez et al. (2005) such as the existence of an optimal pMHC-TCR half-life for TCR 
internalization (data not shown). 
4.5.3 Cytokine Production Model Equations 
Equations 4.28-4.31 describe the cytokine production p rtion of the T cell model. 
 
dFactiv/dt = kresp (Tactiv + BN) F − kdecay Factiv    [4.28] 
F = 1 − Factiv [4.29] 
dGm/dt = ktxn-IFN-γ Factiv − kdeg-Gm Gm  [4.30] 
dG2/dt = ktsl-IFN-γ Gm [ncells / (NA vmedium)] − kdeg-IFN-γ G2 [4.31] 
Briefly, Equation 4.28 represents the first-order activation and deactivation of a 
transcription factor for cytokines produced by the T cell, e.g., NF-κB, in units of fraction 
total transcription factor. Equation 4.29 represent the pool of un-activated transcription 
factor. Equation 4.30 represents the first-order synthesis (i.e., transcription) and 
degradation of cytokine mRNA and in particular the absolute dependence of the synthesis 
of cytokine mRNA on the presence of activated transcription factor. Finally Equation 
4.31 represents the first-order synthesis (i.e., translation) and degradation of cytokine 
protein. Like cytokine mRNA, cytokine protein in the model is completely dependent on 
the presence of its activator, cytokine mRNA. Variables and parameters are defined, and 
parameter values provided, in Tables 4.5 and 4.6. 
4.5.4 Parameters for Figures and Tables 
Parameter values and initial conditions used in solving Equations 4.1-4.31 of the 
model were as provided in Tables 4.3-4.6 with the following exceptions: 
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For Fig. 4.2: (a)-(c) ncells=1 · 10
6, vmedium=1 · 10
-3 L, G0=0, A0=1 · 10
-5 M, koff-
MHC=2 · 10
-3 s-1, kon-TCR=1 · 10
-6 molecule-1s-1. (d) ncells=8 · 10
6, vmedium =1 · 10
-3 L. (e) kon-
TCR=1 · 10
-6 molecule-1s-1. (f) ncells=2 · 10
4, rvol=2 · 10
-4 L. 
For Table 4.1: ncells=1 · 10
6, vmedium=1 · 10
-3 L, koff-MHC=2 · 10
-3 s-1, kon-TCR=1 · 10
-5 
molecule-1s-1. During LHS parameters that were defined in terms of other parameters 
(Tables 4.4 and 4.6) were re-derived, with the exception of ktxn, the MHC transcription 
rate constant. Instead, ktxn was varied during LHS, and kdeg-Mm, the MHC mRNA 
degradation rate constant, was re-derived.  
For Fig. 4.3: ncells=1 · 10
6, vmedium=1 · 10
-3 L, G0=0, A0=1 · 10
-5 M, koff-MHC=2 · 10
-3 
s-1, kon-TCR=1 · 10
-6 molecule-1s-1. 
For Fig. 4.4: ncells=1 · 10
6, vmedium=1 · 10
-3 L, G0=0, A0=1 · 10
-5 M, koff-MHC=2 · 10
-3 
s-1, kon-TCR=1 · 10
-6 molecule-1s-1. 
For Table 4.7: ncells=1 · 10
6, vmedium=1 · 10
-3 L, koff-MHC=2 · 10





Table 4.2. Polymorphisms in antigen presentation affecting susceptibility to TB. 
Gene Allele Odds ratio References 
HLA class II DR2 (serotype) 1.8-2.7 
Bothamley et al. 1989, 
Brahmajothi et al. 1991, 





Mehra et al. 1995, Ravikumar et 
al. 1999, Teran-Escandon et al. 
1999, Sriram et al. 2001 
 DQB1*0503 N/A1 Goldfeld et al. 1998 
IFN-γ +874A 1.6-3.8 Lio et al. 2002, Lopez-Maderuelo et al. 2003, Rossouw et al. 2003 
TAP TAP2*0201 2.4-4.3 
Rajalingam et al. 1997, Gomez et 
al. 2006 
1This polymorphism was not detected in the control population. 
A more complete list of polymorphisms associated with TB susceptibility can be found 
elsewhere (Bellamy 2005, Fernando and Britton 2006, Hill 2006). Odds ratio presents a 




Table 4.3. Initial values in the APC model. 
Variable Description Initial value(1) 
G IFN-γ concentration in medium Varies by experiment 
RG Free IFN-γ receptors per cell 1 × 103 
CG IFN-γ complexes per cell 0 
C2m CIITA mRNA as fraction of basal level 1 
C2 CIITA protein as fraction of basal level 1 
Mm MHC
(2) mRNA per cell 1 × 105 
A* Antigen concentration in medium Varies by experiment 
A Antigen concentration within MIIC 0 
E Peptide concentration within MIIC 0 
S Self peptide concentration within MIIC 4 × 10-4 M(3) 
M Free intracellular MHC per cell 
pin (1 − pbound) Mtot ≈ 6.7 
× 103 
M* Free surface MHC per cell 
[(1 − pin) / pin] M0 ≈ 1.3 × 
104 
MS Intracellular self-MHC complexes per cell 
[pbound / (1 − pbound)] M0 ≈ 
2.7 × 104 
MS* Surface self-MHC complexes per cell 
[(1 − pin) / pin] MS,0 ≈ 5.3 
× 104 
ME 
Intracellular peptide-MHC complexes per 
cell 
0 
ME* Surface peptide-MHC complexes per cell 0 
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(1)When used in the definition of another parameter or variable, the subscript 0 refers to 
the initial value of a particular variable such that, e.g., M0 refers to the initial value of M. 
Units are numbers of molecules per cell (APC or T cell) unless otherwise indicated. 
(2)MHC in this and following entries refers to MHC class II. 
(3)This value was estimated from [kdeg-Mm (MS,0 + MS,0*) + koff-MHC MS,0] / kon-MHC M0 




Table 4.4. Parameters in the APC model. 
Parameter Description Value(1) 
kon-IFN-γ IFN-γ / IFN-γR association rate constant 3 × 109 M-1  h-1 
koff-IFN-γ IFN-γ / IFN-γR dissociation rate constant 7 × 10-1 h-1 
ncells Number of APC in medium Varies by experiment 
vmedium Volume of culture medium Varies by experiment 
kdeg-IFN-γ IFN-γ degradation rate constant 1 × 10-2 h-1 
krecyc IFN-γ receptor recycling rate constant 1 × 101 h-1 
ktxn-C2 CIITA transcription rate constant 
kdeg-C2m C2m,0 = 2 × 10
-1 
h-1 
αC2 IFN-γ-dependent CIITA scaling factor 1 × 10-1 
kdeg-C2m CIITA mRNA degradation rate constant 2 × 10
-1 h-1 
ktsl-C2 CIITA mRNA translation rate constant
 kdeg-C2m C2 / C2m,0 = 1.4 
× 100 h-1 
kdeg-C2 CIITA degradation rate constant 1.4 × 10
0 h-1 
ktxn-M MHC transcription rate constant 
kdeg-Mm Mm,0 ≈ 4 × 10
3 
h-1 
kdeg-Mm MHC mRNA degradation rate constant 4 × 10
-2 h-1 
kpino Pinocytosis rate 1 × 10
-13 L h-1 
kdeg-A* 
Antigen degradation rate constant in 
medium 1 × 10
-2 h-1 
vMIIC Volume of MIIC compartment 4 × 10
-16 L 
kdeg-A Antigen processing rate constant 4 × 10
0 h-1 
klys Lysosomal degradation rate constant 6 × 10
0 h-1 
ksource Self peptide synthesis rate constant 





kdeg-MHC MHC degradation rate constant 2 × 10
-2 h-1 
kon-MHC Peptide-MHC association rate constant 7.2 × 10
8 M-1 h-1 
koff-MHC Peptide-MHC dissociation rate constant 7.2 × 10
4 h-1 
ktsl-M MHC mRNA translation rate constant 
kdeg-MHC (M0 + M* 0 + 
MS,0 + MS* 0) ≈ 2 × 10
-2 
h-1 
αΜ IFN-γ-dependent MHC scaling factor 1 × 10-1 
kout MIIC-to-surface trafficking rate constant 4 × 10
0 h-1 
kin Surface-to-MIIC trafficking rate constant 
[pin/(1–pin)] kout – kdeg-
MHC ≈ 2 × 10
0 h-1 
pin Proportion of MHC intracellular at time 0 1/3 
pbound Proportion of MHC bound to self at time 0 4/5 
Mtot Total number of MHC per cell 1 × 10
5 
(1)When used in the definition of another parameter or variable, the subscript 0 refers to 




Table 4.5. Initial values in the T cell models. 
Variable Description(1) Initial value 
ME
C Peptide-MHC complexes within contact zone 0 
TC Free TCR within contact zone, inactive (σC/σtot-Tcell) Ttot ≈ 4.2 × 103 
B0 Peptide-MHC-TCR complex, inactive 0 
B1 Peptide-MHC-TCR complex, state 1 0 
B2 Peptide-MHC-TCR complex, state 2 0 
B3 Peptide-MHC-TCR complex, state 3 0 
B4 Peptide-MHC-TCR complex, state 4 0 
B5 Peptide-MHC-TCR complex, state 5 0 
BN Peptide-MHC-TCR complex, activated 0 
Tactiv
C Free TCR within contact zone, activated 0 
Tint Internalized TCR 0 
F Inactive NF-κB, fraction of total NF-κB 1 
Factiv Activated NF-κB, fraction of total NF-κB 0 
Gm IFN-γ mRNA 0 
G2 IFN-γ secreted 0 




Table 4.6. Parameters in the T cell models. 
Parameter Description Value(1) 
σC Surface area of APC-T cell contact zone 7 × 10-11 m2 
σtot-APC Total surface area of APC 5 × 10-10 m2 
kon-B pMHC-TCR association rate constant 3.6 × 10-2 h-1 molecule-1 
koff-B pMHC-TCR dissociation rate constant 3.6 × 101 h-1 
σtot-Tcell Total surface area of T cell 5 × 10-10 m2 
µ TCR deactivation rate constant 0 h-1
kp TCR activation rate constant 9 × 102 h-1 
λT Free TCR internalization rate constant 1.08 × 101 s-1 
λB Bound TCR internalization rate constant 1.08 × 100 s-1 
kresp NF-κB activation rate constant 5 × 10-3 h-1 molecule-1 
kdecay NF-κB deactivation rate constant 1 × 10-1 h-1 
ktxn-IFN-γ IFN-γ transcription rate constant kdeg-Gm Gm,0 ≈ 1 × 102 h-1 
kdeg-Gm IFN-γ mRNA degradation rate constant 1 × 0-2 h-1 
ktsl-IFN-γ IFN-γ translation rate constant 6 × 101 
Ttot Total number of TCR per cell 3 × 104 
(1)When used in the definition of another parameter or variable, the subscript 0 refers to 
the initial value of a particular variable such that, e.g., M0 refers to the initial value of M. 
The values of most parameters are identical to the parameters in Coombs et al. (2002), 
including surface areas of the APC and T cells, surface area of the contact zone, TCR 
activation and de-activation rate constants, and TCR internalization rate constants. 
Association and dissociation rate constants for the pMHC-TCR complex were estimated 
from values measured in vitro (reviewed in Davis et al. 1998). The NF-κB activation rate 
constant was estimated by summing constituent rate constants d4, d5, d6, r4, r5, and r6 
from Hoffmann et al. (2002). The NF-κB de-activation rate constant was estimated by 
fitting the time course of activated NF-κB in the model to an experimentally observed 
peak in NF-κB levels occurring approximately 1 h after activation (Hoffmann et al. 
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2002). The IFN-γ transcription rate constant and mRNA degradation rate constant were 
estimated by fitting the time course of cytokine IFN-γ mRNA to match an experimentally 
observed peak in expression approximately 20 hours after exposure to APC (Listvanova 
et al. 2003). The IFN-γ translation rate constant was estimated by fitting he time course 
of cytokine IFN-γ to match an experimentally observed peak in protein levels detected by 





Table 4.7. PRCC values for all 16 parameters that were varied during sensitivity analysis. 
No IFN-γ initially present IFN-γ initially present 
Biological 
process/factor 
pMHC1 TCR2 IFN-γ3 pMHC1 TCR2 IFN-γ3 
IFN-γ dose4 N/A N/A N/A 0.64 0.14 0.15 
MHC 
expression5 
0.41 0.19 0.15 0.29 (0.07) (0.05) 
pMHC 
affinity6 
-0.80 -0.44 -0.40 -0.65 -0.29 -0.28 
Ag dose 0.97 0.70 0.68 0.97 0.71 0.72 
Ag 
processing7 
0.66 0.17 0.16 0.62 0.21 0.24 
pMHC export 
to surface 




N/A -0.26 -0.20 N/A -0.25 -0.20 
TCR 
expression 
N/A 0.55 0.42 N/A 0.55 0.34 
pMHC-TCR 
affinity8 
N/A -0.58 -0.60 N/A -0.56 -0.60 
pMHC-TCR 
activation9 








N/A (0.08) -0.24 N/A (0.07) -0.23 
IFN-γ 
signaling12 
N/A N/A 0.56 N/A N/A 0.66 
Trans. factor 
deactivation 
N/A N/A (-0.04) N/A N/A (-0.07) 
IFN-γ mRNA 
synthesis 
N/A N/A 0.56 N/A N/A 0.66 
IFN-γ mRNA 
degradation 
N/A N/A (0.03) N/A N/A (0.03) 
Parameters corresponding to processes in which genetic polymorphisms have been 
observed are indicated in bold. Non-significant PRCC values (α=0.05, Bonferroni-
adjusted) are shown in parentheses. N/A is indicated for parameters representing 
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processes that occur later in the antigen presentatio  pathway than the indicated output 
and therefore do not affect output value. 
 
1Number of pMHC on the APC surface 4 h after Ag exposure 
2Number of TCR internalized by the T cell 5 h after APC-T cell contact 
3Amount of IFN-γ produced by the T cell 24 h after APC-T cell contact 
4Amount of IFN-γ to which APCs are exposed 24 h prior to Ag exposure 
5Number of MHC molecules initially expressed on the APC 
6As pMHC KD when peptide-MHC dissociation rate constant was varied 
7Rate constant for antigen processing 
8As pMHC-TCR KD when pMHC-TCR dissociation rate constant was varied 
9Rate constant for progressive activation of pMHC-TCR complexes 
10Rate constant for internalization of bound, activated TCR 
11Rate constant for internalization of free, activated TCR 
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Antigen presentation, one of the key events in the initiation and maintenance of 
the immune response, offers many possible avenues of r earch for both experimentalists 
and theoreticians. In the preceding chapters I described my efforts to pursue three such 
avenues – how best to represent events at the cellular scale (tracking the number of 
pMHC on the APC surface), then at the molecular scale (predicting binding between 
peptides and MHC class II molecules), and finally at the multi-cellular scale (between 
APC and T cell leading up to T cell activation). After describing how each model was 
developed, I showed how I applied each model to answer questions related to the immune 
response to infection, particularly with M. tuberculosis.  
5.1.1 APC Model 
In the case of the cellular-scale model, I asked why M. tuberculosis had been 
found to use multiple mechanisms to inhibit antigen presentation, each targeting a 
different intracellular process (Fig. 5.1). The APC model suggested that these 
mechanisms differed in their effects. Some mechanisms were effective at stymieing 
antigen presentation almost immediately but could be overcome by the provision of an 
activating cytokine, IFN-γ, by other cells. Targeting the ability of macrophages to process 
antigens into smaller peptides could be considered one such mechanism. Other 
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mechanisms required a delay of several hours to have an effect on antigen presentation 
but were more effective at longer timescales. Mechanisms targeting MHC class II 
expression, for example, required at least ten hours to have an effect, consistent with the 
length of time required for protein synthesis. M tuberculosis may therefore employ 
multiple mechanisms to a complementary rather than merely redundant effect. 
Furthermore, the application of external IFN-γ in experimental protocols may interfere 
with the ability to detect M. tuberculosis mechanisms that do not target MHC class II 
expression. 
5.1.2 Peptide-MHC Binding Model 
At the molecular scale, I asked whether differences in peptide length affected 
binding affinity to MHC class II, and if so, whether incorporating these differences into 
existing binding prediction algorithms could improve algorithm performance (Fig. 5.1). 
After analyzing binding data from currently available databases, I found that a significant 
and nonlinear relationship existed between length and ffinity. This relationship was 
allele-specific and often revealed an optimal length for maximizing binding affinity, a 
finding that may have implications for the study of antigens from pathogens such as M. 
tuberculosis or for vaccine design (described in more detail below). Furthermore, 
incorporating information about peptide length into binding prediction algorithms 
consistently improved performance, whether through the use of these relationships or 
alternatively through the use of a statistical method for reconciling predicted affinities 
made on multiple binding registers (i.e., 9mer windows that engage the MHC class II 
molecule directly) within longer peptides. 
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5.1.3 T Cell Model 
Finally, at the multi-cellular scale, I asked whether multiple polymorphisms 
affecting different steps in the antigen presentation pathway might interact, either 
canceling or intensifying their effects on the outcme. To answer this question, I 
extended the APC model to include the T cell respones of TCR down-regulation and 
cytokine secretion and then determined whether and u er what conditions a 
polymorphism in one gene might compensate for a polym rphism in another gene (Fig. 
5.5.1). For example, polymorphisms have been observed in both IFN-γ non-coding and 
MHC class II coding sequences, affecting IFN-γ expression and pMHC affinity, 
respectively. In the model, increased IFN-γ expression could compensate for decreased 
pMHC affinity to maintain the same level of cytokine secretion but only when IFN-γ 
levels exceeded a lower threshold. Below this threshold, changes in pMHC affinity had a 
much stronger effect on the level of cytokine secretion. The finding that polymorphisms 
can have similar effects on antigen presentation could explain discrepancies in the 
epidemiological literature where some polymorphisms (e.g., the MHC class II allele 
DRB1*1501) are inconsistently associated with disease susceptibility. 
5.2 Future Work: Additions to the Models 
5.2.1 More Detailed Representation of M. tuberculosis 
While antigen presentation is largely the product of host processes, the pathogen 
ultimately plays a role by supplying antigenic peptides. In each of the sub-models 
constituting the multi-scale model, M. tuberculosis has been represented as a static 
quantity. For instance, in the APC model, the degre of inhibition of a particular process 




Adding M. tuberculosis as a dynamic variable would allow presentation to be 
more realistically represented by the model (Fig. 5.1C). Because the number of M. 
tuberculosis bacilli infecting any given APC is discrete and likely to be low but the ODE 
representation of the APC model assumes continuous variables, the most effective way to 
incorporate M. tuberculosis into the model would be to use some continuously variable 
quantity as a proxy for intracellular bacterial number. One such quantity might be the 
amount of a particular antigen secreted by the bacillus. 
Adding M. tuberculosis as a dynamic variable into the model would also all w 
feedback to be more realistically represented by the model. Since T cell secretion of IFN-
γ was represented in the model and IFN-γ-specific parameter values were used, it is 
possible to use the output of the T cell model as an additional input for the APC model. 
In doing so, the model would depict the increased capa ity of macrophages at the site of 
infection to present antigen after being exposed to effector T cells that have been re-
stimulated by other macrophages. 
However, in addition to its effects on MHC expression, IFN-γ also increases the 
killing capacity of macrophages. The effect that killing M. tuberculosis bacilli has on the 
availability of antigen is currently unknown. While killing may result in the liberation of 
proteins formerly contained within the bacilli and increase the antigen pool, killing may 
also reduce the quantity of proteins that were formerly being secreted and decrease the 
antigen pool. In either case, the sum effect of additional exposure to IFN-γ may be a 
higher capacity to present antigen but a changed antigen pool. 
By representing the growth state of M. tuberculosis and availability of antigen as 
dynamic quantities, it may be possible to simulate ntigen presentation on longer 
timescales. Currently the multi-scale model represents vents to approximately one day. 
However, since the doubling time of the M. tuberculosis bacillus and the lifespan of 
macrophages are both on the scale of days, antigen presentation may extend to longer 
timescales than currently represented. Murray (1999) hypothesized that during 
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tuberculosis a “cycle of antigen frustration” occurs in which periods of greater antigen 
availability alternate with periods of lesser antigen availability. Each period of greater 
antigen availability induces a T cell response and timicrobial activity leading to a 
period of lesser antigen availability during which t e bacilli recover undetected by 
immune surveillance. A model representing M. tuberculosis as a dynamic variable would 
allow virtual experiments of the hypothesis of Murray (1999) to be performed, such as 
the addition of inhibitors of mycobacterial growth that would presumably slow the period 
of oscillations in the cycle. The results could then be used to design new protocols for in 
vitro experiments. 
5.2.2 More Detailed Representation of Particular Processes 
In the APC and T cell models, most processes were represented with mass-action 
or first-order kinetics, depending on whether the process involved two molecular species 
in the model or only one, respectively. While more detailed mechanistic representations 
are possible for nearly all of the processes in these models, it was assumed that on the 
timescales of interest (typically hours after exposure to antigen) the differences between 
such representations and the ones actually used in the models would be negligible. For 
instance, Witt and McConnell (1992) proposed that peptide-MHC binding is more 
accurately described using a two-step binding mechanism. However, this mechanism 
would be expected to produce the same output as the impler, one-step mechanism hours 
after the binding reaction, when pMHC on the APC surface was read as output. Likewise, 
peptide-MHC binding to TCR has also been hypothesized to involve a two-step binding 
mechanism (Wu et al. 2002), but the additional complexity in this model is not expected 
to yield any difference in output on the timescale of hours. In addition, the data 
supporting more complicated binding mechanisms has sometimes been controversial, as 
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in the case of the two-step peptide-MHC binding mechanism which has been disputed 
(Berezhkovskiy 1998). 
Nevertheless, in some cases it may be possible to gain additional insights from the 
model using more complicated representations, especially when different mechanisms of 
regulation are possible (Fig. 5.1C). For instance, in the APC model endocytosis was 
represented in a general way, involving only one intracellular compartment, the MHC 
class II compartment (MIIC). However, different compartments may play distinct roles 
during antigen presentation, particularly during infection with M. tuberculosis. While M. 
tuberculosis resides in specialized phagosomes where access to MHC class II molecules 
is impaired, a subset of antigens is transferred to endosomes accessible to MHC class II 
molecules (Beatty and Russell 2000, Gehring et al. 2003). Therefore, additional 
selectivity is likely conferred by the path that anigens of M. tuberculosis traverse within 
the macrophage, and some antigens may be presented more quickly than others. 
Additional steps may be introduced into the APC model to account for these disease-
specific differences in endocytosis. 
5.3 Future Work: Integration with Other Models 
5.3.1 Models of Antigen Presentation by MHC Class I 
Exceptions to the rule that MHC class I binds antigens from the cytoplasm (i.e., 
endogenous antigens) while MHC class II binds antige s from the extracellular space 
(i.e., exogenous antigens) have been identified, an  lack of complete knowledge 
regarding the mechanisms involved presents an opportunity for models to provide 
insights. 
During cross-presentation, exogenous antigens gain access to MHC class I 
molecules and are presented as peptide-MHC class I complexes on the APC surface 
(Rock and Shen 2005). While a detailed mechanism has yet to be elucidated, cross-
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presentation appears to follow the internalization of exogenous antigens via phagosomes 
that later fuse with the endoplasmic reticulum (ER) (Guermonprez et al. 2003, Houde et 
al. 2003). Once in the ER exogenous antigens are presumably treated like endogenous 
antigens and then exported into the cytoplasm, processed by the proteasome, reintroduced 
into the ER by the transporter associated with antige  presentation (TAP), and bound to 
MHC class I molecules. Cross-presentation has been shown to occur for antigens from 
several bacterial pathogens including M. tuberculosis. 
Antigens from M. tuberculosis are therefore likely to be presented on the surface 
of APCs with both MHC class I and MHC class II molecules. To what extent are antigens 
presented via one type of pMHC complex versus the or? To answer this question, the 
APC model may be extended to account for the loss of antigens due to the cross-
presentation pathway (Fig. 5.1C). This may be accomplished most directly with 
additional first-order loss terms in the ODE model, assuming that a constant proportion of 
antigen is shunted away from MHC class II-accessible compartments. 
However, it may be interesting to first determine whether the antigens lost to 
cross-presentation and the MHC class I pathway are c pable of being bound by MHC 
class II. The two pathways may be non-competing if antigens destined for the cross-
presentation pathway are enriched in MHC class I-binding sequences but deficient in 
MHC class II-binding sequences. Because the antigens of M. tuberculosis are normally 
not considered candidates for binding MHC class I, a study has not been done to identify 
possible MHC class I-binding sequences within the M. tuberculosis proteome, though a 
similar study has been done to identify MHC class II-binding sequences (McMurry et al. 
2005). Models that represent selectivity at the steps of TAP binding and pMHC binding 




5.3.2 Larger-Scale Models of the Immune System 
Of the three main types of professional APC that are commonly distinguished 
(dendritic cells, macrophages, and B cells), macrophages are most closely represented by 
the APC model. The majority of the parameters in the APC model were derived from in
vitro murine macrophage data, and initial testing was performed against other in vitro 
macrophage data. Because the steps involved in MHC class II-mediated antigen 
presentation are common to all APC cell types, however, the structure and mathematical 
representation in the model are likely to be correct for other cell types as well. Indeed, the 
APC and T cell models were shown to reproduce both time course and dose-response 
data from a variety of experiments. Dendritic cells have been found to differ from 
macrophages with respect to two antigen presentatio-relevant parameters, the level of 
MHC expression and rate of antigen uptake (Inaba and Steinman 1985, Inaba et al. 
1997). Using different values for these parameters may be sufficient to distinguish these 
two cell types in the APC model as well as in the multi-scale model. 
Accounting for differences between dendritic cells and macrophages may help 
extend the model to two different instances of antigen presentation during the course of 
an immune response: antigen presentation to naïve T cells in the lymph node by dendritic 
cells and antigen presentation to effector T cells at a site of infection by macrophages. 
Both instances are likely to play important roles during the immune response to M. 
tuberculosis, especially given the additional role of macrophages as the preferred host 
cells to the M. tuberculosis bacillus. In conjunction with a more realistic repsentation of 
M. tuberculosis growth and antigen availability (discussed above, in Section 5.2.1), 
distinct models of the dendritic cell and the macrophage would allow additional, stage-
specific questions to be approached. For example, are the mechanisms by which M. 
tuberculosis inhibits antigen presentation more likely to be effective on the timescales of 
the initial instance of antigen presentation (when d dritic cells commingle with naïve T 
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cells shortly after infection) or the timescales of later instances of antigen presentation 
(when macrophages encounter and receive stimulation from effector T cells)? Likewise, 
are differences in peptide-MHC affinity resulting from differences between MHC alleles 
more likely to play a role in initial or later instances of antigen presentation? 
Comparisons of the results from dendritic cell and macrophage versions of the APC 
model and larger multi-scale model could provide answers to these questions and 
experimentally testable predictions. 
In addition, representation of additional cell types would help the current model to 
be integrated with other larger-scale models of antige  presentation (Fig. 5.1C). Models 
of both the site of infection during tuberculosis and the lymph node have been developed 
by Kirschner and colleagues (Segovia-Juarez et al. 2004, unpublished data). In both of 
these models, APCs and T cells are represented as discrete objects and their interaction is 
probabilistic. An APC that displays more pMHC complexes on its surface would 
presumably either have a higher probability of a successful interaction with a T cell or be 
able to elicit a stronger T cell response following a successful interaction (Bekkhoucha et 
al. 1984). The probability of a successful APC-T cell interaction is a static quantity in 
these larger-scale models, but using the output of the multi-scale model of the APC and T 
cell presented herein (Fig. 5.1B), this probability could be set as a dynamic quantity that 
more accurately reflects the infection scenario. 
5.4 Applications to Disease 
5.4.1 Mechanisms of HLA-Disease Association 
Several alleles of MHC class II have been found to be either over-represented or 
under-represented in patients with certain diseases relative to healthy controls and 
thereby associated with either susceptibility or resistance to these diseases, respectively. 
For instance, in the case of tuberculosis, MHC class II alleles of the HLA-DR2 and HLA-
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DR3 serotypes have been associated with susceptibility and resistance, respectively. 
Although the mechanisms underlying these associations are not known, several 
hypotheses exist (Vukmanovic et al. 2003). In the case of associations with infectious 
diseases, the most direct hypotheses concern the ability of the MHC variants to bind 
peptides from the antigens of the pathogen and elicit an immune response.  
Here I show preliminary data for how two possible hypotheses for MHC-TB 
associations may be tested using statistical analyses and models (Fig. 5.1C). According to 
one hypothesis, an MHC variant associated with susceptibility may bind a broad range of 
peptides with lower affinity than MHC variants associated with resistance or other MHC 
variants in the population. If this were the case th n the average affinity for the 
susceptibility allele, as calculated from a database of pMHC affinities, would be expected 
to be lower than the average affinity for the resistance allele. In the case of HLA-DR2 
and HLA-DR3, the opposite was found to be true: in fact, peptides binding HLA-DR2 do 
so with a significantly higher average affinity than peptides that bind HLA-DR3, even 
when affinities for repeated and highly sequence-similar peptides have been removed 
(Fig. 5.2). 
Another hypothesis is that the allele associated with susceptibility, HLA-DR2, 
binds only disease-relevant peptides with lower affinities than the allele associated with 
resistance, HLA-DR3. To investigate this possibility, I predicted affinities for all possible 
9mers from one M. tuberculosis antigen found to be secreted by the bacillus at high 
levels, Ag85B, with the two MHC alleles, HLA-DR2 and HLA-DR3. The predictions 
were generated using a previously published binding algorithm, ISC-PLS (Doytchinova 
and Flower 2003). The average affinity of each allele for the same set of peptides could 
then be compared statistically as well as visualized on a plot. The second hypothesis, that 
an MHC allele associated with susceptibility binds di ease-relevant peptides with lower 
affinity than a non-associated MHC allele, also turned out to be false in this case: HLA-
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DR2 was not predicted to bind 9mers from M. tuberculosis Ag85B with lower affinity 
than HLA-DR3 (Fig. 5.3). 
Nevertheless, these preliminary data show how statistical models of peptide-MHC 
binding may be used to test hypotheses regarding HLA-disease associations. As part of 
future work, the model used here and other models predicting pMHC affinity may be 
applied to a wider range of M. tuberculosis antigens and HLA alleles. 
5.4.2 Vaccine Design: rBCG30 
Several new vaccines to tuberculosis are currently i  development (reviewed in 
Martin 2005). Among these one strategy has been to gineer the only vaccine in current 
use, the BCG strain of M. bovis, to over-express particular antigens from M. tuberculosis 
to elicit a more lasting and more directed immune response. In one of these candidate 
vaccines, rBCG30, M. bovis BCG has been engineered to express Ag85B from M. 
tuberculosis (Horwitz 2005). Currently in phase I clinical trials, this candidate vaccine 
and others like it offer an opportunity for models of antigen presentation and the immune 
response to answer key questions. 
One question that might arise, particularly if rBCG30 progress to phase II clinical 
trials and a larger test population, is how well this candidate vaccine performs in a 
heterogeneous population displaying polymorphisms in many genes. Some of these 
polymorphisms (such as IFN-γ +874T leading to increased IFN-γ expression) may 
predispose individuals to a stronger immune response, while other polymorphisms may 
have the opposite effect. Different MHC variants present in the population are likely to 
vary in their ability to bind peptides from the antigen being over-expressed, and these 
differences in binding affinity may also affect the magnitude of the immune response. 
With the refinements discussed above, such as a dynamic representation of M. 
tuberculosis, the multi-scale model could incorporate information such as the observed 
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allele frequencies for antigen presentation-relevant ge es in a population and the dose at 
which a vaccine is administered and predict the range of T cell responses and the 
frequency of each response that might be expected. In this way the multi-scale model 
may offer not only a tool to understand in vitro results in the laboratory but also a tool to 






Figure 5.1. Multi-scale model of antigen presentation. A, Overview of the three models. 
B, Schematized output of the three models. C, Overview of applications and future work 




Figure 5.2. Analysis of affinities for TB-associated HLA alleles. A, Affinities of peptides 
for HLA-DR2, associated with TB susceptibility. B, Affinities of peptides for HLA-DR3, 
associated with TB resistance. In both cases, affinities for homologous peptides were first 
removed using UniqueProt (Mika and Rost 2003). pIC50 = -log IC50 approximates 




Figure 5.3. Predicted affinities of TB-associated HLA alleles for Ag85B 9mers. 9mers 
with human homology are indicated in crosshairs. The ISC-PLS algorithm (Doytchinova 
and Flower 2003) was used to make predictions afterbeing trained on DR2- and DR3-
binding peptides from AntiJen from which homologous peptides had been removed using 
UniqueProt (Mika and Rost 2003). The protein sequence of Ag85B was obtained from 
the NCBI Entrez Protein database (www.ncbi.nlm.nih.gov/sites/entrez, accession 
#AAO62005), and predictions were made on all possible 9mers within Ag85B. Ag95B 
9mers with human homology were identified using blastp with default parameter settings 
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